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Summary 
This dissertation is divided into two parts. The first project addresses the role of 
presenilin 1 and 2 in the regulation of the oxygen sensing pathway. In the second part, 
we investigated a potential role for the onconeural cerebellar degeneration related 
antigen Cdr2 as a novel tumor marker in papillary renal cell carcinoma. The two projects 
will be described and discussed separately, with a general introduction about hypoxia at 
the beginning. 
 
The availability of free oxygen on Earth was one of the prerequisites for the evolution of 
eukaryotic life. Multicellular organisms need oxygen to efficiently produce ATP. 
Therefore, mechanisms for adequate adaptation to low oxygen environments (hypoxia) 
was developing during evolution. The main research interest of our group is to 
understand the molecular and cellular mechanism of sensing and adaptation to hypoxic 
environments.  
Hypoxia is a driving force in many physiological and pathophysiological processes such 
as high mountain climbing, red blood cell synthesis, wound healing, cancer progression 
and neurodegenerative disorders. 
The molecular sensors of hypoxia are the prolyl-4-hydroxylase domain containing 
proteins (PHDs) that regulate the degradation of the hypoxia-inducible factors  (HIFs) 
via oxygen dependent hydroxylation. In normoxia, the von Hippel-Lindau tumor 
suppressor protein (pVHL) binds to hydroxylated HIF which leads to polyubiquitination 
and subsequent proteasomal destruction. In hypoxia, the cofactor oxygen is limited and 
the hydroxylation reaction is therefore reduced. The stabilized HIF subunit then 
translocates to the nucleus and forms a potent transcription factor together with its 
constitutive counterpart HIF. HIF regulates the expression of more than 200 genes that 
are involved in the adaptation to low oxygen partial pressure. Apart from oxygen-
dependent HIF protein regulation, there is growing evidence that HIF mRNA is 
regulated by oxygen-independent mechanisms, for example by pro-inflammatory stimuli 
such as nitrogenmonoxide or cytokines. 
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Project I: 
Recently, we have shown that the peptidyl/prolyl cis/trans isomerase FKBP38 
specifically interacts with PHD2 and negatively regulates its protein stability (Barth et al. 
2007). A report suggesting that presenilin 1 and 2 (PSEN1/2) interact with FKBP38 and 
are involved in the negative regulation of FKBP38 protein levels (Wang et al. 2005) 
draw our attention to a potential role of PSEN1/2 in PHD/HIF signaling. 
Presenilin (PSEN) 1 and 2 are the catalytic components of the -secretase complex 
which cleaves a variety of proteins, including the amyloid precursor protein (APP). 
Proteolysis of APP leads to the formation of the APP intracellular domain (AICD) and 
amyloid beta (A) that is crucially involved in the pathogenesis of Alzheimer’s disease.  
We found that PSEN1/2-deficient mouse embryonic fibroblasts (MEFs) express more 
FKBP38 protein that leads to reduced constitutive PHD2 protein levels. While 
decreased PHD2 levels would predict an increased hypoxic response, we interestingly 
found the opposite. Increased FKBP38 protein levels and decreased PHD2 protein 
levels were found in PSEN1/2-deficient mouse embryonic fibroblasts (MEFs) and in the 
cortex of forebrain-specific PSEN1/2 conditional double knock-out mice and resulted in 
a blunted hypoxic induction of specific HIF-target genes. While HIF-1 protein stability 
was not altered, we found decreased HIF-1 mRNA levels as well as reduced HIF-
1promoter activity in the absence of PSEN1/2. Proteolytic -secretase function of 
PSEN1/2 was needed for proper HIF activation. Intriguingly, PSEN1/2 mutations 
identified in Alzheimer patients differentially affected the hypoxic response, involving the 
generation of AICD. Taken together, our results suggest a direct role for PSEN in the 
regulation of the oxygen sensing pathway via the APP/AICD cleavage cascade.  
Little is known about the biological function of PSEN1/2 and our data might help to 
elucidate the physiological role of PSEN1/2 and the -secretase complex. Additionally, 
the number of Alzheimer’s patients is steadily growing with increasing life expectancy. 
Hypoxic regions in the brain correlate with pathologic protein deposits but the 
mechanistic connection is still unclear. Therefore, our work may contribute to the 
understanding of the role of hypoxia in the pathology of neurodegenerative diseases.  
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Project II: 
Neoplastic expression of the onconeuronal cerebellar degeneration-related antigen 
Cdr2 in ovary and breast tumors is associated with cerebellar degeneration. Cdr2 
protein expression is normally restricted to neurons, but tumoral Cdr2 expression 
triggers tumor immunity, thereby constraining tumor growth but also resulting in 
paraneoplastic cerebellar degeneration (PCD). So far, aberrant Cdr2 expression has 
mainly been described for breast and ovarian tumors. We found strong Cdr2 protein 
expression in 54.2% of papillary renal cell carcinoma (pRCC) and to a much lesser 
extent (7.8%) in clear cell (cc) RCC (Balamurugan et al. 2009). We identified Cdr2 as a 
novel PHD1 interacting protein and found increased PHD1 protein levels when Cdr2 
was concomitantly overexpressed. High Cdr2 protein levels correlated with decreased 
HIF target gene expression in cells as well as in pRCC, providing a possible explanation 
why pRCCs are the most hypovascular renal tumors. Interestingly, survival analysis 
revealed a negative correlation between Cdr2 expression and patient survival in ccRCC 
patients. These findings provide evidence that Cdr2 might represent a novel important 
tumor antigen in kidney cancer and that its interaction with PHD1 could be involved the 
hypovascular morphology. Therefore, PHD1 expression was analyzed by 
immunohistochemical staining of tissue micro arrays (TMAs) of a wide number of RCC 
patients that have previously been analyzed for Cdr2 expression. PHD1 protein levels 
strongly correlated with the previously shown Cdr2 expression and was strong in pRCC. 
In addition, we developed enzyme-linked-immunosorbent-assays (ELISAs) to detect 
Cdr2 auto-antibodies as a diagnostic tool for cancer patients. While Cdr2 antibodies 
were present in the serum of paraneoplastic cerebellar degeneration patients, no Cdr2 
antibodies were found in any of the analyzed pRCC or other RCC sera. This supports 
the fact that Cdr2 protein expression in cancer does not always correlate with the 
generation of Cdr2 auto-antibodies and the development of PCD. 
ZUSAMMENFASSUNG 
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Zusammenfassung 
Die vorliegende Dissertation ist in zwei Sektionen unterteilt. Im ersten Projekt wurde 
eine neue Rolle von Presenilin 1 und 2 (PSEN1/2) in der Regulierung der Hypoxie-
Signalkaskade untersucht. Der zweite Teil befasst sich mit dem Protein Cdr2 (cerebellar 
degeneration-related protein 2) als potentieller Tumormarker für das papilläre 
Nierenzellkarzinom. Die beiden Projekte werden separat beschrieben und diskutiert mit 
einer allgemeinen Einführung über die Hypoxie zu Beginn. 
 
Die Verfügbarkeit von Sauerstoff war eine der Grundvoraussetzungen für die 
Entwicklung von höherem Leben. Multizelluläre Organismen benötigen Sauerstoff, um 
effizient ATP zu produzieren. Deshalb hat die Evolution Mechanismen zur adäquaten 
Anpassung bei Sauerstoffmangel (Hypoxie) hervorgebracht. Unser 
Forschungsschwerpunkt liegt auf den molekularen und zellulären Mechanismen der 
Sauerstoffmessung. 
Sauerstoffknappheit ist eine treibende Kraft für viele physiologische und 
pathophysiologische Prozesse, wie Höhenbergsteigen, die Bildung von roten 
Blutkörpern, Wundheilung, Krebs und auch neurodegenerativen Erkrankungen. 
Die molekularen Sauerstoffsensoren einer Zelle sind Prolyl-4-hydroxylase Domänen 
enthaltende Proteine (PHDs), die die Degradation des Hypoxie-induzierbaren Faktors  
(HIF) via sauerstoffabhängige Hydroxylierung regulieren. Unter normoxischen 
Bedingungen bindet der von Hippel-Lindau Tumor Suppressor (pVHL) an das 
hydroxylierte HIF, was zur poly-Ubiquitinierung und zum proteasomalen Abbau führt. 
In der Hypoxie ist der Kofaktor Sauerstoff limitiert und die Hydroxylierungsreaktion 
findet nur noch reduziert statt. Das stabilisierte HIF transloziert in den Zellkern und 
bildet mit seinem konstitutiven Bindungspartner HIF einen potenten 
Transkriptionsfaktor. Der Transkriptionsfaktor HIF reguliert mehr als 200 Gene, die in 
der Anpassung an veränderten Sauerstoffbedingungen involviert sind. Es gibt 
zunehmend Hinweise darauf, dass neben der sauerstoffabhängigen Proteinregulation 
von HIF, pro-inflammatorische Stimuli wie Stickstoffmonoxid oder Zytokine HIF auf 
der mRNA-Ebene regulieren.  
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Projekt I: 
Wir konnten kürzlich zeigen, dass die Peptidyl-Prolyl cis/trans Isomerase FKBP38 
spezifisch mit PHD2 interagiert und dessen Proteinstabilitiät negativ reguliert (Barth et 
al.). Zudem wurde gezeigt, dass Presenilin 1 und 2 (PSEN1/2) an FKBP38 binden und 
dessen anti-apoptotische Wirkung verringern können. Die gleiche Gruppe fand, dass 
Presenilin-defiziente Maus embryonale Fibroblasten (MEFs) mehr FKBP38 Protein 
exprimieren als die wildtyp Kontrollen (Wang et al. 2005). Diese Publikation weckte 
unser Interesse an der Erforschung der Rolle der Preseniline in der PHD/HIF-
Signalkaskade. 
PSEN1/2 sind die Hauptkomponenten des -Sekretasekomplexes, der eine Vielzahl von 
Proteinen, wie das Amyloid Precursor Protein (APP) oder Notch, spaltet. Die Proteolyse 
von APP führt zur Bildung von Amyloid beta (A), das in der Pathogenese der 
Alzheimers Erkrankung eine Rolle spielt. Gleichzeitig wird auch die Amyloid Precursor 
Intrazelluläre Domäne (AICD) gebildet, deren Funktion weitgehend unbekannt ist aber 
die in der Regulierung der Transkription involviert sein soll. 
Wir konnten zeigen, dass PSEN1/2-defiziente MEFs und der Kortex von Vorderhirn-
spezifischen konditionalen PSEN1/2 doppel knock-out Mäusen mehr FKBP38 Protein 
exprimieren und dass dies zu weniger PHD2 Protein führt. Während eine verringerte 
PHD2-Menge eine verstärkte hypoxische HIF-Akkumulierung erwarten lassen würde, 
fanden wir interessanterweise genau das Gegenteil. PSEN1/2 knock-out MEFs zeigten 
eine reduzierte HIF-Induktion in der Hypoxie, was auch zu einer reduzierten Expression 
der spezifischen HIF-abhängigen Zielgene führte. Während die HIF mRNA- und 
Proteinstabilität in den beiden Zelllinien gleich war, fanden wir weniger HIF-1 mRNA 
und eine verringerte HIF-1 Promotoraktivität in PSEN1/2 knock-out Zellen. Die 
proteolytische Funktion von PSEN1/2 war notwendig für eine normale HIF-Aktivierung. 
Faszinierenderweise beeinträchtigten die in Alzheimer Patienten beschriebenen 
Mutationen in PSEN1/2 die Hypoxieantwort auf unterschiedliche Weise. APP und die 
Generierung von AICD war entscheidend involviert in diesem Effekt. Zusammenfassend 
deuten unsere Daten auf eine direkte Rolle von PSEN1/2 über -Sekretase-abhängige 
Spaltung von APP/AICD in der Regulierung der Hypoxie Signalkaskade hin. 
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Bisher ist wenig über die biologische Funktion der Preseniline bekannt, so dass unsere 
Daten einen wichtigen Beitrag zu deren Verständnis leisten können. Mit steigender 
Lebenserwartung nimmt auch die Zahl der Alzheimerpatienten jährlich zu. Hypoxische 
Regionen im Gehirn korrelieren mit pathologischen Proteinablagerungen aber die 
Pathogenese ist weitgehend unbekannt. Unsere Resultate tragen deshalb zum 
Verständnis der Rolle von Hypoxie in der Pathologie von neurodegenerativen 
Erkrankungen bei. 
 
Projekt II: 
Neoplastische Expression des onconeuronalen Antigens Cdr2 is assoziiert mit 
cerebellären Degeneration in Brust- und Ovarkrebs. Die Cdr2 Protein Expression ist 
normalerweise auf Neuronen beschränkt, aber aberrante Cdr2 Expression in Tumoren 
kann zur Entwicklung einer Tumorimmunität führen, wobei das Krebswachstum 
beschränkt wird, was aber unglücklicherweise auch zu paraneoplastischer cerebellärer 
Degeneration führt. Bis jetzt wurde die Cdr2 Expression in Brust und Ovarkrebs 
beschrieben. Wir fanden eine starke Cdr2 Protein Exprimierung in 54.2 % der 
untersuchten papillären Nierenzellkrebs (pRCC) Tumoren im Vergleich zu einer viel 
niedrigeren Expression im klarzell Nierenzellkarzinom (ccRCC, 7.8%) (Balamurugan et 
al. 2009). Wir identifizierten PHD1 als neuen Cdr2 Interaktor und fanden eine erhöhte 
PHD1 Proteinmenge, wenn Cdr2 überexprimiert wurde. Die hohe PHD1 Proteinmenge 
korrelierten mit einer verminderten hypoxischen Antwort in Zelllinien wie auch in pRCC. 
Dies könnte eine Erklärung liefern, dass die pRCC die hypovaskulärste Nierenkrebsart 
ist. Interessanterweise korrelierte eine hohe Cdr2 Expression in ccRCC Patienten 
negativ mit ihren Überlebensraten. Diese Daten weisen auf eine wichtige neue Rolle 
von Cdr2 als prognostischer Marker für das Nierenzellkarzinom hin und die Interaktion 
mit Cdr2 könnte eine Erklärung für den hypovaskulären Phenotypen von pRCC liefern. 
Deshalb analysierten wir die PHD1 Expression in den zuvor mit Cdr2 gefärbten Tissue 
Microarray (TMA). Die PHD1 Proteinmenge war hoch in pRCC und korrelierte mit der 
zuvor gezeigten starken Cdr2 Färbung. Dies konnte im Immunoblot bestätigt werden. 
Die PHD1 Proteinexpression der kleineren, 40 kDa Isoform war in den pRCC höher als 
in den normalen Nieren. Zudem entwickelten wir enzymgekoppelte 
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Immunoadsorptionstest-assays (ELISAs) zur Detektierung von Cdr2 Antikörper in 
Patientenseren mit pRCC. Während Cdr2 Antikörper im Serum von Kontrollpatienten 
mit paraneoplastischer cerebellärer Degeneration detektiert wurden, konnten wir keine 
Cdr2 Antikörper in Seren von Patienten mit pRCC oder einem anderen RCC 
nachweisen. Da bisher keine pRCC-Patienten mit cerebellärer Degeneration 
beschrieben wurden, ist dieses Resultat auch nicht weiter erstaunlich. Zudem ist es mit 
dem Befund im Einklang, dass die aberrante Cdr2 Expression in Krebs nicht zwingend 
zu einer cerebellären Degeneration führen muss. 
GENERAL INTRODUCTION 
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General Introduction: Hypoxia 
Free oxygen on Earth was not available for many billions of years before the first 
photosynthetic organisms evolved about 3 – 4 billion years ago (Pavlov and Kasting 
2002). Initially, the oxygen in the oceans combined with dissolved iron and built banded 
iron formations. About 2.7 billion years ago, free oxygen started to outgas from the 
oceans and the period between 2.4 and 2.0 billion years has become generally known 
as the Great Oxygenation Event (GOE) (Barley et al. 2005). The availability of large 
amounts of free and dissolved oxygen may have allowed the aerobic organisms to 
produce more ATP than the anaerobic organisms, helping them to dominate Earth’s 
atmosphere. The development of eukaryotic cells, complex multicellular organisms and 
ultimately plants and animals is highly intertwined with the evolution of photosynthesis 
and cellular respiration of oxygen. 
Life has become highly dependent on oxygen and low oxygen partial pressures or 
hypoxia represent a major stress to cells and organisms. Hypoxia has many features 
and is involved in a wide range of physiological and pathophysiological processes such 
as adaptation to high altitude, glucose metabolism, wound healing as well as apoptosis, 
cancer and neurodegenerative processes. Scientific studies of adaptation to high 
altitude started in the 1860s when Viault counted his red blood cells before going and 
after adaptation to high altitude (Viault 1890). It then took almost 100 years until Allen 
Erslev discovered the responsible humoral factor, known today as erythropoietin (EPO) 
(Erslev 1953). A keystone in the elucidation of the molecular mechanism was the 
identification of the hypoxia inducible factor (HIF) by the discovery of a 3’ flanking 
sequence in the erythropoietin gene that was sufficient for the expression of EPO under 
hypoxic conditions (Semenza and Wang 1992).  
 
1 The Hypoxia-Inducible Factor (HIF) 
1.1 Structure and Expression 
One of the key oxygen sensors within the cell is the hypoxia-inducible transcription 
factor (HIF). HIF was purified in 1995 when Wang and Semenza characterized its 
hypoxic DNA binding activity (Wang and Semenza 1995). HIF is a heterodimeric 
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transcription factor consisting of an oxygen labile HIF- subunit and an oxygen 
insensitive HIF- subunit, also known as aryl hydrocarbon receptor nuclear translocator 
(ARNT). Both subunits are members of the basic helix-loop-helix Par/Arnt/Sim (bHLH-
PAS) transcription factor family (Wang and Semenza 1995). In mammals, three HIF-
isoforms have been found: HIF-1, HIF-2 (also known as endothelial PAS domain 
protein (EPAS)1 or HIF-1like factor (HLF)) and HIF-3, all heterodimerizing with  
HIF-. While HIF-1 is ubiquitously expressed in all tissues and organs, HIF-2 is 
primarily expressed in vascular endothelial cells, fibroblasts and epithelial cell lines 
(Tian et al. 1997; Wiesener et al. 1998)  and HIF-3 is predominantly expressed in the 
kidney (Hara et al. 2001). HIF- consists of an N-terminal bHLH domain which is 
essential of DNA binding and a PAS domain that is responsible for dimerization with 
ARNT (Jiang et al. 1996). The N-terminal and C-terminal oxygen-dependent 
degradation domains (NODDD and CODDD) are required for the oxygen-regulated 
degradation of HIF-. The ODDD contains two conserved proline residues (P402 and 
P564 in HIF-1). Additionally, two transactivation domains (TADs) are found within HIF-
1 and 2. The C-terminal domain is responsible for the recruitment of transcriptional 
co-activators and the expression of target genes (Jiang et al. 1996). HIF- contains a C-
terminal nuclear localization sequence (NLS). 
 
Fig.1. Schematic representation of the HIF family member protein domains (Dayan et al. 2008). 
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Genetic ablation of HIF-1 results in embryonic lethality at day (E)11. Hif1a-/- embryos 
display developmental arrest with a defective neural tube, cardiovascular 
malformations, cell death within the cephalic mesenchyme and defective neural crest 
cell migration (Compernolle et al. 2003; Iyer et al. 1998). On the other hand, viable Hif-
2a-deficient mice have been reported to have a syndrome of multiple-organ pathology 
and altered gene expression patterns together with enhanced generation of reactive 
oxygen species (ROS) (Scortegagna et al. 2003). Other studies revealed that HIF-2a 
knockout results in neonatal death proceeded by vascular disorganization, cardiac 
malfunction and insufficient production of surfactant that is likely to be fatal 
(Compernolle et al. 2002; Peng et al. 2000; Tian et al. 1998). Genetic ablation of the 
HIF-3 subunit in mice has not yet been reported. 
1.2 Regulation 
1.2.1 Oxygen-dependent Regulation of HIF Protein Stability 
The HIF- protein stability, but not HIF- mRNA expression, is tightly and directly 
regulated by the availability of oxygen. HIF- subunits undergo rapid oxygen-dependent 
degradation via the ubiquitin-proteasome pathway (Kallio et al. 1999; Salceda and Caro 
1997). In normoxia, two prolines (HIF-1: 402 and 564) within the ODD of the human 
HIF- protein are hydroxylated by specific HIF prolyl-4-hydroxylases (PHDs). This 
hydroxylation is a prerequisite for binding of the von Hippel Lindau pVHL tumor 
suppressor protein complex (Maxwell et al. 1999) and subsequent destruction by the 26 
proteasome. When oxygen becomes limiting, the prolyl hydroxylation reaction is 
inhibited and the stabilized HIF- translocates to the nucleus where it heterodimerizes 
with HIF- (Kallio, et al. 1998; Jewell et al. 2001). Normoxic HIF- stabilization due to 
loss of pVHL was documented in vascular tumors like clear cell renal cell carcinoma 
(ccRCC), hemangioblastoma and pheochromocytoma (Maxwell et al. 1999). The 
heterodimeric HIF transcription factor binds to hypoxia responsive elements (HRE) 
within the promoter and enhancer region of its target genes (Wenger 2002). 
In addition to prolyl hydroxylation, HIF-is hydroxylated in oxygenated cells at a specific 
asparagine residue (hHIF-1: Asn803) by another hydroxylase named factor inhibiting 
HIF (FIH) (Lando et al. 2002; Mahon et al. 2001). This hydroxylation blocks the 
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interaction of HIF with the coactivators p300 and CBP (Lando et al. 2002). Like the 
PHDs, FIH activity is inhibited under hypoxia, allowing HIF to act as a powerful 
transcription factor. 
 
Fig.2. Oxygen-dependent regulation of HIF-1 (Metzen and Ratcliffe 2004) Under normoxia, HIF-1 
is hydroxylated on two conserved prolines which leads to the recognition by pVHL and ubiquitin-
mediated proteasomal degradation. The availability of oxygen also results in hydroxylation of an 
asparagine residue by FIH which inactivates the C-terminal transactivation domain. Since the 
hydroxylase activity is inhibited in hypoxia, HIF-1 is stabilized, translocates to the nucleus where HIF-
1 and p300/CBP are recruited to activate the transcription of its target genes. 
 
1.2.2 Oxygen-independent Regulation 
Besides the oxygen-dependent post-translational regulation of HIF-, a number of other 
mechanisms contribute to the regulation of HIF. S-nitrosylation of the cysteine residue 
800 (C800) has been reported to activate the interaction between stabilized HIF-1 and 
the co-activator CBP/300, eventually stimulating the transactivation of the HIF-complex 
(Yasinska and Sumbayev 2003). Another mechanism that has been shown to increase 
HIF transcriptional activity is via the phosphorylation of threonine 796 and of the serine 
641 and 643 by the mitogen-activated protein kinases (MAPKs) (Lancaster et al. 2004; 
Richard et al. 1999; Sang et al. 2003). Conflicting results about SUMOylation increasing 
or decreasing HIF- stability have been reported (Bae et al. 2004; Berta et al. 2007; 
Carbia-Nagashima et al. 2007; Cheng et al. 2007). A recent study showed that 
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sumoylation increases HIF-1 stability, thereby improving brain stem cardiovascular 
regulation in experimental rat models of brain death (Chan et al. 2011). There is 
growing evidence that hormones and cytokines like IL1-, TNA- as well as ROS and 
LPS can regulate normoxic HIF-1 mRNA levels via a conserved NFB site in the 
HIF1a promoter (Bonello et al. 2007; Frede et al. 2006; Gonzalez-Perez et al. 2010; 
Görlach 2009; Qian et al. 2004). A variety of oncoproteins, and growth factors have 
been shown to regulate normoxic HIF-1 synthesis via the activation of the 
phosphatidylinositol 3-kinase (PI3K) or mTOR pathways (Fukuda et al. 2002; Zhong et 
al. 2000), reviewed in (Semenza 2003).  
Furthermore, the inhibitory PAS domain protein (IPAS), an alternative splice variant of 
HIF-3, acts as a dominant negative transcription factor that represses HIF- activity 
(Makino et al. 2001). 
 
2 The Prolyl-4-Hydroxylases 
The identification and characterization of the first HIF prolyl-4-hydroxylase resulted from 
work in C. elegans where it was named egg-laying abnormal 9 (EGL-9) (Epstein et al. 
2001). Three ortholog isoforms could be identified in humans and were named PHD1 
(alternatively termed egl nine homolog EGLN2 or HIF prolyl-hydroxylase (HPH) 3), 
PHD2 (EGLN1, HPH2), and PHD3 (EGLN3, HPH1) (Bruick and McKnight 2001; Ivan et 
al. 2002). In addition, a fourth PHD-related protein (PH-4) with an endoplasmic 
reticulum transmembrane domain has been identified (Koivunen et al. 2007; Oehme et 
al. 2002). PH-4 is capable of hydroxylating HIF- in vitro and in cultured cells but it 
remains to be established whether it also participates in the regulation of HIF- in vivo . 
2.1 PHD1 
PHD1 is located on chromosome 19q13.2 and encodes a 407 AA protein. Its mRNA is 
ubiquitously expressed but most abundant in testis (Lieb et al. 2002). GFP-tagged 
PHD1 overexpression experiments suggested that PHD1 is mainly localized in the 
nucleus (Metzen et al. 2003). Other studies using monoclonal PHD1 antibodies showed 
predominantly cytoplasmic localization (Soilleux et al. 2005). Homozygous knock out of 
PHD1 facilitated HIF-1-mediated cardio-protection in ischemia/reperfused myocardium 
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and protected against the development of colitis though reduced epithelial apoptosis 
and increased barrier function (Adluri et al. 2011; Tambuwala et al. 2010) (Schneider et 
al. 2010). Furthermore, genetic ablation and inhibition of PHD1 was shown to induce 
hypoxia tolerance by reprogramming basal metabolism and therefore protecting 
myofibres against lethal ischemia (Aragonés et al. 2008).  
2.2 PHD2 
The PHD2 gene is located on chromosome 1q42-43 and encodes a 426 AA protein. Its 
mRNA is ubiquitously and abundantly expressed (Lieb et al. 2002). In non-malignant 
tissue, PHD2 is mainly localized in the cytoplasm but increases nuclear expression was 
observed in less differentiated types of cancer cells (Jokilehto et al. 2006). Since only 
PHD2, but not PHD1 or PHD3, knock out embryos die between E12.5 and E14.5, PHD2 
is often regarded as the main regulator of HIF (Minamishima et al. 2008; Takeda et al. 
2008). Mutations in the PHD2 gene have been demonstrated to cause erythrocytosis, a 
familial hereditary disease characterized by excessive production of erythrocytes 
(Ladroue et al. 2012; Percy et al. 2006)  
2.3 PHD3 
The PHD3 gene is located on chromosome 14q13.1 and encodes a 239 AA protein. Its 
mRNA is ubiquitously expressed and particularly abundant in heart and liver (Lieb et al. 
2002). PHD3 was shown to be localized both in the cytoplasm and the nucleus  
(Soilleux et al. 2005). PHD3 knock-out mice show reduced neuronal apoptosis, 
abnormal sympathoadrenal development and reduced blood pressure (Bishop et al. 
2008). Addionally PHD3 was shown to be essential for hypoxic regulation of neutrophilic 
inflammation and that loss of PHD3 enhances the innate immune response to 
abdominal sepsis (Kiss et al. 2012; Walmsley et al. 2011). 
2.4 PHD-interacting Proteins 
Screening for novel PHD interacting proteins, a number of candidates have been 
identified in the last years that affect PHD stability, enzymatic activity and function in 
different ways. Characterized PHD interacting proteins are listed in Fig. 3 (Wenger et al. 
2009).  
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Fig.3. Simplified schematic overview on the PHD interacting proteins and their function (Wenger et al. 
2009). 
 
In our previous studies, we found the FK506-binding protein FKBP38 to specifically 
interact with PHD2 and to regulate PHD2 protein stability (Barth et al. 2009; Barth et al. 
2007). Furthermore, we showed that the cerebellar degeneration-related antigen Cdr2 
interacts PHD1 and leads to a blunted hypoxic response (Balamurugan et al. 2009). 
This thesis is based on this previous work from our group and was divided into two 
projects that will be discussed separately. 
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4 Aims of the Thesis 
Project I 
The first aim of this thesis was to investigate the role of presenilin 1 and presenilin 2 in 
the regulation of the PHD/HIF signaling pathway. 
Project II 
The aim of the second project was to characterize Cdr2 as a potential marker for 
papillary renal cell carcinoma. 
 
Project I: Presenilin Function in the Oxygen Sensing Pathway 
1 Introduction 
1.1 FKBP38 
1.1.1 Discovery and Structure 
The FK506binding protein 38 (FKBP38) is a member of the FKBP family that binds the 
immunosuppressive drug FK506. FK506-binding proteins belong to the superfamily of 
PPIases together with cyclophilins (Cyps), parvulins and the recently found protein 
serine/threonine phosphatase 2a (PP2A) (Barik 2006). The name FK506 comes from 
the catalogue number of Fermentek, the company that synthesized Tacrolimus, a 
macrolid lactone of the gram-positive bacteria Streptomyces tsukubaensis that was 
discovered in 1984. FKBP38 was first described in 1995 by (Lam et al. 1995). Novel 
FKBP homologs were identified by screening Jurkat cDNAs that contain the DNA 
sequence for the well conserved second -sheet region of FKBP12 from AA26 to 34 
(Lam et al. 1995). A cDNA was found that encodes a 38 kDa protein that is 33% 
identical to FKBP12. It later turned out that the 38 kDa resulted from a truncated open 
reading frame. A 47 AA encoded extended open reading frame of FKBP38 was found 
and named FKBP8 (Nielsen et al. 2004). 
The human FKBP38 gene is located on chromosome 19p12. FKBP38 contains a 
PPIase domain, three 34 AA long tetratricopeptide repeat domains (TPRs) similar to 
FKBP52, a CaM binding site and a transmembrane domain (TM) at the C-terminus. 
FKBP38 is an integral membrane protein located in the mitochondria and ER 
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membranes exposed to the cytosolic side. FKBP38 was suggested to be cell type 
specifically posttranslationally modified during development (Bulgakov et al. 2004).  
 
Fig.1. FKBP38 protein structure. Schematic diagram of functional domains. Other FKBP38.interacting 
domains are also shown.  FKBD = FK binding domain, TRP = tetratricopeptide repeat domains, CBD = 
calmodulin binding domain, TM = transmembrane domain (Kang et al. 2008). 
 
FKBP38 is ubiquitously expressed with highest levels in brain, followed by moderate 
expression in the heart, lung, skeletal muscle and pancreas. FKBP38 protein is widely 
expressed  in murine embryonic and adult tissues as well as in human cancer cell lines 
(Bulgakov et al. 2004; Kang et al. 2005).  
FKBP38 is distinct from its other family members as it lacks the conserved amino acid 
tryptophan (W) at position 59 and has instead a Leucin (L). Tryptophan forms the basis 
of the hydrophobic FK506 drug-binding cavity. It is therefore thought that FKBP38 does 
not contain a PPIase activity (Lam et al. 1995). FKBP38 alone does not show in vitro 
cis/trans isomerase activity. However, it absolutely requires Ca2+ and CaM as co-factors 
to function as an active enzyme (Edlich et al. 2005). 
Genetic disruption of FKBP38 resulted in embryonic lethality at embryonic day E13.5 
(Bulgakov et al. 2004). Detailed analysis revealed defects in the development of the 
central nervous system. The phenotype seems to comparable to constitutively active 
sonic hedgehog signaling pathway (SHH) or inhibition of the SHH antagonist protein 
kinase A (PKA) (Perron et al. 2003).  
1.1.2 Functions and Regulation of FKBP38 
FKBP38 was shown to have multiple functions in cell regulatory processes such as cell 
signaling, apoptosis, cell growth and proliferation. 
FKBP38 was proposed to play a role in apoptosis by binding to the anti-apoptotic 
protein Bcl-2 but its mechanism and relevance are still under debate (Shirane and 
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Nakayama, 2003). A recent study demonstrated that the binding of FKBP38 to Bcl-2 is 
mainly mediated by the charge-sensitive loop near the putative active site of FKBP38 
(Haupt et al. 2012). In HeLa cells, FKBP38 targets Bcl-2 as well as Bcl-xL to 
mitochondrial membranes thereby facilitating Bcl-2 and Bcl-xL in their antiapoptotic role 
(Shirane and Nakayama 2003). FKBP38 downregulation by RNAi strongly reduced 
HeLa cell viability and greatly enhanced caspase-3 activity as well as PARP cleavage 
(Kang et al. 2005). FKBP38 has been shown to play a role in the mTOR pathway by 
competing with Rheb for mTOR binding (Bai et al. 2007; Rosner et al. 2003). Under 
conditions of sufficient nutrients, GTP-Rheb was shown to accumulate and prevent 
FKBP38 binding to mTOR and activate the phosphorylation of the mTOR targets S6K 
and 4E-BP. Therefore, FKBP38 might function as an endogenous mTOR inhibitor by 
interfering with Rheb and modulating cell growth and size. Overexpression of FKBP38 
has been observed in various human cancer cells and tumor tissues, such as breast, 
colon, liver, lung, lymph node, prostate and stomach cancers (Choi et al. 2010) (Kang et 
al. 2005). Furthermore, Edlich et al. reported a Ca2+/CaM dependent interaction of 
FKBP38 with Bcl-2 that is blocked by Hsp90 binding to FKBP38. However, they propose 
that FKBP38 promotes cell death in SH-SY5Y neuroblastoma cells (Edlich et al. 2005; 
Erdmann et al. 2007). FKBP38 was shown to have an intrinsic inhibitory effect on 
calcineurin (Shirane and Nakayama 2003). Tagged isolated FKBP38 from HeLa cells 
reduced the dephosphorylation capacity of calcineurin on synthetic phosphopeptide of 
RII subunit of PKA. Contrary to Shirane et al., other groups did not observe the 
inhibitory effect on calcineurin phosphatase activity by FKBP38 in vitro (Kang et al. 
2005; Weiwad et al. 2005). More recently, FKBP38 was proposed t promote the folding 
of cystic fibrosis transmembrane conductance regulator (CFTR) in the ER and therefore 
to play a role in membrane protein biogenesis (Banasavadi-Siddegowda et al. 2011).  
We previously identified FKBP38 to specifically interact with PHD2 and to negatively 
regulate its protein stability (Barth et al. 2009; Barth et al. 2007). Protein stability of 
FKBP38 and Bcl-2 was shown to be determined by presenilin 1 and 2 (PSEN1 and 
PSEN2) and genetic ablation of PSEN1/2 increased FKBP38 and Bcl-2 protein 
abundance, rendering cells less susceptible to apoptotic stimuli (Wang et al. 2005). 
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1.2 Presenilins 
1.2.1 Structure, Expression and Function 
Presenilins (PSEN) were discovered through their linkage to early onset familial 
Alzheimer’s disease (FAD) in 1995 (Sherrington et al. 1995). PSEN1 is localized on 
chromosome 14q24.3 and PSEN2 on 1q31-q42. The PSEN1 gene was found by direct 
cDNA selection of yeast artificial chromosomes comprising the putative chromosomal 
region. Subsequently, the PSEN2 gene was identified due to its high sequence 
homology with PSEN1 and its location with the candidate regions was defined in AD 
linkage studies. Two years after its discovery, PSEN1 was shown to be essential for the 
generation of the Notch intracellular domain (NICD) in C. elegans (Wong et al. 1997). 
Subsequent research elucidated the function of PSEN as the catalytic subunit of the -
secretase complex (reviewed in De Strooper and Annaert 2010).  
PSEN 1 and 2 contain 9 transmembrane domains and are cleaved in a N-terminal (27-
30 kDa) and C-terminal (16-18 kDa) fragment that remain associated with the complex 
(Henricson et al. 2005). Whereas PSEN1 is uniformly expressed throughout the brain 
and in peripheral tissues, PSEN2 expression in the brain is relatively low, except in the 
corpus collosum. PSEN2 is highly expressed in some peripheral tissues, such as 
pancreas, heart and skeletal muscle (Rogaev et al. 1997). PSEN1 knockout is 
embryonically lethal and resembles the Notch knockout phenotype, indicating its 
essential role during development (De Strooper et al. 1998; Shen et al. 1997; Wong et 
al. 1997). PSEN2 ablation leads to a mild pulmonary phenotype and no changes in 
amyloid precursor protein (APP) processing suggesting that PSEN1 and 2 have at least 
partially overlapping functions in vivo but that PSEN1 is essential for normal Notch 
signaling (Herreman et al. 1999). Several groups made  
PSEN1+/-/PSEN2-/- or forebrain-specific conditional knockout mice to study the role of 
PSEN in long term development and brain function (Donoviel et al. 1999; Saura et al. 
2004). These studies have shown that besides the central nervous system, the skin 
(Soriano et al. 2001; Xia et al. 2001) and the immune system (Beglopoulos et al. 2004; 
Tournoy et al. 2004) are severely affected by the loss of PSEN1/2.  
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Fig.2. Presenilin nine-transmembrane domain structure. A view on the reported PSEN1 mutations (red) 
and the nine-transmembrane domain structure. Drawing by R. Crook (Hardy 2007) 
1.2.2 Presenilins and the -Secretase Complex 
The -secretase complex is a intramembrane multisubunit protease consisting of either 
PSEN1 or PSEN2, presenilin enhancer 2 (Pen-2), nicastrin (NCT), anterior pharynx 1 
(Aph-1) that cleaves many type I transmembrane proteins (De Strooper et al. 1999; 
Parks and Curtis 2007). Pen-2 is a small hairpin-like protein with a molecular weight of 
~12 kDa (Francis et al. 2002). NCT is a 130 kDa type I integral membrane glycoprotein 
and Aph-1 is a ~25 kDa protein with 7 TM-domains (Goutte 2002; Yu et al. 2000). 
Extensive reconstitution studies in mammalian and yeast cells have demonstrated that 
all four proteins are necessary and sufficient for the generation of an active -secretase 
(Edbauer et al. 2003; Kimberly et al. 2003). The -secretase belongs to an unique group 
of intramembrane-cleaving proteases (I-CLiPs) (Wolfe and Kopan 2004). Electron 
microscopy studies revealed that the -secretase complex forms a large spherical 
structure containing two small central cavities with opposite orientations (Lazarov et al. 
2006). These small extracellular and cytoplasmic openings were proposed to be exit 
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sites for cleavage products from the water-containing cavity. Supporting these findings, 
succeeding studies demonstrated that the active-site region in PSEN’s TMD6 and 
TMD7 are water accessible (Sato et al. 2006; Tolia et al. 2006) and that the TMD9 and 
the hydrophobic domain in the large cytoplasmic loop of PSEN are dynamic parts of the 
water-containing cavity (Tolia et al. 2008). A recent study showed that the first 
hydrophobic region in TMD1 is facing the catalytic pore, indicating a functional role in 
the catalytic pore structure (Takagi et al. 2010). 
 
Fig.3. PSEN/-secretase complex (Haapasalo and Kovacs 2011). The -secretase consists of four 
components, PSEN 1 or 2, Nicastrin, Aph-1 and Pen-2.  
 
The most prominent targets of the -secretase are the amyloid- (A) precursor protein 
(APP) and Notch but to date, more than 90 substrates have been described (Haapasalo 
and Kovacs 2011). Some of the well-known substrates are listed in table 1 and are 
extensively described in (Haapasalo and Kovacs 2011). 
 
Substrate Function -secretase product 
Alcadein  Regulation of APP signaling and processing 1. -Alc 
2. Alc-ICD 
APLP1 Synaptogenesis 1. ALID1 
2. p3-like fragment 
APLP2 Neurite outgrowth 1. ALID2 
2. p3-like fragment 
3. A-like fragment 
ApoER2 Lipid metabolism ApoER2ICD 
APP Cell adhesion, neurite outgrowth, protein transport 
(?) 
1. A 
2. AICD 
3. p3 
CD44 Cell adhesion, hyaluronan receptor 1. CD44-ICD 
2. CD44- 
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Delta1 Notch ligand, cell fate determination DICD 
E-Cadherin Cell adhesion E-Cad/CTF2 
EphrinB1 Cell-cell adhesion eB1ICD 
EphrinB2 Axon guidance ephrinB2-CTF2 
ErbB4 Cell proliferation, differentiation, apoptosis, 
myelination 
E4ICD 
IGF-1R Insulin-like growth factor 1 receptor IGF-1R-ICD 
Jagged 2 Notch ligand, cell fate determination JICD 
N-Cadherin Cell adhesion, synapse formation and maintenance N-cad/CTF2 
Neuregulin-1 ErbB receptor ligand, regulation of Schwann cell 
proliferation 
NRG1-ICD 
Notch 1-4 Signaling receptor, cell fate determination NICD 
p75
NTR
 Neurotrophin receptor, cell survival/death, cell 
migration, axon guidance 
p75-ICD 
Syndecan 1-3 HSP, neurite outgrowth, cell migration, learning, 
memory 
SICD/ n.d. 
VEGF-R1 Angiogenesis VEGF-R1-ICD 
Table 1. PSEN/-secretase substrates and the proposed roles of their cleavage products (modified from 
(Haapasalo and Kovacs 2011). 
 
1.2.3 Amyloid Precursor Protein Processing 
The APP gene is located on chromosome 21 and encodes a 770 AA protein (Goldgaber 
et al. 1987). APP is a single pass type I transmembrane protein that undergoes 
sequential cleavage via two different pathways with functionally different outcomes (De 
Strooper and Annaert 2000). The primary cleavage occurs by either the - or the -
secretase and leads to the generation of the extracellular domain (sAPP). Subsequent 
intramembrane processing of the remaining membrane tethered C-terminal fragment by 
the -secretase complex releases the APP intracellular domain (AICD). Initial cleavage 
by -secretase occurs within the A domain, generating the secreted sAPP fragment 
with neurotrophic properties and thus preventing the generation of toxic A peptide 
(Hardy 1992). Therefore, it is also referred to as the “non-amyloidogenic pathway” 
(Lammich et al. 1999). Sequential cleavage by - and -secretase releases the A 
peptide that has neurotoxic properties and is believed to be central to AD as postulated 
in the amyloid cascade hypothesis (Hardy and Selkoe 2002).  
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The physiological function of APP is incompletely understood but it has been shown to 
be important in early development, such as mediating cell adhesion, cell migration and 
synaptogenesis (reviewed in Guo et al. 2012). APP ko mice are viable and fertile 
despite reduced body and brain weight (Müller et al. 1994), increased levels of copper 
and iron in the liver and cerebral cortex (Duce et al. 2010; White et al. 1999) and suffer 
from lower forelimb grip strength, impaired locomotor activity and passive learning 
avoidance (Dawson et al. 1999; Senechal et al. 2008). 
While the function of A in the pathogenesis of AD is widely studied, the role of AICD is 
less well understood. Since AICD was discovered only 23 years after the identification 
of APP (Ohsawa et al. 1999) and it is rapidly degraded after release from the membrane 
(Cupers et al. 2001; Edbauer et al. 2002), research on AICD is lagging behind. AICD 
has been proposed to be involved in transcriptional regulation, in a manner analogous 
to Notch signaling. The first hint that AICD might be involved in transcriptional regulation 
came from Gal4-DBD-AICD fusion construct experiments in yeast (Cao and Sudhof 
2001). In subsequent studies, several genes regulated by AICD have been identified, 
including KAI1 (Baek et al. 2002), glycogen synthase 3 (Kim et al. 2003), Neprilysin 
(Belyaev et al. 2009) APP and BACE (von Rotz et al. 2004), cyclins B1 and D1 (Ahn et 
al. 2008), the vesicular glutamate transporter VGLUT2 (Schrenk-Siemens et al. 2008) 
and C/ebP homologous protein (CHOP) (Takahashi et al. 2009). Addionally, EGF 
receptor and LRP1 were described to be downregulated by AICD (Liu et al. 2007; 
Zhang et al. 2007). 
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Fig.4. Simplified schematic presentation of APP processing. The first cleavage occurs by either the - 
or the -secretase that releases the extracellular domain (sAPP). Subsequent processing by the -
secretase. leads to the generation of the amyloid precursor intracellular domain (AICD). Initial 
secretase cleavage occurs with the A domain, generating the sAPPa fragment. Cleavage by the  and 
-secretase leads to the generation of the neurotoxic A peptide. 
 
1.2.4 Notch and Other -Secretase Substrates 
Besides the growing list of proteins that are cleaved by the -secretase, the Notch 
receptors (Notch 1-4) are amongst of the most well known and important substrates of 
the -secretase (De Strooper et al. 1999; Donoviel et al. 1999; Herreman et al. 2000; 
Wong et al. 1997). Notch is an evolutionary conserved transmembrane receptor that is 
involved in the regulation of many developmental aspects such as cell fate and stem 
cell maintenance. Notch functions at the cell surface and mediates cell-cell signaling 
interactions to specify cell fates during development (Bray 2006).  
The dysregulation of the Notch pathway is involved in a wide range of human disorders 
and cancer progression and Notch inhibition is a promising approach for cancer 
treatment (Purow 2012). 
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The Notch receptor is activated by binding to a ligand presented by a neighboring cell. 
Upon ligand binding, Notch gets cleaved by a membrane tethered metalloprotease 
(ADAM). Subsequent -secretase cleavage releases the Notch intracellular domain 
(NICD) and N (De Strooper et al. 1999). NICD then translocates to the nucleus 
where it associates with the DNA-binding protein CSL (CBF1/FBPjk/Su(H)/Lag-1) 
(Schroeter et al. 1998). Upon NICD binding, allosteric changes occur in CSL that 
facilitate displacement of transcriptional repressors and the recruitment of co-activators 
that leads to the transcription of target genes. PSEN1 knockout or PSEN1/2 double 
knockout mice  have defects reminiscent of Notch knockout phenotypes (De Strooper et 
al. 1998; Shen et al. 1997; Wong et al. 1997). 
 
Fig.5. Simplified schematic presentation of Notch processing. Upon Notch ligand binding, ADAM-type 
metalloprotease and subsequent intramembrane -secretase cleavages release the Notch intracellular 
domain (NICD). NICD drives the expression of its target genes such as Hey, Hes and SNAIL.  
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1.2.5 -Secretase Independent Functions of Presenilins 
PSENs were described to have -secretase independent functions but it is difficult to 
provide strong evidence since genetic knock-out models of PSEN and pharmacological 
inactivation of -secretase are difficult to compare in vivo (Wakabayashi et al. 2008). 
The described -secretase independent functions rely mostly on its ability to interact 
with other proteins. PSEN was found in complex with -catenin and other members of 
the armadillo family (Zhang et al. 1998; Zhou et al. 1997). Some of the most notable -
secretase independent roles of PSEN are the regulation of calcium homeostasis, insulin 
and PI3K signaling (Maesako et al. 2011) reviewed in (LaFerla 2002). The first 
description of a Ca2+ defects in fibroblasts from AD patients dates back to 1994, even 
before the discovery of PSEN (Ito et al. 1994). Subsequent work clearly showed that 
PSENs are involved in Ca2+ homeostasis but full mechanistic insight is still missing 
(Bezprozvanny and Mattson 2008; De Strooper and Annaert 2010). 
PSEN-deficiency has been shown to lead to a sorting defect of intracellular adhesion 
molecule 5 (ICAM 5) or telecephalin (Esselens et al. 2004), epidermal growth factor 
receptor (EGFR) (Repetto et al. 2007) and 1 integrin (Zou et al. 2008). More recently, 
PSEN1 was suggested to be involved in the maturation of the V0a subunit and 
subsequent assembly of the V-APTase proton pump (Lee et al. 2010). Further evidence 
that PSEN might be involved in membrane trafficking comes from a report that shows 
that several members of the Rab family of small GTPases bind to PSEN (Dumanchin et 
al. 1999). 
1.2.6 Presenilins in Alzheimer’s Disease 
Alzheimer’s disease is the world’s most common neurodegenerative disease (Selkoe 
2001). It is estimated that about 18 million people worldwide are currently suffering from 
AD. While the molecular mechanism of disease progression is not fully understood, the 
main risk factor of AD is ageing. With increasing life expectancy, the number of patients 
is predicted to be double by 2025.  
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Histopathology of Alzheimer’s Disease 
In 1906, the German psychiatrist Alois Alzheimer was the first to describe the symptoms 
of a disease that was later named after him. One of his patients suffered from 
“progressive memory impairment, disordered cognitive function, altered behavior 
including paranoia, delusions, loss of social appropriateness and a progressive decline 
in language function” – symptoms that are still relevant for diagnosis more than 100 
years later. Postmortem analysis of the brain of the first AD patient, Auguste D revealed 
cerebral atrophy, “many fibrils” in the cell and “military foci” all over the cortex.. The 
lesions that Alzheimer reported are still the pathological hallmarks of AD and are 
described as neuronal cell loss, intracellular accumulation of neurofibrillary tangles and 
the extracellular accumulation of senile plaques. The senile plaques are composed of 
the 4 kDa A40 and the more amyloidogenic A42, highly hydrophobic peptides that 
aggregates to form oligomers (for review see Hardy et al. 2002).  
Genetics of Alzheimer’s Disease 
5 – 10% of AD cases are genetically inherited as familial AD (FAD) while the majority of 
the cases are sporadic (Selkoe 2001). Most FAD cases are caused by mutations in the 
PSEN1 gene whereas mutations in the amyloid precursor protein (APP) and PSEN2 are 
rather rare. To date, more than 170 coding single nucleotide polymorphisms (SNPs) in 
PSEN1 have been identified in 370 AD families, with onset ranging between 16 and 65 
years of age. SNPs in PSEN2 are variably penetrant and rare, despite significant 
structural similarities with PSEN1. Only 10 PSEN2 mutations in 18 AD families have 
been reported (www.molgen.ua-ac.be/ADMutations). Most of the known mutations 
cause amino acid substitution and result in the relative increase in the ratio of the -
amyloid 42 (A)42 to A40 peptides (Scheuner et al. 1996). Since this can be caused by 
either an increase in A42 or a decrease in A40, there is an ongoing debate whether 
clinical mutations cause a “gain of function” or rather a “loss of function” -secretase 
activity (Bertram et al. 2010). Bentahir et al significantly contributed to the 
understanding of altered -secretase function of PSEN mutations by expressing clinical 
relevant mutants in PSEN deficient cells (Bentahir et al. 2006). Their study revealed a 
(partial) loss of function in all investigated clinical mutants. This was the consequence of 
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either lowering A40 or increasing A42 or both. The cleavage of other analyzed -
secretase substrates such as Notch, syndecan and N-cadherin were differentially 
affected by the clinical mutations. 
In contrary to the cases of FAD, the reasons for developing sporadic AD are unclear. It 
is discussed that the balance between generation and clearance of A is altered by 
aging but further investigations are required the cause of sporadic AD. Whether A 
clearance is sufficient or clinical benefits over time is currently evaluated in AD patients 
who received active vaccination (Holmes et al., 2008). 
 
2 Working Hypothesis 
A recent publication showed that PSEN1/2 interact with FKBP38 and hence promote 
apoptosis by reducing mitochondrial Bcl-2 (Wang et al. 2005). Wang et al. demonstrate 
that FKBP38 and PSEN1/2 form macromolecular complexes together with the anti-
apoptotic Bcl-2. PSEN1/2 thereby promote the degradation of FKBP38 and Bcl-2 and 
sequester these proteins from the mitochondria to the the ER/Golgi compartments.  
They suggest that PSEN1/2 increase by this means the susceptibility to apoptosis. 
Furthermore, FAD-linked PSEN1/2 mutants were shown to enhance the pro-apoptotic 
activity by causing more efficient reduction in mitochondrial Bcl-2 than wt PSEN1/2. Our 
previous results on PHD2 regulation by FKBP38  together with this report let us 
hypothesize that PSEN1/2 might be involved in proteolytic PHD2 regulation and in the 
regulation of the oxygen sensing pathway in general. 
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Abstract 
Presenilin (PSEN) 1 and 2 are the catalytic components of the -secretase complex 
which cleaves a variety of proteins, including the amyloid precursor protein (APP). 
Proteolysis of APP leads to the formation of the APP intracellular domain (AICD) and 
amyloid beta that is crucially involved in the pathogenesis of Alzheimer’s disease. 
Prolyl-4-hydroxylase-domain (PHD) proteins regulate the hypoxia-inducible factors 
(HIFs), the master regulator of the hypoxic response. We previously identified the 
FK506 binding protein 38 (FKBP38) as a negative regulator of PHD2. Genetic ablation 
of PSEN1/2 has been shown to increase FKBP38 protein levels. Therefore, we 
investigated the role of PSEN1/2 in the oxygen sensing pathway using a variety of 
genetically modified cell lines, mouse tissues and pharmacological inhibitors. Increased 
FKBP38 protein levels and decreased PHD2 protein levels were found in PSEN1/2-
deficient mouse embryonic fibroblasts (MEFs) and in the cortex of forebrain-specific 
PSEN1/2 conditional double knock-out mice. Hypoxic HIF-1 protein accumulation and 
transcriptional activity were decreased, despite reduced PHD2 protein levels. Proteolytic 
-secretase function of PSEN1/2 was needed for proper HIF activation. Intriguingly, 
PSEN1/2 mutations identified in Alzheimer patients differentially affected the hypoxic 
response, involving the generation of AICD. Taken together, our results suggest a direct 
role for PSEN in the regulation of the oxygen sensing pathway via the APP/AICD 
cleavage cascade.  
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Introduction 
Hypoxia is a characteristic feature of many neurodegenerative disorders such as familial 
Alzheimer's disease (FAD) or Parkinson's disease (PD) (reviewed by Ogunshola and 
Antoniou 2009). The central regulators of the response to low oxygen partial pressures 
are the hypoxia-inducible factors (HIFs) (Semenza 2007; Wenger et al. 2005). Under 
normoxic conditions, a family of prolyl-4-hydroxylase domain (PHD) proteins 
hydroxylate the HIF subunits, tagging them for ubiquitin-mediated proteasomal 
degradation (Bruick and McKnight 2001; Maxwell et al. 1999). When oxygen becomes 
limiting, the activity of PHDs decreases, resulting in the stabilization and accumulation 
of HIF subunits that translocate to the nucleus and heterodimerize with their 
constitutive counterpart HIF-1/aryl hydrocarbon receptor nuclear translocator (ARNT) 
(Kaelin and Ratcliffe 2008; Schofield and Ratcliffe 2004). The now active HIF 
complexes regulate genes that are involved in hypoxic adaptation, including glucose 
metabolism, angiogenesis, cancer progression and neurodegeneration. 
 Recently, we reported that the peptidyl-prolyl cis/trans isomerase FKBP38 
specifically interacts with PHD2 and negatively regulates its stability (Barth et al. 2009; 
Barth et al. 2007). FKBP38 has been shown previously to interact with presenilin 
(PSEN) 1 and 2 which antagonizes its antiapoptotic function (Wang et al. 2005). PSEN 
1 and 2 form the catalytic core of the -secretase complex (De Strooper et al. 1998; 
Wolfe et al. 1999). This complex cleaves many type I membrane proteins such as 
amyloid precursor protein (APP) (De Strooper et al. 1998) or Notch (De Strooper et al. 
1999). PSEN1 and 2 have been discovered through their genetic linkage to early onset 
FAD (Sherrington et al. 1995). Despite thorough research, the underlying pathologic 
processes causing AD remain elusive. However, tissue hypoxia and hypoperfusion 
have been linked to the pathological progression of FAD (Ogunshola and Antoniou 
2009; Zhang and Le 2010). Vascular ischemia/hypoxia increase APP expression and 
the production of A (Kalaria et al. 1993; Li et al. 2009; Webster et al. 2002) as well as 
the amyloidogenic -secretase BACE1 (Sun et al. 2006; Zhang et al. 2007), suggesting 
that oxygen signaling is also involved in the progression of AD.  
 The finding that PSEN1/2 deficient mouse embryonic fibroblasts (MEFs) have 
higher FKBP38 protein levels (Wang et al. 2005) led us to hypothesize that presenilins 
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could be involved in the regulation of the oxygen signaling pathway. To explore a 
putative role of PSEN1/2 in PHD/HIF regulation, we analyzed wild-type (wt), PSEN1 
and PSEN2 single knock-out (ko) as well as PSEN1/2 double-ko MEFs (Herreman et al. 
1999; Herreman et al. 2003). We confirmed that MEF cells lacking PSEN1/2 have 
increased constitutive FKBP38 protein levels causing decreased PHD2 protein levels. In 
addition, we found that the lack of PSEN1/2 leads to an attenuated hypoxic response 
that in turn results in a decreased feedback regulation of PHD2 transcript levels. The 
observed effects were dependent on the generation of the APP intracellular domain 
(AICD) but not on the Notch cleavage cascade.  
 
Materials and Methods 
Plasmid generation and lentiviral transduction. psG5-mPSEN1 and pcDNA3.1-mPSEN2 
expression plasmids were kind gifts of B. de Strooper (Leuven, Belgium). pcDNA3.1-
hPSEN1 was kindly provided by R. Nitsch (Zürich, Switzerland). The pUKBK-citAICD 
expression vector was described previously (Goodger et al. 2009). PSEN and citAICD 
Entry vectors were generated by cloning PCR fragments into the NcoI/XhoI (for 
mPSEN1) or EcoRI/XhoI (for mPSEN2) sites of pENTR4 (Invitrogen, Basel, 
Switzerland). Cloning of pLenti-mPSEN and G4-DBD-PSEN1 constructs was performed 
using Gateway technology (Invitrogen). The inserts of the Entry vectors were verified by 
sequencing (Microsynth, Balgach, Switzerland). Viral particles were produced in 
HEK293T human embryonic kidney cells using the ViraPower lentiviral expression 
system according to the manufacturer’s protocol (Invitrogen). 
 Cell culture and transient transfections. PSEN wt, PSEN1 ko and PSEN1/2 ko, 
as well as MEFs containing wt human PSEN1 or clinically relevant mutations of PSEN1 
(E9, A246E, L166P) or PSEN2 (N141I), were kindly provided by de Strooper (Bentahir 
et al. 2006; Herreman et al. 1999; Herreman et al. 2003). The HeLa cervix carcinoma 
cell line HeLa/trTAA/TRE-N1-ICD, capable of doxycycline-induced expression of human 
Notch1-IC (Lee et al. 2009), was a kind gift from C. O. Joe (South Korea). APP ko 
MEFs and APP/APPLP2 ko MEFs were derived from the corresponding ko mice (von 
Koch et al. 1997; Zheng et al. 1995). All cells were grown in high-glucose Dulbecco’s 
modified Eagle’s medium (DMEM; Sigma, Buchs, Switzerland) and Notch1-IC 
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expression was induced by 1 g/ml doxycycline (Sigma). The HEK293-citAICD cells 
were described previously (von Rotz et al. 2004). Expression of citAICD was induced 
with 1 M tebufenozide for 24 hours. For hypoxic exposure, cells were grown in a gas-
controlled glove box (InvivO2 400, Ruskinn Technologies, Leeds, United Kingdom). 
Transient transfections of MEFs were performed using Lipofectamine2000 (Invitrogen). 
HeLa cells were transiently transfected using the polyethylenimine (Polysciences, 
Warrington, PA, USA) method as described previously (Stiehl et al. 2006). The specific 
-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl 
ester (DAPT) was purchased from Sigma. 
 Immunoblotting. Immunoblotting was performed as described previously (Martin 
et al. 2005). Primary antibodies used were rabbit anti-APP, C-terminal (Sigma A8717), 
rabbit anti-human PHD2 (Novus Biologicals, Cambridge, United Kingdom), rabbit anti-
mouse PHD2 (Novus Biologicals), rabbit anti-FKBP38 (Edlich et al. 2005), rabbit anti-
HIF-1 (Novus Biologicals), mouse anti-N-cadherin (BD Biosciences, Heidelberg, 
Germany), mouse anti--actin (Sigma). Horseradish peroxidase coupled secondary 
anti-mouse and anti-rabbit antibodies were purchased from Pierce (Lausanne, 
Switzerland). Chemiluminescence detection was performed using Supersignal West 
Dura (Pierce) and signals were recorded with a charge-coupled device camera 
(Lightimager LAS-4000mini, Fujifilm, Dielsdorf, Switzerland). 
 Reporter genes and mammalian two hybrid assays. Cloning of the HIF-
dependent firefly luciferase reporter gene pH3SVL and the 885 bp mouse Hif1a 
promoter constructs were described previously (Wanner et al. 2000; Wenger et al. 
1997; Wenger et al. 1998). Cells were co-transfected with 1 g pH3SVL and 20 ng 
pRLSV40 Renilla luciferase reporter vector (Promega, Madison, Wisconsin, USA). Cells 
were harvested in passive lysis buffer (Promega) and luciferase reporter gene activity 
was determined using the dual-luciferase reporter system according to the 
manufacturer’s instructions (Promega). Mammalian two hybrid analysis was performed 
using the mammalian Matchmaker system (Clontech, BD Biosciences) as previously 
described (Barth et al. 2007). 
 Animal experimentation. Male C57BL/6 mice were maintained at the animal 
facility of the University of Heidelberg, Germany. All animal procedures were approved 
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by the animal welfare committee (Regierungspräsidium Karlsruhe, Germany). Hypoxia 
was induced in adult mice by substituting nitrogen for oxygen using a Digamix 5SA 
18/3A pump (Woesthoff, Bochum, Germany). Mice breathed 8% O2 for 2 to 108 hours 
or were kept at room air. After hypoxic exposure, organs were removed and snap frozen 
in liquid nitrogen. The generation of fPSEN1/fPSEN1;αCaMKII-Cre;PSEN2ko mice was 
described previously (Saura et al. 2004).  
 RNA extraction and quantification. Total RNA from cells or from the cortex of 
CaMKIIcre PSEN1/2 cdko mice was extracted as described previously (Wollenick et al. 
2011). First-strand cDNA synthesis was performed with 1.5 g RNA using affinity script 
reverse transcriptase (RT) enzyme (Stratagene, Amsterdam, Netherlands). mRNA 
expression levels were quantified by real-time quantitative (q) PCR using a SybrGreen 
qPCR reagent kit (Sigma) and a MX3000P cycler (Stratagene). Initial template 
concentrations of each sample were calculated by comparison with serial dilutions of a 
calibrated standard. To control for equal input levels, ribosomal protein S12 or L28 
mRNA was determined and data were expressed as relative ratios.  
 Data analysis. Unless otherwise indicated, results are shown as mean values ± 
standard error of the mean (SEM) of at least three independent experiments. Statistical 
analysis was performed applying two-tailed Student’s t-test using GraphPad Prism 
version 4.0 (GraphPad Software, La Jolla, California, USA).  
 
Results 
PSEN 1 and 2 regulate constitutive FKBP38 and PHD2 levels and are ubiquitously 
expressed 
To explore the function of PSEN1/2 in the hypoxia signaling pathway, PSEN1 and 
PSEN2 single as well as PSEN1/2 double ko MEFs (MEF PSEN1 ko, and MEF 
PSEN1/2 ko, respectively) were used (Herreman et al. 1999; Herreman et al. 2003). As 
determined by immunoblotting, constitutive FKBP38 protein levels were increased 
whereas PHD2 protein levels were strongly downregulated in PSEN1/2 ko MEFs (Fig. 
1A, left panel). Quantification of relative band intensities of three independent 
experiments revealed 1.7-fold FKBP38 upregulation and 5-fold PHD2 downregulation 
(Fig. 1A, right panel). This finding is consistent with a previous report that the lack of 
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PSEN1/2 leads to increased FKBP38 protein abundance as well as with our published 
results on the negative regulation of PHD2 protein stability by FKBP38 (Barth et al. 
2007; Wang et al. 2005).  
 Since FKBP38 was clearly less increased than PHD2 was decreased in 
PSEN1/2 ko MEFs, it is likely that at least one additional mechanism is involved in the 
regulation of PHD2 in cells lacking PSEN1/2. RT-qPCR analysis demonstrated that 
PHD2 mRNA levels were also significantly lower in PSEN1/2 ko MEFs whereas there 
was no difference in FKBP38 mRNA levels (Fig. 1B). We further analyzed hypoxic 
PHD2 protein induction in PSEN1/2 wt and ko MEFs. Both, normoxic and hypoxic PHD2 
protein levels were substantially lower in the absence of PSEN1/2 at each timepoint 
tested (Fig. 1C). FKBP38 protein levels did not change in hypoxia, like reported 
previously (Barth et al. 2007). Relative hypoxic PHD2 induction, however, remained 
unchanged when compared to normoxic PHD2 protein levels in each cell line (Fig. 1D).  
 In vivo, we found ubiquitous PSEN1/2 expression in adult mouse tissues with 
most abundant PSEN1 mRNA levels in the testis and the brain, and with high PSEN2 
mRNA levels in the liver and the brain (Fig. 1E). While exposure to inspiratory hypoxia 
(8% O2) for 12 or 108 hours induced mRNA levels of the HIF-target gene EPO in the 
brain by 25-fold and 26-fold, respectively, and in the kidney by 168-fold and 53-fold, 
respectively (data not shown), no hypoxic induction of PSEN1 or PSEN2 itself could be 
detected, neither in these mouse tissues (Fig. 1E), nor in various human cell lines (data 
not shown).  
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Fig.1. Regulation of FKBP38 and PHD2 by PSEN1 and PSEN2 in normoxia and hypoxia. (A) Total 
cell extracts from PSEN1/2 wt and ko MEFs were analyzed for PHD2, FKBP38 and -actin protein levels 
by immunoblotting (left panel). Relative band intensities of three independent experiments were 
quantified by densitometry (right panel). Data are shown as mean values ± SD; *p < 0.05, **p < 0.005, 
t-test. (B) Total RNA was extracted from PSEN1/2 wt and ko MEFs. Transcript levels of FKBP38 and 
PHD2 were quantified by RT-qPCR and normalized to ribosomal protein S12 mRNA levels. Data are 
presented as mean values ± SD; n.s. not significant, *p < 0.05, t-test. (C) PSEN1/2 wt and ko MEFs were 
cultured in normoxia or hypoxia for the time indicated and PHD2 and FKBP38 protein levels were 
analyzed by immunoblotting. (D) Relative band intensities of three independent experiments were 
quantified by densitometry. The 0 hours timepoint of each cell line was defined as 1. (E) Total RNA was 
derived from organs of mice that were kept at 20% or 8% oxygen for the time indicated. PSEN1 and 
PSEN2 transcript levels were quantified by RT-qPCR and normalized to the ribosomal protein S12 mRNA 
levels. Data are shown as mean values ± SEM of three independent RNA extractions from different mice. 
 
PSEN deficient cells show an attenuated hypoxic response 
To investigate whether the constitutive decrease in PHD2 levels in PSEN1/2 deficient 
cells affects the hypoxic response functionally, wt, single ko, double ko, and lentivirally 
reconstituted MEFs were transiently co-transfected with a hypoxia response element 
(HRE)-driven firefly luciferase reporter gene together with a constitutive Renilla 
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luciferase control vector. After transfection, cells were split and exposed to normoxia or 
hypoxia for 16 hours. Unexpectedly, despite decreased PHD2 levels both hypoxic HIF-
1 protein levels and HIF-dependent reporter gene expression were decreased in 
PSEN1/2 ko MEFs (Fig. 2A). Reconstitution by lentiviral re-expression of wt PSEN1 
(C1) or PSEN2 (C2) almost completely rescued the hypoxic HIF-1 protein levels and 
reporter gene induction, excluding clonal artifacts and demonstrating that both PSEN1 
and PSEN2 are independently involved in HIF regulation. Hypoxic induction of mRNA 
levels derived from the well-established HIF-target genes carbonic anhydrase IX (CaIX), 
PHD2, N-myc downstream regulated gene (NDRG1) and BCL2/adenovirus E1B 
interacting protein 3 (BNIP3) was blunted in PSEN1/2 ko MEFs (Fig. 2B), confirming a 
functional decrease of endogenous HIF activity in the absence of PSEN1/2.  
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Fig.2. HIF transcriptional response to hypoxia in PSEN1/2 deficient cells. (A) wt, PSEN1/2 ko (ko), 
PSEN1 ko (1ko) and two reconstituted clones of PSEN1/2 ko (C1 or C2) MEFs were transiently 
transfected with the HIF-dependent reporter pH3SVL and pRL-SV40 constructs and cultured in 20% or 
0.2% O2 for 16 hours before relative luciferase activities were determined. The results are shown as mean 
values ± SEM of three independent experiments performed in triplicates (top panel); *p < 0.05, t-test. 
HIF-1 and -actin protein levels were determined by immunoblotting (bottom panel). (B) PSEN1/2 wt 
and ko MEFs were cultured in 20% or 0.2% O2 for 4, 8, 16 and 32 hours and total RNA was extracted. 
CAIX, PHD2, NDRG1 and BNIP3 transcript levels were quantified by RT-qPCR and normalized to the 
expression of ribosomal protein S12 mRNA. Data are shown as mean values ± SEM of five independent 
experiments. 
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PSEN1 is required for normal Hif1a gene expression 
To further analyze the PSEN1/2 dependent regulation of the hypoxia pathway, HIF-1 
protein stability was examined. Since in normoxia HIF-1 is virtually undetectable due to 
rapid hydroxylation-dependent proteasomal degradation, HIF-1 protein decay was 
estimated under hypoxic conditions only. After 16 hours of hypoxia, the translation 
inhibitor cycloheximide (CHX) was added to PSEN1/2 wt and ko MEFs. HIF-1 protein 
levels were analyzed by immunoblotting after 0, 0.5, 1, 2 and 4 hours of ongoing 
hypoxia and cycloheximide treatment (Fig. 3A). Quantification of the protein degradation 
rate of three independent experiments revealed that the hypoxic half-life of HIF-1 
protein was around 2.5 hours and did not differ between the two cell lines (Fig. 3B).  
 Since HIF-1 protein stability was not altered in a PSEN ko MEFs, HIF-1 mRNA 
levels were determined by RT-qPCR. Transcript levels in PSEN1/2 ko MEFs were 
decreased by almost 50% compared to the wt control (Fig. 3C). To determine HIF-1 
mRNA stability in PSEN1/2 wt and ko MEFs, cells were treated with actinomycin D for 
up to 24 hours and transcript levels quantified by RT-qPCR. Neither HIF-1, PHD2 nor 
VEGFA mRNA stability was found to be altered in PSEN1/2 ko MEFs (Fig. 3D), 
suggesting that HIF-1 mRNA is transcriptionally regulated and not via degradation.  
Because Hif1a promoter activity likely is responsible for the difference in HIF-1 mRNA 
levels, a previously published 885 bp fragment upstream of the transcriptional start site 
of the mouse Hif1a gene, cloned into a promoterless firefly luciferase reporter gene 
vector (Wenger et al. 1998), was used to determine HIF-1 transcription rates. A co-
transfected pSV40-Renilla vector served as an internal control to correct for differences 
in transfection efficiency and extract preparation. Luciferase expression was determined 
48 hours after transfection and values were normalized to the activity of the 
promoterless vector pGL3basic in wt MEFs. As shown in Fig. 3E, Hif1a promoter activity 
was significantly lower in PSEN1/2 ko than in wt MEFs. Hif1a promoter activity was 
rescued to almost wt levels in two different clones of ko MEFs that were lentivirally 
reconstituted with PSEN1/2. 
 
MANUSCRIPT I 
 
45 
 
 
Fig.3. HIF-1 regulation in PSEN1/2 deficient cells. (A) PSEN1/2 wt and ko MEFs were cultured in 
20% or 0.2% O2 for 16 hours before treatment with 100 M CHX. Total cell extracts were prepared after 
0.5, 1, 2 and 4 hours of treatment. HIF-1, PHD2 and -actin protein levels were analyzed by 
immunoblotting. (B) Relative band intensities of three independent experiments were quantified relative 
to the -actin levels and normalized to the 0 hours hypoxia time points. Mean values ± SEM of three 
independent experiments are shown. n.s. = not significant, t-test. (C) Quantification of HIF- mRNA 
levels in PSEN1/2 wt and ko MEFs by RT-qPCR. Transcript levels were normalized to the mRNA levels of 
ribosomal protein S12 and the wt level was defined as 1. (D) PSEN1/2 wt and ko MEFs were incubated at 
0.2% O2 for 16 hours before 5 g/ml actinomycin D was added to the cells. Total RNA was extracted 
after 0, 4, 8, 12 and 16 hours of actinomycin D treatment and HIF-1, PHD2 and VEGFA transcript 
levels were quantified by RT-qPCR. mRNA levels were normalized to ribosomal protein S12 mRNA and 
the 0 hours time point was defined as 1. The results are shown as mean values ± SEM of three 
independent experiments. (E) PSEN1/2 wt, ko and two PSEN1/2 reconstituted clones were transiently co-
transfected with the Hif1a promoter-driven pGL3-885Hif1a or the promoterless pGL3-basic plasmid 
together with the pSV40-RL control vector. Data were normalized to the Renilla luciferase activities and 
are shown as mean values ± SEM of three independent experiments performed in triplicates; *p < 0.05,  
t-test.  
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-Secretase enzymatic activity is required for PSEN dependent regulation of HIF-
1 but not of FKBP38/PHD2 
Most of the known functions of PSEN1/2 require -secretase proteolytic activity 
(Wakabayashi and De Strooper 2008). To determine whether -secretase activity is also 
required for the regulation of the hypoxia pathway, PSEN1/2 wt and ko MEFs were 
cultured under normoxic or hypoxic conditions for 12 hours in the presence of either 
DMSO alone (control) or 2 M or 4 M DAPT, a specific -secretase inhibitor. As shown 
in Fig. 4A, inhibition of -secretase activity reduced HIF-1 protein levels but did not 
have any effect on FKBP38 or PHD2 protein levels. The accumulation of the C-terminal 
fragment of N-cadherin served as a control for DAPT function. This finding further 
supports that the regulation of the hypoxia pathway takes place on more than one level, 
comprising -secretase dependent and -secretase independent mechanisms. 
 Notch is one of the many -secretase substrates and has been described to 
potentiate the hypoxic response in certain cell lines on various levels, involving the 
direct interaction of HIF-1 with Notch intracellular domain (NICD) and the recruitment 
of HIF-1 to NICD responsive promoters (Gustafsson et al. 2005). To analyze if PSENs 
act on the hypoxia pathway via Notch signaling, HeLa/trTAA/TRE-N1-IC cells were 
used, allowing induced expression of the human Notch1-IC by doxycycline (Lee et al. 
2009). Protein levels of doxycycline or vehicle treated HeLa cells were analyzed after 16 
hours exposure to 21% or 0.2% O2. As shown in Fig. 4B, hypoxic accumulation of HIF-
1 and PHD2 were not affected by NICD induction. Consistently, while PHD2, CAIX and 
GLUT1 mRNA levels were induced 2.5 to 100-fold after 16 hours of hypoxic exposure, 
they remained unchanged by NICD induction (Fig. 4C). Increased SNAIL mRNA levels 
confirmed the activation of the Notch pathway (Fig. 4C). These findings suggest that 
PSEN dependent HIF regulation in our models is not due to alterations in the Notch 
signaling pathway. 
 Gain-of-function as well as (partial) loss-of-function mutations in PSEN1/2 are 
strongly associated with FAD. Therefore, we sought to analyze the effects of several 
clinically relevant PSEN mutations on the hypoxia pathway by using PSEN1/2 wt and ko 
MEFs, or ko MEFs stably reconstituted with human PSEN mutants commonly found in 
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FAD patients (PSEN1-E9, PSEN1-A246E, PSEN1-L166P, PSEN1-G384A and 
PSEN2-NI41I) (Bentahir et al. 2006). These cells were transiently transfected with the 
HIF-dependent reporter gene pH3SVL and luciferase activity was measured after 16 
hours of exposure to either 20% or 0.2% O2. While re-introduction of PSEN1-A246E, 
PSEN1-G384A and PSEN2-N141I rescued HIF activity in hypoxic PSEN1/2 ko MEFs, 
PSEN1-E9 and PSEN1-L166P failed to do so (Fig. 4D). Of note, whereas the former 
three mutations are still able to cleave some substrates (e.g. APP) but not others (e.g. 
Notch), -secretase function of the latter two mutations has been shown to be severely 
impaired and to abolish canonical APP cleavage as well as NICD formation (Bentahir et 
al. 2006), confirming the results obtained with the DAPT -secretase inhibitor. 
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Fig.4. Requirement of -secretase enzymatic activity for presenilin dependent regulation of HIF-1, 
FKBP38 and PHD2. (A) PSEN1/2 wt and ko MEFs were pretreated with 0, 2 or 4 M of the -secretase 
inhibitor DAPT before culturing at 0.2% O2 for 12 hours. HIF-1, FKBP38, PHD2, N-cadherin and -
actin protein levels were determined by immunoblotting. (B, C) HeLa/trTAA/TRE-N1-ICD cells were 
cultured for 24 hours in the presence or absence of 1 M doxycycline before exposure to 20% or 0.2% O2 
for 16 hours. Thereafter, HIF-1, PHD2 and -actin protein levels were determined by immunoblotting 
(B) and PHD2, GLUT1, CAIX and Snail mRNA levels were quantified by RT-qPCR (C). Transcript levels 
were normalized to the mRNA levels of ribosomal protein L28. The untreated normoxic control was 
defined as 1 and data are shown as mean values ± SEM of three independent experiments. (D) PSEN1/2 
wt, ko and ko MEFs stably expressing PSEN1 or PSEN2 FAD mutations (E9, A246E, L166P, G384A, 
N141I) were transiently cotransfected with the HRE-driven luciferase reporter plasmid (pH3SVL) 
together with the pSV40-RL control vector. Cells were cultured for 16 hours at 20% or 0.2% O2 before 
luciferase activity was determined. The results are shown as mean values ± SEM of three independent 
experiments performed in triplicates. 
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Regulation of HIF-1 protein and mRNA levels via APP/AICD  
The finding that MEFs bearing PSEN mutations that are unable to generate the NICD 
but still cleave the APP show a functional hypoxic response led us to hypothesize that 
AICD might be crucial for HIF regulation. Therefore, HIF-1 protein levels were 
determined in HEK293-citAICD, a human embryonic kidney cell line that allows for 
tebufenozide induction of AICD expression (von Rotz et al. 2004). Following 
tebufenozide treatment, HIF-1 but not PHD2 protein levels were increased (Fig. 5A). 
since normoxic HIF-1 protein is rapidly degraded and therefore not detectable in the 
left panel of Fig. 5A, camera exposure time of the immunoblot of HEK293-citAICD cells 
cultured in 20% O2 was increased. As shown in Fig. 5A right panel, normoxic HIF-1 
protein levels were induced after AICD overexpression. On the mRNA level, HIF-1 was 
increased by 70% in normoxia and to a lesser extent in hypoxia after AICD induction 
(Fig. 5B). Hypoxic CAIX levels were clearly over-induced after AICD induction whereas 
the effect on PHD2 mRNA levels was rather mild. AICD overexpression was verified by 
immunoblotting (Fig. 5A) as well as RT-qPCR (Fig. 5B).  
 To further explore the involvement of APP/AICD in the hypoxic response, we 
analyzed HIF-1 and PHD2 protein levels in APP wt, APP ko and APP/APP like protein 
2 (APLP2) double ko MEFs by immunoblot analysis. APLP2 has been shown to be able 
to partially take over the function of APP (Heber et al. 2000; Yang et al. 2005). Hypoxic 
protein accumulation was blunted in the absence of APP and even further decreased in 
APP/APLP2 ko MEFs (Fig. 5C). Normoxic and hypoxic transcript levels of HIF-1 were 
lower in APP/APLP2 MEFs and hypoxic induction of CAIX was blunted in APP ko and 
APP/APLP2 ko MEFS whereas PHD2 was not affected (Fig. 5D). Finally, we 
investigated if AICD overexpression is sufficient to rescue the blunted hypoxic response 
following -secretase inhibition. Therefore, AICD overexpression in Hek293-citAICD 
cells was induced for 16 hours before -secretase activity was blocked by DAPT 
treatment for 8 hours and the cells incubated at 20% or 0.2% O2. While AICD 
overexpression resulted in increased hypoxic HIF-1 protein levels, -secretase 
inhibition reduced HIF-1 but not PHD2 protein levels in the presence and absence of 
AICD (Figs. 5E and F). These findings indicate that the APP/AICD cleavage cascade is 
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involved in PHD/HIF signaling but is likely not the only -secretase substrate involved in 
these effects. 
 
Fig.5. Regulation of HIF by the APP/AICD cleavage cascade. (A) Hek293-citAICD cells were 
pretreated with 1 M tebufenozide for 24 hours before culturing at 20% or 0.2% O2 for 16 hours and 
determination of HIF-1, PHD2, APP and -actin by immunoblotting (left panel). Long immunoblot 
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exposure for normoxic HIF-1 in Hek293-citAICD cells with or without tebufenozide treatment (right 
panel). (B) Hek293-citAICD cells were cultured for 24 hours in the presence or absence of 1 M 
tebufenozide and exposed to 20% or 0.2% O2 for the time indicated, before mRNA levels of HIF-1, 
PHD2, CAIX and AICD were quantified by RT-qPCR. The transcript levels were normalized to ribosomal 
protein L28 mRNA levels and the zero hour timepoint of the control cells was defined as 1. (C) APP wt, 
APP ko and APP/APPLP2 ko MEFs were cultured in 20% or 0.2% O2 for 16 hours and HIF-1, PHD2 
and -actin protein levels were determined by immunoblotting. (D) APP wt, APP ko and APP/APLP2 ko 
MEFs were exposed to 0, 4, 8, 16 or 24 hours of 0.2% O2 and mRNA levels of HIF-1, PHD2 and CAIX 
were quantified by RT-qPCR. Transcript levels were normalized to ribosomal protein S12 mRNA levels. 
(E, F) Hek293-citAICD cells were grown in the presence or absence of 1 M tebufenozide for 16 hours 
before 8 hours pretreatment with DMSO or DAPT and subsequent incubation at 20% or 0.2% O2 for 16 
hours. HIF-1, PHD2 and AICD were determined by immunoblotting (E) and HIF-1 band intensities 
were quantified and normalized to -actin. (F). All data are shown as mean values ± SEM of three 
independent experiments; *p < 0.05, t-test. 
 
Decreased HIF-1 expression in the cortex of forebrain-specific PSEN1/2 
conditional double knock-out mice  
To confirm the relevance of our findings in vivo, we analyzed the cortex region of 
forebrain-specific fPSEN1/fPSEN1;αCaMKII-Cre;PSEN2ko PSEN1/2 conditional double 
knock-out (PSEN1/2 cdko) mice (Saura et al., 2004). HIF-1, HIF-2, PHD2 and 
VEGFA mRNA levels were found to be significantly downregulated in the cortex of 
these mice, whereas there was no difference in FKBP38 and the HIF-target gene 
NDRG1 mRNA levels (Fig. 6A). In line with the mRNA levels, PHD2 protein levels were 
decreased by approx. 65% whereas FKBP38 protein remained unaffected in the cortex 
of PSEN1/2 cdko mice (Figs. 6B and C). Furthermore, we investigated BACE1 
expression that was shown to be induced in hypoxia by HIF-1(Zhang et al., 2007). In 
line with the decreased HIF-1 mRNA levels, BACE1 expression was lower in the 
brains of PSEN1/2 cdko mice (Fig. 6A), suggesting that reduced A production in 
PSEN1/2 cdko mice could be mediated via HIF-1 and BACE1. 
 In summary, our findings demonstrate that PSEN1/2 are involved in the 
regulation of the oxygen sensing pathway in cells of various origins in vitro as well as in 
cortical neurons in vivo. 
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Fig.6. PSEN1/2 regulate PHD2/HIF in the brain. (A) Cortical mRNA of control C57BL6/129 and 
fPSEN1/fPSEN1;αCaMKII-Cre;PSEN2ko mice was quantified by RT-qPCR and normalized to the 
transcript levels of the ribosomal protein S12. PHD2, FKBP38 and -actin protein levels were 
determined by immunoblotting (B) and PHD2 and FKBP38 band intensities were quantified and 
normalized to -actin (C). All data are shown as mean values ± SEM of n = 3 animals per group;  
*p < 0.05, **p < 0.01, ***p < 0.001, t-test. 
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Discussion 
Many neurological diseases such as AD and PD are characterized by tissue hypoxia, 
but whether hypoxia is a cause or a consequence of the disease remains unclear 
(Peers et al. 2009). In this report, we show that PSEN1 and PSEN2 modulate the 
functional response to hypoxia on more than one level (schematically summarized in 
Fig. 7).  
 
 
Fig.7. Scheme of the mechanisms involved in the regulation of HIF by PSENs. PSEN1/2 -secretase-
mediated cleavage of the APP generates A involved in AD as well as the AICD that induces Hif1a gene 
expression and HIF-1 protein stability but does not regulate FKBP38/PHD2. On the other hand, 
PSEN1/2 increases PHD2 activity by inhibiting FKBP38 in a -secretase-independent manner. These two 
mechanisms overlap with hypoxic induction of HIF-1 protein stability and finally converge in the 
downregulation of HIF-dependent target gene expression following deletion or functional mutation of 
PSEN1/2.  
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MEFs lacking PSEN1/2 showed increased constitutive FKBP38 and concomitantly 
decreased PHD2 protein levels. These findings are in line with a previous report, 
showing that genetic ablation of PSEN1/2 increases FKBP38 protein levels (Wang et al. 
2005), and with our previous results showing that FKBP38 negatively regulates PHD2 
protein levels (Barth et al. 2009). Neither PSEN1 nor PSEN2 themselves were 
regulated by hypoxia in any of the mouse tissues or cell lines analyzed, even though 
some reports showed an induction of PSEN1 after hypoxic exposure of glial cells 
(Bazan and Lukiw 2002; Cui et al. 2004). However, FKBP38 protein levels were only 
slightly upregulated, suggesting that additional mechanisms contribute to the decreased 
PHD2 levels. Consistently, not only PHD2 protein but also mRNA levels were 
substantially downregulated in PSEN1/2 deficient MEFs.  
 Because we and others previously showed that even slight changes in PHD2 
protein levels affect HIF-1 protein stability (Ginouvès et al. 2008; Henze et al. 2010; 
Stiehl et al. 2006), the clearly reduced PHD2 levels in PSEN1/2 deficient MEFs led us to 
expect that HIF-1 protein and HIF target gene expression will be induced in these 
cells. However, quite surprisingly PSEN1/2 deficient MEFs also showed a decreased 
HIF response, despite the strongly decreased PHD2. Since PHD2 is a direct target of 
HIF-1, these findings might provide the additional mechanism involved in PHD2 
downregulation, but they cannot explain the HIF-1 downregulation. PHD3 protein 
levels were not affected by the loss of PSEN1/2 while PHD1 expression was almost 
undetectable in PSEN1/2 wt and ko MEFs (data not shown). 
Interestingly, the lack of PSEN1/2 lowered both Hif1a promoter activity and HIF-
1 mRNA levels in MEFs. In line with the in vitro data, HIF-1, HIF-2, PHD2 and 
VEGFA RNA and PHD2 protein levels were decreased in the cortex of forebrain-specific 
PSEN1/2 cdko mice. These in vitro and in vivo results confirm previous descriptive in 
vivo gene array data demonstrating that HIF-1 mRNA levels are decreased in PSEN1 
hypomorphic mice (Liauw et al. 2002; Rozmahel et al. 2002). However, it is currently 
unclear whether the 50% decrease in HIF-1 mRNA levels alone could explain the 
more pronounced (80%) decrease in hypoxic HIF-1 protein. During the progression of 
our study, Gasperi et al. showed that PSEN1 ko MEFs display impaired induction of 
HIF-1 following stimulation with hypoxia mimetics, insulin and calcium chelators (De 
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Gasperi et al. 2010). These authors attributed their findings to a shorter half live of HIF-
1 in PSEN1-deficient MEFs. However, using PSEN1/2-deficient MEFs, we could not 
find any decrease in HIF-1 protein stability. Two main differences between our 
experiments and those performed by Gasperi et al. might explain this discrepancy: first, 
we conducted our analysis in double-ko MEFs; and second we measured HIF-1 decay 
following a controlled hypoxic accumulation since HIF-1 is normally not detectable 
under normoxic conditions. 
 Together with PSEN enhancer (Pen-2), nicastrin, and anterior pharynx 1 (Aph-1), 
PSENs form the core of the -secretase complex that cleaves a variety of type I 
transmembrane proteins (De Strooper et al. 1999; Parks and Curtis 2007). Several 
studies implied that PSEN also have -secretase independent functions (reviewed by 
Wakabayashi and De Strooper 2008). Accordingly, we showed that whereas the -
secretase function of PSEN1/2 is essential for hypoxic HIF-1 induction it does not 
affect the protein levels of FKBP38 and PHD2, further underlining that at least two 
independent mechanisms are involved in PSEN-dependent HIF regulation. 
 NICD and AICD are two major -secretase dependent intracellular cleavage 
products (derived from the Notch and APP precursors, respectively) and NICD has 
been shown previously to potentiate the HIF response in neuronal and myogenic cells 
(Gustafsson et al. 2005). However, in the cell models used in this study AICD but not 
NICD regulated HIF-1 and HIF target gene expression. The function of AICD remains 
incompletely understood but it has been shown to be present in nuclear complexes 
involved in nuclear signaling (Cao and Sudhof 2001; von Rotz et al. 2004). Of note, 
several genes regulated by AICD have been identified, including KAI1 (Baek et al. 
2002), glycogen synthase 3 (Kim et al. 2003), APP and BACE (von Rotz et al. 2004). 
Our results suggest that HIF-1 might represent a novel AICD target gene but further 
mechanistic experiments need to be performed to corroborate this hypothesis. Since 
 -secretase inhibition decreased hypoxic accumulation even in the presence of 
overexpressed AICD, other -secretase substrates are likely to be involved in HIF 
regulation. A recent report by (Le Moan et al. 2011) showed that -secretase activity is 
increased in hypoxia by an unknown mechanism, leading to increased HIF-1 stability. 
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Even though PSEN1/2 was not investigated, the authors found that genetic ablation of 
the -secretase substrate p75 neurotrophin receptor reduced hypoxic HIF-1 
stabilization. Their findings were explained through decreased Siah2 abundance after 
p75 abrogation. Siah2 has been proposed previously to negatively regulate PHD1 and 
PHD3, and decreased Siah2 hence would lead to lowered HIF-1 protein and HIF 
target gene expression (Nakayama et al. 2004). Accordingly, Le Moan et al. found 
decreased PHD3 mRNA levels as a result of a blunted HIF-response in p75 ko MEF 
cells. However, in our hands overexpression of the full-length p75 or the p75 
intracellular domain did not affect hypoxic HIF-1 protein levels, suggesting that the 
p75/p75ICD cascade is not the major regulator of the hypoxia pathway in our cellular 
model (data not shown). To date, it remains unclear which other -secretase substrates 
besides APP is involved in the regulation of the HIF-signaling cascade. 
To investigate the role of APP and APLP2 of the mouse brain in vivo, C57BL/6 
wt, APPfl/fl/APLP2 ko (Mallm et al. 2010) and Nex-Cre/APPfl/fl/APLP2 cdko mice were 
exposed to 6 hours of 20% or 6% O2 and transcript levels quantified. While EPO and 
VEGFA mRNAs were hypoxically induced by 20-fold and 4-fold, respectively, there was 
no difference between the three genotypes (data not shown). APP deletion efficiency in 
the cortex of Nex-Cre/APPfl/fl/APLP2 cdko mice was approximately 70% on both mRNA 
and protein levels (data not shown). Of note, APP expression levels are very high in the 
brain and the remaining levels of APP might be sufficient to elicit a normal HIF 
response, making the results of these mouse models inconclusive.  
 Despite several in vitro and in vivo studies showing a direct link between A and 
toxicity in FAD, the molecular nature of this interplay remains elusive (reviewed by 
Hardy and Selkoe 2002). An increasing number of reports provide evidence for non-
physiological metal accumulation in the brains of patients with neurodegenerative 
diseases such as AD or PD (Barnham and Bush 2008). Iron and other transition metals 
can interact with A, leading to increased A
oxidative damage (Smith et al. 1997). A novel class of drugs target the abnormal metal 
accumulation, thereby reducing A deposition and oxidative stress in the brain 
(Cuajungco et al. 2000; Doraiswamy and Finefrock 2004). Recently, M30 (5-(N-methyl-
N-propargyaminomethyl)-8-hydroxyquinoline) and HLA20 (5-[4-propargylpiperazin-1-
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ylmethyl]-8-hydroxyquinoline), two novel iron chelating drugs have been evaluated as 
therapeutic agents in AD (Zheng et al. 2005). Of note, iron chelators are well-known as 
PHD-inhibiting and HIF-activating compounds (Linden et al. 2003; Wang and Semenza 
1993; Wanner et al. 2000). In particular, M30 has been shown to upregulate HIF and 
HIF-target genes in cortical neurons (Avramovich-Tirosh et al. 2010). This suggests that 
HIF-activation in the brain is beneficiary for patients suffering from AD and cognitive 
dysfunction, and that mechanisms impeding HIF-activation might be involved in the 
pathogenesis of the disease. Indeed, the classical HIF-targets EPO and VEGFA have 
been shown to improve cognitive function in mouse models when activated in the brain 
(Plaschke et al. 2008; Sargin et al. 2011). Additional studies to investigate if HIF-1 is 
able to rescue the age-dependent neurodegeneration in PSEN1/2 cdko mice (Saura et 
al., 2004) would clarify many open questions. On the other hand, it has been suggested 
that hypoperfusion/hypoxia may mediate AD progression (Ogunshola and Antoniou 
2009). Of note, a recent study showed elevated expression of HIF-1α in the brain 
microvasculature of an AD mouse model (Grammas et al. 2011). Furthermore, hypoxia 
has been shown to increase the expression of BACE1 (Sun et al., 2006; Zhang et al., 
2007) and as a consequence the production of Ab (Webster et al., 2002; Li et al., 2009; 
Kalaria et al., 1993). In line with these data, we found lower BACE1 expression in the 
brain of PSEN1/2 cdko mice with decreased HIF-1. This suggests that decreased A 
production after PSEN1/2 ablation might be at least partly mediated vie HIF and 
BACE1. Furthermore, BACE1 was described to be an AICD target gene (von Rotz et 
al., 2004). It is not clear if AICD regulates BACE1 and HIF independently or if AICD is 
regulating HIF that in turn regulates BACE1. 
 Intriguingly, PSEN1/2-deficient MEFs that were reconstituted with mutations 
originally identified in AD patients displayed a differential response to hypoxia. While the 
most severe -secretase loss-of-function mutations (E9, L199P) did not rescue HIF 
transcriptional activity, other mutations with mostly normal -secretase activity (A246E) 
showed a hypoxic response comparable to the wt response, confirming the importance 
of -secretase enzymatic activity for HIF regulation. Taking into consideration that FAD 
is a multifactorial progressive neurodegenerative disease, these results suggest that 
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HIF-1 protein levels and HIF transcriptional activity in the brain of AD patients deserve 
more clinical attention.  
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4 Unpublished Data 
4.1 Materials and Methods 
Plasmids and chemicals. Full-length p75 and p75-ICD were kind gifts of Moses V. Chao 
(Skirball Institute, New York, USA). The cell-permeable proteasomal inhibitor MG-132 
(Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal) and was purchased from Calbiochem 
(Nottingham, UK). The specific -secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-
alanyl]-S-phenylglycine t-butyl ester (DAPT), 5-aza-2-deoxycytidine and Imatinib 
(Gleevec) were purchased from Sigma (Buchs, Switzerland). 
 
Cell lines and transfections. All cells were grown in high-glucose Dulbecco’s modified 
Eagle’s medium (DMEM; Sigma, Buchs, Switzerland). For hypoxic exposure, cells were 
cultured in a gas-controlled glove box (InvivO2 400, Ruskinn Technologies, Leeds, 
United Kingdom). Transient transfections of MEFs were performed using 
Lipofectamine2000 (Invitrogen, Basel, Switzerland). HeLa, HepG2 and Hek293T cells 
were transiently transfected using the polyethylenimine (Polysciences, Warrington, PA, 
USA) method as described previously (Stiehl et al. 2006). For PION knock-down 
experiments, HepG2 and Hek293 cells were transfected with 100 nM siRNA 
oligonucleotides (Stealth®, Invitrogen) using Lipofectamine 2000 (Invitrogen). 
 
Mammalian-two-hybrid assay. Mammalian two-hybrid assays were performed using the 
mammalian Matchmaker system (Clontech, BD Biosciences, Heidelberg, Germany) as 
described previously (Balamurugan et al. 2009). Cloning of G4-DBD-PSEN1 constructs 
was performed using Gateway technology (Invitrogen). HeLa cells were transiently co-
transfected with 1.5g of G4-DBD- and 1.5 g of VP16-AD fusion protein vectors 
together with 500 ng of firefly luciferase vector pGRE5xE1b and 20 ng of pRL-SV40. 
Total transfected DNA amounts were equalized in each experiments using the 
corresponding empty vector. Luciferase reporter gene activities were determined using 
the dual-luciferase reporter assay system (Promega, Madison, WI, USA). 
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Immunoblotting. Immunoblotting was performed as described previously (Balamurugan 
et al. 2009). Primary antibodies used were mouse anti-APP, clone 22C11 (Millipore, 
Zug, Switzerland, MAB348SP), anti-mHIF-1 (Novus Biologicals, NB100-479, 
Cambridge, UK), mouse anti-hHIF-1 (BD Transduction Laboratories, 610958), rabbit 
anti-p75 (Millipore, 07-476), mouse anti--actin (Sigma). Horseradish peroxidase 
coupled secondary anti-mouse and anti-rabbit antibodies were purchased from Pierce 
(Lausanne, Switzerland). Chemiluminescence detection was performed using 
Supersignal West Dura (Pierce) and signals were recorded with a charge-coupled 
device camera (Lightimager LAS-4000mini, Fujifilm, Dielsdorf, Switzerland). 
 
Protein extraction of mouse brains. Brain sections were homogenized in Solution D and 
the first phase separation was performed following the RNA-extraction protocol 
described by (Chomczynski and Sacchi 1987). Protein was precipitated from the 
organic phase according the TRIZOL protein extraction protocol (Invitrogen). Final pellet 
was dissolved in 1% SDS followed by ultrasonication. 
 
RNA extraction and quantification. Total RNA from cells or from the mouse brains was 
extracted as described previously (Wollenick et al. 2011). First-strand cDNA synthesis 
was performed with 1.5 g RNA using affinity script reverse transcriptase (RT) enzyme 
(Stratagene, Amsterdam, Netherlands). mRNA expression levels were quantified by 
real-time quantitative (q) PCR using a SybrGreen qPCR reagent kit (Sigma) and a 
MX3000P cycler (Stratagene). Initial template concentrations of each sample were 
calculated by comparison with serial dilutions of a calibrated standard. To control for 
equal input levels, ribosomal protein S12 mRNA was determined and data were 
expressed as relative ratios.  
 
4.2 Results 
PSEN1 regulates HIF-1 protein transcription or translation and interacts with HIF-1 
To further analyze the PSEN-dependent regulation of HIF-1, interference with HIF-1 
protein degradation was eliminated. Therefore the proteasomal inhibitor MG132 was 
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applied to PSEN1/2 wt and ko MEFs and HIF-1 protein accumulation was analyzed 
after exposure to 20% or 0.2% O2 for 16 hours. Both normoxic and hypoxic HIF-1 
protein levels were lower in PSEN1/2 ko MEFs compared to the wt controls (Fig 1A), 
suggesting that HIF-1 protein is transcriptionally and/or translationally regulated by 
PSEN1/2. 
Mammalian two-hybrid experiments were performed to investigate whether PSEN 
the translation of HIF-1 by protein-protein interaction. Therefore, PSEN1 was 
fused to the Gal4 DNA binding domain and HIF-1 to the VP16 activation domain. 
Hypoxic Gal4 dependent luciferase activity was substantially higher when the Gal4-
PSEN1 and VP16-HIF-1 fusion constructs were co-transfected compared to the 
transfections of either construct alone (8-fold over VP16-HIF-1 and 17-fold over Gal4-
PSEN1) (Fig 1B). Co-transfection of Gal4-PHD2 with VP16-HIF1 was used as a 
positive control. Normoxic luciferase activities are low because VP16-HIF1 is 
constantly degraded. As published previously, PHD2 and Cdr2 do not interact and co-
transfection of Gal4-PHD2 and VP16-Cdr2 expression vectors served as a negative 
control (Balamurugan et al. 2009). 
 
 
Fig.1. PSEN1 interacts with HIF-1 and regulates HIF-1a protein transcription or translation 
(A) PSEN1/2 wt and ko MEFs were grown in the presence or absence of 10 M MG132 for 1 hour before 
cultivating in 20% or 0.2% O2 conditions for 16 hours. HIF-1 and -actin protein levels were 
determined by immunoblotting. (B) HeLa cells were transiently transfected with Gal4-DNA-binding 
domain and VP16 activation domain fusion protein vectors and a Gal-4 response element-driven firefly 
luciferase reporter, as well as a Renilla luciferase control vector. Luciferase activities were determined 
16 hours after exposure to 20% or 0.2% O2. Mean values ± SEM of three independent experiments 
performed in triplicates are shown. Relative normoxic luciferase activities after transfection with Gal4-
PSEN1 were arbitrarily defined as 1. 
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Inhibition of A generation via PION does not affect the hypoxia pathway  
A recent report showed that a newly discovered -secretase activating protein (GSAP or 
pigeon homolog (drosophila) PION) selectively increases A production through a 
mechanism involving its interaction with both -secretase and APP (He et al. 2010). 
Gleevec (imatinib) that was previously found to inhibit A formation without affecting 
Notch cleavage (Netzer et al. 2003) was shown to function through preventing PION 
interaction with APP. To test if PION-mediated specific APP cleavage is involved in the 
PSEN-dependent regulation of the hypoxia pathway, HepG2 and HEK293T cells were 
transiently transfected with siPION and cultured in 20% or 0.2% O2 for 16 hours. PION 
knockdown had no effect on normoxic or hypoxic HIF-1 and PHD2 protein levels 
whereas PHD2 knockdown increased the normoxic HIF-1 protein accumulation in 
HepG2 cells (Fig. 2A). To confirm the results on transcript levels, siPION was transiently 
transfected in HepG2 cells and normoxic and hypoxic mRNA levels of PHD2, PHD3 and 
PION were analyzed by RT-qPCR (Fig. 2B). Whereas siPHD2 increased normoxic and 
hypoxic HIF-target genes, siPION did not affect constitutive expression or hypoxic 
induction of any of the analyzed HIF-target genes. To further investigate the 
involvement of specific A inhibition on the hypoxia pathway, PSEN1/2 wt and ko MEFs 
were treated with 10 M imatinib for 8 hours before incubating at 20% or 0.2% O2 for 16 
hours. PHD2, CAIX and HIF-1 mRNA levels were determined by RT-qPCR. 
Confirming our previous results, hypoxic PHD2 and CAIX accumulation was blunted in 
PSEN1/2 ko MEFs and constitutive HIF-1 levels were lower in the absence of 
PSEN1/2, but imatinib treatment did not have an effect (Fig. 2C). These results suggest 
that the PION/APP pathway is not involved in the PSEN dependent regulation of the 
HIF pathway in our models. 
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Fig.2. GSAP is not involved in PSEN-dependent HIF-1 regulation. HepG2 and Hek293 cells were 
transiently transfected with different siRNAs and cultured in 20% or 0.2% O2 for 16 hours. HIF-1 , 
PHD2 and -actin protein levels were analyzed by immunoblotting (A) and mRNA levels were determined 
by RT-qPCR (B). (C) HepG2 cells were treated with 10 M imatinib for 8 hours before incubated in 20% 
or 0.2% O2 for 16 hours. PHD2, CAIX and HIF-1 transcript levels were determined by RT-qPCR. 
Expression levels were normalized to the ribosomal protein S12 mRNA levels. 
 
DNA methylation status is not regulated in a PSEN-dependent manner 
We further analyzed if the blunted HIF-1 response in PSEN1/2 ko MEFs could result 
from PSEN-dependent chromatin modifications. A recent report showed that the HIF-1 
promoter contains a hypoxia response element that is normally repressed by 
methylation of a CpG dinucleotide within the core element. In colon cancer cell lines and 
in primary colon cancer specimens, aberrant demethylation of this element is frequently 
found, enabling binding of the HIF-1 to its own promoter resulting in auto-
transactivation of HIF-1 expression (Koslowski et al. 2010). To test if PSEN dependent 
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regulation of the HIF-pathway could involve aberrant DNA methylation, PSEN1/2 wt and 
ko cells were treated with 1 M 5-aza-2-deoxycytidine (5-aza-dC) for 72 hours before 
exposing to 20% or 0.2% O2 for 16 hours. Transcript levels of HIF-1 and CAIX were 
analyzed by RT-qPCR. DNA demethylation by 5-aza-2-dC did not affect HIF-1 or CAIX 
transcript levels in MEFs. These data suggest that CpG demethylation does not affect 
hypoxic gene regulation in MEFs.  
s 
Fig.3. 5-aza-dC treatment does not increase hypoxia-induced gene expression in PSEN MEFs. To 
induce genomic DNA demethylation, cells were cultured in medium supplemented with 1M 5-aza-2-
deoxycytidine for 72 hours before incubating exposing to hypoxia. HIF-1, CAIX and PHD2 mRNA 
levels were quantified by RT-qPCR after 16 hours exposure to 20% or 0.2% O2. mRNA levels were 
normalized to expression levels of the ribosomal protein S12. Data is shown as values ± SEM of three 
independent experiments. 
 
p75 cleavage is not altered in hypoxia nor affects HIF-1 levels 
A recent report by (Le Moan et al. 2011) showed that -secretase activity is increased in 
hypoxia by an unknown mechanism, leading to increased HIF-1 stability. Even though 
PSEN1/2 were not investigated, the authors found that genetic ablation of the -
secretase substrate p75 neurotrophin receptor reduced hypoxic HIF-1 stabilization. 
Their findings were explained through decreased Siah2 abundance after p75 
UNPUBLISHED DATA I 
 
69 
 
abrogation. Siah2 has been proposed previously to negatively regulate PHD1 and 
PHD3, and decreased Siah2 hence would lead to lowered HIF-1 protein and HIF 
target gene expression (Nakayama et al. 2004). Accordingly, Le Moan et al. found 
decreased PHD3 mRNA levels as a result of a blunted HIF-response in p75 ko MEF 
cells. However, we did not observe increased p75 cleavage different cell lines after 
exposure to hypoxia (Fig 4A). Furthermore, overexpression of full-length p75 or the p75 
intracellular domain (p75ICD) did not affect hypoxic HIF-1 protein levels, suggesting 
that the p75/p75ICD cascade is not the major regulator of the hypoxia pathway in our 
cellular models (Fig 4).  
 
 
Fig.4. p75 cleavage is not changed in hypoxia or affects HIF-1(A) Different cell lines were exposed 
to 20% or 0.2% O2 for 16 hours and p75 protein levels were analyzed by immunoblotting. (B) HeLa cells 
were transiently transfected with full length and p75-ICD. HIF-1 and p75 protein levels were analyzed 
by immunoblotting after 16 hours exposure to 20% or 0.2% O2.  
 
Brain specific conditional APP/APLP2 ko does not affect the HIF pathway 
Since hypoxic HIF-1 accumulation was blunted in APP ko and even further decreased 
in APP/APLP2 ko MEFs, we sought to analyze the involvement of APP and APLP2 in 
vivo. APP wt, APLP2ko/APPfl/fl and APLP2/APPfl/fl/NexCre mice (Ulrike Müller, 
Heidelberg) and exposed for 6 hours to 20% or 6% O2 respectively. Since the NexCre 
specific APP knockdown was shown to be more efficient in the cortex (70%) than in the 
rest of the brains (Goebbels et al. 2006), the cortex (P) was dissected from the rest of 
the brain (N) and analyzed separately. While EPO and VEGFA mRNAs were 
hypoxically induced by 20-fold and 4-fold, respectively, there was no difference between 
the three genotypes (Fig 5A). APP deletion efficiency in Nex-Cre/APPfl/fl/APLP2 cdko 
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mice was approximately 70% on both mRNA (Fig 5B) and protein levels (Fig 5C) in the 
(P) sections and 30% in the (N) sections. Of note, APP expression levels are very high 
in the brain and the remaining levels of APP might be sufficient to elicit a normal HIF 
response, making the results of these mouse models inconclusive. Furthermore, we 
cannot exclude that the decreased HIF-1 levels in the APP ko and APP/APLP2 dko 
MEF cell lines are not due to clonal variability of the different cell lines. 
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Fig.5. Normal hypoxic response in the brain of conditional APP/APLP2 ko mice. APP wt, 
APLP2ko/APPfl/fl and APLP2ko/APPfl/fl/NexCre mice were exposed to 20% or 6% O2 for 6 hours and 
total RNA (A and B) and protein (C) was extracted from the Cortex (P) and the rest of the brain (N). 
EPO, VEGFA, PHD2, HIF-1, HIF-2, APLP2 and APP transcript levels were quantified by RT-qPCR 
and normalized to the expression of ribosomal protein S12 mRNA. Data is shown as mean values ± SEM 
of three different mice (A and B). APP protein levels were analyzed by immunoblotting (C). 
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5 Discussion 
The role of PSEN in the regulation of the oxygen-sensing pathway 
We could show that PSEN affects HIF-signaling on more than one level. MEFs lacking 
PSEN1/2 showed increased constitutive FKBP38 and concomitantly decreased PHD2 
protein levels. These findings are in line with a previous report that PSEN1/2 increases 
FKBP38 protein levels (Wang et al. 2005) and with our previous results showing that 
FKBP38 negatively regulates PHD2 protein abundance (Barth et al. 2007). Together 
with PSEN enhancer (Pen-2), nicastrin, and anterior pharynx 1 (Aph-1), PSENs form 
the core of the -secretase complex that cleaves a variety of type I transmembrane 
proteins (De Strooper et al. 1999; Parks and Curtis 2007). Several studies implied that 
PSEN also have -secretase independent functions (reviewed by Wakabayashi and De 
Strooper 2008). The PSEN1/2-dependent regulation of FKBP38 was shown to 
independent of the -secretase function since DAPT treatment did not affect the PSEN-
FKBP38 interaction an neither FKBP38 protein levels (Wang et al. 2005). Accordingly, 
we showed that -secretase inhibition did not affect neither FKBP38 nor PHD2 protein 
levels. PHD2 protein levels were substantially downregulated, FKBP38 protein levels 
were only slightly upregulated, suggesting that additional mechanisms contribute to the 
decreased PHD2 levels. Consistently, PHD2 mRNA levels were significantly 
downregulated in PSEN1/2 deficient MEFs as well as in the cortex of forebrains-specific 
conditional PSEN1/2 ko mice. Since PHD2 is considered to be the main oxygen sensor 
that promotes HIF- degradation in normoxia and we and others previously showed that 
slight changes in PHD2 protein levels affect HIF-1 abundance under normoxic as well 
as hypoxic conditions (Ginouvès et al. 2008; Henze et al. 2010; Stiehl et al. 2006), we 
expected an increased hypoxic response in the PSEN1/2 ko MEFs. Surprisingly, we 
found a decreased HIF response in PSEN1/2 deficient MEFs. Since PHD2 is a direct 
target of HIF-1, these findings might provide the additional mechanism involved in the 
substantial downregulation of PHD2 in the absence of PSEN1/2.  
Even though HIF-1 and HIF-2 enhance the expression of a specific set of target 
genes, they have as well overlapping functions and a vast majority of hypoxia-induced 
genes are regulated by both HIF-1 and HIF-2. One prominent difference between  
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HIF-1 and HIF-2 is observed in their spatial expression patterns. HIF-1 is 
ubiquitously expressed, whereas HIF-2 expression is highest in alveolar epithelial cells 
in the lung but also in endothelial cells of various tissues, such as brain, heart, kidney 
and liver (Ema et al. 1997; Flamme et al. 1997). While HIF-1 and HIF-2 have been 
used interchangeably for in vitro hydroxylation analysis (Epstein et al. 2001; Jaakkola et 
al. 2001; Lando et al. 2002), there is growing evidence that they play distinct roles, 
especially during tumor progression (reviewed in Keith et al. 2012). To investigate if 
HIF-2 is also regulated in a PSEN-dependent manner in MEFs, constitutive HIF-2 
mRNA expression was quantified by RT-qPCR in PSEN1/2 wt and ko MEFs. While HIF-
1 mRNA levels were reduced by almost 50% in the absence of PSEN1/2, surprisingly 
HIF-2 mRNA levels were found to be even higher (data not shown). Nevertheless, 
whereas lentiviral silencing of HIF-1 completely abolished the hypoxic induction of all 
analyzed HIF-target genes, HIF-2 knockdown did not affect any of the analyzed genes, 
independent of oxygen exposure. These data suggest, that HIF-1 is the main regulator 
of the hypoxic response in MEFs. These results are in line with a publication from Park 
et al., where hypoxia-induced gene expression was found to occur solely through the 
action of HIF1in MEFs(Park et al. 2003). HIF-2 was shown to be expressed at 
constant levels regardless of oxygenation and to be primarily localized to the cytoplasm. 
HIF-2 was not capable of stimulating transcription of known HIF-1 target genes in 
response to hypoxia. Nevertheless, HIF-2is known to play a critical role in the brain. 
Consistently, HIF-1 and HIF-2 mRNA were decreased in the cortex of PSEN1/2 
conditional double knock-out brains, suggesting that PSEN1/2 regulate both isoforms. 
Further studies are needed to pin down the role of HIF-1 versus HIF-2 in the PSEN-
dependent regulation of the oxygen sensing pathway. 
During the progression of our study, Gasperi et al. showed that PSEN1 ko MEFs display 
impaired induction of HIF-1 following stimulation with hypoxia mimetics, insulin and 
calcium chelators (De Gasperi et al. 2010). These authors attributed their findings to a 
shorter half life of HIF-1 in PSEN1-deficient MEFs. However, using PSEN1/2-deficient 
MEFs, we could not find any decrease in HIF-1 protein stability. Two main differences 
between our experiments and those performed by Gasperi et al. might explain this 
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discrepancy: first, we conducted our analysis in double-ko MEFs; and second we 
measured HIF-1 decay following a controlled hypoxic accumulation since HIF-1 is 
normally not detectable under normoxic conditions. 
Using mammalian two hybrid assays, we found that PSEN1 interacts with HIF-1. Since 
HIF-1 protein stability was not decreased by the absence of PSEN1/2, PSEN1/2 might 
rather be involved in the regulation of transcription and translation of HIF-1. PSEN1/2 
have been shown to be essential for maturation and transport of integrin-1 in the ER-
Golgi compartment (Zou et al. 2008) which raises the possibility that HIF-1 regulatory 
function of PSEN1/2 localizes to the ER membrane. However, we currently do not know 
how PSEN1/2 affects HIF-1 translation. 
 
Role of APP/AICD cleavage cascade in the regulation of HIF 
NICD and AICD are two major -secretase dependent intracellular cleavage products 
(derived from the Notch and APP precursors, respectively) and NICD has been shown 
previously to potentiate the HIF response in neuronal and myogenic cells (Gustafsson 
et al. 2005). However, in the cell models used in this study AICD but not NICD regulated 
HIF-1 and HIF target gene expression. The function of AICD remains incompletely 
understood but it has been shown to be present in nuclear complexes involved in 
nuclear signaling (Cao and Sudhof 2001; von Rotz et al. 2004). Of note, several genes 
regulated by AICD have been identified, including KAI1 (Baek et al. 2002), glycogen 
synthase 3 (Kim et al. 2003), APP and BACE (von Rotz et al. 2004). Our results 
suggest that HIF-1 might represent a novel AICD target gene, but further mechanistic 
experiments need to be performed to corroborate this hypothesis. It is for instance not 
clear, whether AICD directly or via the interaction with other proteins localizes to the 
HIF-1 promoter. Chromatin immunoprecipitation (ChIP) experiments for AICD on the 
HIF-1 promoter would be needed to investigate this hypothesis. 
In line with our results in AICD overexpressing cells, hypoxic HIF-1 accumulation as 
well as hypoxic induction of HIF-target genes was blunted in APP/APLP2 ko MEFs and 
to a lesser extent in APP ko MEFs. APP, APLP1 and APLP2 have been shown to be 
partially redundant and the APP/APLP-ICDs were also found to be involved in 
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transcription (Eggert et al. 2004; Pardossi-Piquard et al. 2005; Scheinfeld et al. 2002; 
Walsh et al. 2003). A NPTY motif in the C-termini of APP, APLP1 and APLP2 interacts 
with several phosphotyrosin/protein binding (PTB) proteins, including the FE65 protein 
family (Bressler et al. 1996; Guenette et al. 1996; McLoughlin and Miller 1996; 
Tanahashi and Tabira 1999). To corroborate our results, we exposed wt, 
APLP2ko/APPfl/fl and the conditional Nex-Cre/APPfl/fl/APLP2 cdko mice to 6 hours 20% 
or 6 % O2 respectively and extracted mRNA and protein from two different brain regions 
that are expected to have different efficiencies of APP deletion. While EPO and VEGFA 
mRNAs were hypoxically induced 20-fold and 4-fold, respectively, there was no 
difference between the three genotypes. APP deletion efficiency in the cortex of mice 
was approximately 70% on both mRNA and protein levels Of note, APP expression 
levels are very high in the brain and the remaining levels of APP might be sufficient to 
elicit a normal HIF response, making the results of these mouse models inconclusive. 
Furthermore, we cannot exclude that the decreased HIF-1 levels in the APP ko and 
APP/APLP2 dko MEF cell lines are not due to clonal variability of the different cell lines. 
 
A recent report by (Le Moan et al. 2011) showed that -secretase activity is increased in 
hypoxia by an unknown mechanism, leading to increased HIF-1 stability. Even though 
PSEN1/2 were not investigated, the authors found that genetic ablation of the -
secretase substrate p75 neurotrophin receptor reduced hypoxic HIF-1 stabilization. 
Their findings were explained through decreased Siah2 abundance after p75 
abrogation. Siah2 has been proposed previously to negatively regulate PHD1 and 
PHD3, and decreased Siah2 hence would lead to lowered HIF-1 protein and HIF 
target gene expression (Nakayama et al. 2004). Accordingly, Le Moan et al. found 
decreased PHD3 mRNA levels as a result of a blunted HIF-response in p75 ko MEF 
cells. However, in our hands overexpression of the full-length p75 or the p75 
intracellular domain did not affect hypoxic HIF-1 protein levels, suggesting that the 
p75/p75ICD cascade is not the major regulator of the hypoxia pathway in our cellular 
models.  
Intriguingly, PSEN1/2-deficient MEFs that were reconstituted with mutations originally 
identified in AD patients displayed a differential response to hypoxia. While the most 
DISCUSSION I 
 
76 
 
severe -secretase loss-of-function mutations (E9, L199P) did not rescue HIF 
transcriptional activity, other mutations with mostly normal -secretase activity (A246E) 
showed a hypoxic response comparable to the wt response, confirming the importance 
of -secretase enzymatic activity for HIF regulation. 
 
Additional mechanisms of PSEN-dependent regulation of HIF-1 
Recently, a novel -secretase activating protein (GSAP or PION) was identified which 
selectively increased A production through a mechanism involving its interaction with 
the APP-CTF (He et al. 2010). Knockdown of PION in a mouse model of AD reduced 
A levels and plaque development. Since PION represents a new type of -secretase 
regulators that affects some of its substrates (like APP) but not others (like Notch), we 
sought to investigate whether PION could play a role in the PSEN-dependent regulation 
of the hypoxia pathway. Knock-down experiments in different cell lines did not show any 
affect on hypoxic HIF-1 protein levels and neither on the hypoxic induction of HIF-
target genes. Since GSAP regulates the production of A but not of the concomitantly 
formed AICD that we found to be involved in the regulation of HIF-1, these results are 
not surprising. 
A recent report showed that the HIF-1 promoter harbors a hypoxia response element 
that is normally repressed by methylation of a GcG dinucleotide located in the core 
element (Koslowski et al. 2010). Since HIF-1a mRNA is regulated in a PSEN-dependent 
manner, we hypothesized that the blunted HIF-1 response in PSEN1/2 ko MEFs could 
result from PSEN-dependent chromatin modifications. Treating PSEN1/2 wt and ko 
MEFs with the DNA-demethylation agent 5-aza-dCT did not affect HIF-1, CAIX or 
PHD2 mRNA levels in normoxia or hypoxia. These data suggest that CpG 
demethylation does not affect hypoxic gene regulation in MEFs. 
 
The role of hypoxia in Alzheimer’s disease 
The brain is one of the most susceptible organ to oxygen deprivation. Only a few 
minutes of severe hypoxia initiates significant dysfunction and can ultimately result in 
cell death (Siesjo 1988). Oxygen delivery to the aging brain, to cells and tissues gets 
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impaired, thereby increasing the susceptibility to neuronal damage. In addition, cellular 
adaptation to hypoxia is significantly compromised with increasing age and ischemia 
has more severe effects in old versus young patients (Kolb 2003; Yager et al. 2006).  
Alzheimer’s disease is a multifactorial disorder in which both genetic and environmental 
factors contribute to disease progression. Genetic predisposition though mutations in 
APP or PSEN are responsible for only 5% of all AD cases and result in familial early 
onset AD (Coppede et al. 2006). Exposure to other pathogenic conditions, including 
chronic inflammation, cerebrovascular disease and hypoxia/ischemia episodes could be 
important contributing factors (Jellinger and Attems 2005; Aliev et al. 2002; Coppede et 
al. 2006). 
In vitro, simultaneous treatment of cortical neurons with A and hypoxia drastically 
increases the number of apoptotic cells compared to A treatment alone (Egashira et al. 
2002). Nevertheless, the molecular mechanisms that link hypoxia to AD progression are 
incompletely understood. It has been shown that hypoxia/ischemia and hypoperfusion 
upregulates APP at both the mRNA and protein levels and leads to subsequent A 
accumulation (Jendroska et al. 1997; Shi et al. 2000). However, we did not find any 
evidence of  increased APP mRNA or protein levels in hypoxia, neither in the cortex of 
wt or APLP2 ko mice, nor in the cell lines analyzed. There is evidence that short periods 
of hypoxia enhances the A-induced expression of the pro-inflammatory markers 
cyclooxygenase-2 (COX-2) as well as PSEN1, hence accelerating the inflammatory 
neuropathology that characterized AD brains (Bazan and Lukiw 2002). Again, we did 
not observe any changes of PSEN1, PSEN2 in hypoxia, whereas COX-2 expression 
was slightly increased in the analyzed cell lines or mouse tissues. This suggests that 
the hypoxic induction of AD-related genes is highly cell type and context dependent and 
further studies are needed to better understand the role of hypoxia in AD. 
Since over a decade, there is evidence that iron chelators such as desferroxamine, 
protect cultured cells from A (Schubert and Chevion 1995) and inhibit AD progression 
in patients (Mclachlan et al. 1991). Of note, iron chelators are well-known as PHD-
inhibiting and HIF-activating compounds (Linden et al. 2003; Wang and Semenza 1993; 
Wanner et al. 2000). Another metal chelator, clioquinol, was concurrently shown to 
reverse AD pathology in mice (Mclachlan et al. 1991) and induce in vitro HIF-1 
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expression (Soucek et al. 2003). Recently, M30 (5-(N-methyl-N-propargyaminomethyl)-
8-hydroxyquinoline) and HLA20 (5-[4-propargylpiperazin-1-ylmethyl]-8-
hydroxyquinoline), two novel iron chelating drugs have been evaluated as therapeutic 
agents in AD (Zheng et al. 2005). In particular, M30 has been shown to upregulate HIF 
and HIF-target genes in cortical neurons (Avramovich-Tirosh et al. 2010). Soucek et al. 
showed that low levels A directly induce HIF-1 expression and activity in vitro that 
protects cells from A-induced neurotoxicity. In line with this, HIF-1 levels were found to 
be reduced in brains from AD compared to age-matched controls (Liu et al. 2008). To 
further support the beneficial effects of HIF in AD progression, EPO was found to be 
both necessary and sufficient to prevent A-induced apoptosis in the early and later 
stages of neurodegeneration (Chong et al. 2005). The underlying mechanism involves 
the expression and translocation of NF-B p65. However, the precise role of the 
pathway and whether it is beneficial or detrimental remains a matter of debate. 
Particularly since HIF-signaling pathways have been implicated in cell death as well as 
cell survival, depending on the cell type and condition (Vangeison et al. 2008). Notably, 
Zhang et al. showed that BACE expression is upregulated during acute hypoxia by HIF-
1, thus promoting A production in neuroblastoma cells (Zhang et al. 2007). 
Furthermore HIF-1 has been shown to bind to the APH-1 promoter that leads to 
subsequent -secretase-mediated A and Notch generation during hypoxia (Wang et al. 
2006).  
Thus, the overall contribution of hypoxia to the pathogenesis of AD remains elusive and 
may greatly depend on whether it is the cause or the consequence of the disease 
progression. Further studies are needed to understand the role of hypoxia in the context 
of neurodegeneration since the modulation of HIF-signaling may represent new hope for 
the development of novel AD therapies. 
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Project II: Onconeuronal Cerebellar Degeneration-Related Antigen 
Cdr2 as a Novel Diagnostic Marker for Renal Cancer 
 
1 Introduction 
1.1 The Cerebellar Degeneration-Related Onconeural Antigen Cdr2 
The cerebellar degeneration-related antigen Cdr2 was discovered in connection with the 
paraneoplastic cerebellar degeneration (PCD) syndrome in cancer patients with anti-
tumor immunity. PCD is mainly found in patients with breast and ovarian tumors and is 
characterized by the presence of specific auto-antibodies against Cdr2 (also termed 
anti-Yo) (Anderson et al. 1988). Corradi et al (Corradi et al. 1997) analyzed the first 
PCD tumors for the expression of different Cdr isoforms (Cdr 1-3). Whereas all three 
Cdr transcripts could be detected in the cerebellum, only Cdr2 could be detected in the 
PCD ovarian tumors. Analysis of Cdr2 protein expression in gynecological tumors 
obtained from neurologically normal cancer patients revealed that five out of nine 
representative ovary tumors expressed a 52 kDa protein, migrating at the same position 
as Cdr2 from Purkinje cells. Cdr2 expression was as well found in breast tumor patients 
without PCD. These findings suggest an ectopic expression of Cdr2 in a large number 
of gynecological tumors, independent of the presence of paraneoplastic neurological 
degeneration (Darnell and Albert 2000). 
Cdr2 has two family members, Cdr1 and Cdr3. Whereas Cdr2 and Cdr3 show 44% 
protein homology, Cdr2 and Cdr1 overlap only to 13%. We generated a polyclonal anti-
Cdr2 antibody by immunizing rabbits with the synthetic peptide PEYKALFKEIFSCIK, a 
conserved C-terminal part of Cdr2 (aa420-434) and does not recognize the other 
isoforms (licensed to Novus, NBP2-10509). 
1.1.1 Cdr2 Expression 
While Cdr2 mRNA is ubiquitously expressed, protein expression is restricted to the 
brain and testis (Corradi et al. 1997). Sequence analysis of the brain and spleen Cdr2 
cDNA showed 100% identity, suggesting a tissue-specific post-translational regulation 
mechanism. Immunohistochemical analysis showed that Cdr2 protein is expressed in 
cerebellar Purkinje neurons, brainstem neurons and spermatogonia (Corradi et al. 
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1997). Neoplastic Cdr2 expression in gynecological tumors was detected in five out of 
nine representative ovary tumors as well as in some breast tumor patients without PCD 
(Darnell et al. 2000; Darnell and Albert 2000). 
1.1.2 Physiological Function and Regulation 
The physiological function of Cdr2 is incompletely understood. Cdr2 was found to 
interact with c-Myc in yeast and in vitro. (Okano et al. 1999). Immunohistochemical 
analysis of rat brain sections showed a significant co-localization of Cdr2 and c-Myc in 
the cytoplasm of purkinje neurons (Okano et al. 1999). Overexpression of Cdr2 was 
shown to lead to a redistribution of c-Myc into the cytoplasm, where it co-localized with 
Cdr2. Furthermore, Cdr2 attenuated c-Myc-dependent reporter gene expression. 
Additionally, the leucine zipper motif has been demonstrated to interact with cell cycle-
related proteins (Sakai et al. 2004; Sakai et al. 2002) and with a protein kinase 
(Takanaga et al. 1998). More recently, Cdr2 was found to be regulated in a cell cycle 
dependent manner in cancer cells with highest protein levels during mitosis (O'Donovan 
et al. 2010). Cdr2 is phosphorylated after mitosis by the anaphase promoting 
complex/cyclosome (APC/C) and rapidly degraded by the proteasome. Loss of Cdr2 
was found to lead to aberrant mitotic spindle formation, suggesting that Cdr2 acts in 
mitosis to regulate c-myc target genes in tumor cells. 
1.1.3 The Role of Cdr2 in Paraneoplastic Neuronal Degradation  
PNDs are a diverse group of human neurological diseases that are associated with 
cancer anti-tumor immunity. By yet unknown mechanisms, tumors of mainly breast, 
ovarian or lung cancer patients express neuronal antigens that triggers an antitumor 
immune response. The neoplastic expression of these antigens suppresses tumor 
growth, but also develops in an autoimmune neurodegenerative disease. (Albert and 
Darnell 2004). The most commonly found tumor antigens include the nerve-terminal 
vesicle-associated proteins such as the breast cancer/stiff-person PND antigen 
amphiphysin (Folli et al. 1993), cytoplasmic signaling proteins such as the PCD antigen 
cerebellar degeneration-related-antigen Cdr2 (Corradi et al. 1997; Okano et al. 1999) 
and RNA-binding proteins that have various regulatory functions, such as the POMA 
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and Hu PND antigens neuro-oncological ventral antigen (NOVA) and Hu (Brennan and 
Steitz 2001; Dredge et al. 2001; Keene 1999). 
Cdr2 is expressed in 60% of ovarian tumors and approximately in 25% of the breast 
tumors (Darnell et al. 2000). Yet not all of these patients develop neurodegenerative 
disorders (Peterson et al. 1992). 
 
Development of tumor immunity and pathogenesis of PND 
A model for the development of tumor immunity in paraneoplastic neurological disease 
is depicted in Figure 1 (Albert and Darnell 2004). PNDs are thought to be initiated when 
tumor cells (in blue) start expressing proteins (red star) that are normally restricted to 
neurons. The expression of such onconeural antigens triggers an anti-tumor immune 
response. Some of the antigens, like Cdr2, are also expressed in other 
immunoprivileged organs such as the testis. Even though the tumor antigen is identical 
to the neural antigen, it elicits an immune response that is not fully understood. 
Apoptotic tumor cells are phagocytosed by dendritic cells (purple) that migrate to the 
lymph nodes and activate antigen-specific CD4+, CD8+ and B cells. Activated CD8+ 
cells return to the tumor, where they induce apoptotic death triggering a positive-
feedback loop that potentiates the immune response. At the same time, the antibodies 
and T cells raised against the tumor antigen are able to cross the blood brain barrier 
and attack neurons that physiologically express the antigen (Albert and Darnell 2004; 
Darnell and Posner 2003).  
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Fig.1. Model for the development of tumor immunity in paraneoplastic neurological disorders from 
(Albert and Darnell 2004). Paraneoplastic neurological degenerations are initiated when tumor cells 
(blue) express proteins (red star) that are normally only expressed in neurons. This elicits an immune 
response. The development of the neurological disease then involves B and T cells that cross the blood-
brain-barrier (red dashed line). The recognition of neurons that normally express the PCD antigens leads 
to the development of neuronal degeneration. 
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Abstract  
The onconeuronal cerebellar degeneration-related antigen Cdr2 is associated with 
paraneoplastic syndromes. Neoplastic expression of Cdr2 in ovary and breast tumors 
triggers an autoimmune response that suppresses tumor growth by developing tumor 
immunity, but culminates in cerebellar degeneration when Cdr2-specific immune cells 
recognize neuronal Cdr2. We identified Cdr2 as novel interactor of the hypoxia-inducible 
factor (HIF) prolyl-4-hydroxylase PHD1 and provide evidence that Cdr2 might represent 
a novel important tumor antigen in renal cancer. Strong Cdr2 protein expression was 
observed in 54.2% of papillary renal cell carcinoma (RCC) compared to 7.8% of clear 
cell RCC and no staining in chromophobe RCC or oncocytoma. High Cdr2 protein levels 
correlated with attenuated HIF target gene expression in these solid tumors and Cdr2 
overexpression in tumor cell lines reduced HIF-dependent transcriptional regulation. 
This effect was due to both attenuation of hypoxic protein accumulation and 
suppression of the transactivation activity of HIF-1. Papillary (p)RCC is known for its 
tendency to avascularity, usually associated with a lower pathological stage and higher 
survival rates. We provide evidence that Cdr2 protein strongly accumulates in pRCC, 
attenuates the HIF response to tumor hypoxia and may become of diagnostic 
importance as novel renal tumor marker.  
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Introduction 
Hypoxia is a characteristic feature of the micro-environment of many tumor types, and 
contributes to malignant tumor behavior associated with therapy resistance and poor 
prognosis (Brown and Wilson, 2004; Pouysségur et al., 2006). Heterodimeric hypoxia-
inducible transcription factors (HIFs) are master regulators of oxygen homeostasis and 
many HIF-target genes are involved in adaptive changes of cancer cells to their hypoxic 
micro-environment (Wenger, 2002; Wenger et al., 2005). On the molecular level, cells 
sense alterations in oxygen levels by oxygen-dependent HIF prolyl and asparaginyl 
hydroxylation which determines HIF- protein stability and transactivation activity, 
respectively. Oxygen-dependent hydroxylation of two distinct HIF- prolyl residues by 
the three HIF prolyl-4-hydroxylase domain proteins PHD1, 2 and 3 (alternatively termed 
HPH3/EGLN2, HPH2/EGLN1 and HPH1/EGLN3, respectively) is necessary for the 
interaction with the von Hippel-Lindau tumor suppressor protein (pVHL) that serves as 
recognition unit of a multiprotein ubiquitin E3 ligase and targets HIF- for proteasomal 
degradation (Bruick and McKnight, 2001; Epstein et al., 2001; Ivan et al., 2002; 
Jaakkola et al., 2001; Maxwell et al., 1999). Compared with collagen prolyl-4-
hydroxylase and mitochondrial cytochrome c oxidase, PHDs have a lower O2 affinity 
that suits these enzymes to regulate HIF- protein levels in response to a wide range of 
physiologically relevant pO2 (Schofield and Ratcliffe, 2004). Hydroxylation of an 
asparaginyl residue in the transactivation domain of HIF- by factor inhibiting HIF (FIH) 
blocks the interaction with the transcriptional co-activator p300 and thus impairs the 
induction of target genes by regulating the transactivation activity of HIF (Mahon et al., 
2001).  
Importantly, mass spectroscopic evidence for hydroxylation of ankyrin repeats in 
IB and NF-B family members as well as in ASB4, a suppressor of cytokine signaling, 
by FIH demonstrated that hydroxylation is not restricted to HIF- subunits (Coleman et 
al., 2007; Ferguson et al., 2007). Although direct mass spectroscopic evidence for 
hydroxylation is missing, PHD1 and PHD3 have recently been shown to regulate IB 
kinase- (IKK) and activating transcription factor-4 (ATF-4), respectively (Cummins et 
al., 2006; Koditz et al., 2007). Apart from mediating HIF- protein stability, these data 
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indicate that PHDs might regulate additional oxygen-dependent signaling pathways. We 
identified Cdr2 as novel PHD1 interacting partner and comprehensive analysis on 
tissues and tumor cell lines demonstrated that abundant Cdr2 protein levels are a 
characteristic feature of papillary RCC and might lead to attenuated hypoxic response 
pathways in these tumors.  
 
Materials and Methods 
Plasmids. Cloning work was carried out using Gateway technology (Invitrogen, Basel, 
Switzerland). Cloning of PHD 1 to 3 vectors was previously described (Barth et al., 
2007). Entry vectors were generated by cloning PCR fragments into NcoI/XhoI-digested 
pENTR4 (all restrictions enzymes were purchased from MBI Fermentas, Labforce, 
Nunningen, Switzerland). Full-length Cdr2 (residues 1 to 454) was amplified by PCR, 
digested with NcoI/XhoI and cloned into pENTR4. The N-terminal Cdr2 fragment 
(residues 1 to 208) was cloned by PvuII/NcoI digestion of pENTR4-Cdr2. The inserts of 
the entry vectors were verified by DNA sequencing (Microsynth, Balgach, Switzerland).  
 
Cell culture and transient transfections. Human HeLa cervical carcinoma, MCF-7 and 
BT474 breast carcinoma, SKOV3 and OVCAR3 ovary adenocarcinoma, HCT116 
colorectal carcinoma, HepG2 hepatoma, U2-OS osteosarcoma, HEK293 embryonic 
kidney carcinoma, mouse embryonic fibroblasts lacking HIF-1 (MEFs Hif1a-/-) or PHD1 
(MEFs Phd1-/-) cells were cultured in high-glucose Dulbecco’s modified Eagle’s medium 
(DMEM) (Sigma) as described previously (Camenisch et al., 1999). For long-term 
hypoxia, cells were grown in a gas-controlled glove box (InvivO2 400, Ruskinn 
Technologies, Leeds, UK). Transient transfections were performed using the 
polyethylenimine (Polysciences, Warrington, PA) method (Stiehl et al., 2006).  
 
Immunoblotting. Immunoblot analyses were performed as previously described (Martin 
et al., 2005). Protein concentrations were determined by the Bradford method. 
Antibodies used were mouse monoclonal antibody (mAb) anti-HIF-1 (Transduction 
Laboratories, BD Biosciences), mAb anti-Cdr2 (Supplementary Figure S2), anti-mouse 
Cdr2 (Abcam), mAb anti-V5 (Invitrogen), mAb anti-myc (Roche Diagnostics, Rotkreuz, 
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Switzerland), mAb anti--actin (Sigma), rabbit polyclonal anti-PHD2 antibody (Novus, 
Abcam, Cambridge, United Kingdom), anti-mouse PHD2 (Novus), secondary polyclonal 
goat anti-mouse and anti-rabbit antibodies coupled to horseradish peroxidase (Pierce, 
Perbio, Lausanne, Switzerland). Chemiluminescence detection was performed using 
Supersignal West Dura (Pierce), and signals were recorded with a charge-coupled 
device camera (Lightimager LAS-4000 mini, Fujifilm, Bucher Biotec, Basel, Switzerland) 
or by exposure to X-ray film (Fujifilm, Dielsdorf, Switzerland). 
 
Co-immunoprecipitation. HeLa cells were co-transfected with full-length or deletion 
constructs of pcDNA3.1/V5-Cdr2 and pcDNA3.1/myc-PHD1 and co-immunoprecipitation 
experiments were done as previously described (Barth et al., 2007). 
 
Reporter gene and mammalian one- and two-hybrid assays. Cloning of the HIF-
dependent firefly luciferase reporter gene constructs pGLTfHBSww and pGLTfHBSmm 
and pH3SVL was described previously (Rolfs et al., 1997; Wanner et al., 2000). Cells 
were co-transfected with 500 ng pH3SVL and 20 ng pRLSV40 Renilla luciferase 
reporter vector (Promega, Madison, WI, USA) to control for differences in transfection 
efficiency. Sixteen hours post-transfection, cells were equally distributed and exposed to 
20% or 0.2% oxygen for another 16 hours. After washing with PBS and cell lysis with 
passive cell lysis buffer (Promega), luciferase reporter gene activity was determined 
using the dual-luciferase reporter assay system according to the manufacturer’s 
instructions (Promega). Mammalian one- and two-hybrid analyses were performed 
using the mammalian Matchmaker system (Clontech, BD Biosciences) as previously 
described (Barth et al., 2007).  
 
mRNA quantification. Total cellular RNA was extracted as described previously (Barth 
et al., 2007) and total tissue RNA was extracted using RNeasy Mini Kit (Qiagen, 
Hombrechtikon, Switzerland). First-strand cDNA synthesis was performed with 1-5 g 
total RNA using reverse transcriptase (RT) and mRNA levels were measured by real-
time quantitative (q) PCR using a SybrGreen qPCR reagent kit (Sigma) in combination 
with the MX3000P light cycler (Stratagene, Amsterdam, The Netherlands). Initial 
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template concentrations of each sample were calculated by comparison with serial 
dilutions of a calibrated standard. To verify RNA integrity and equal input levels, 
ribosomal protein L28 or S12 mRNA was determined, and the data were expressed as 
ratios relative to L28 or S12 levels. 
 
RNAi. HeLa or MEF cells were transfected with 100 nM siRNA oligonucleotides using 
Lipofectamine 2000 (Invitrogen). The following stealth RNAi (Invitrogen) sequences 
were used:  
control siRNA, forward 5’-gcuccggagaacuaccagaguauua-3’;  
control siRNA, reverse 5’-uaauacucugguaguucuccggagc-3’;  
hCdr2 siRNA#1, forward 5’-cucaacuccauucacaaauggaugc-3’;  
hCdr2 siRNA#1, reverse 5’-gcauccauuugugaauggaguugag-3’;  
hCdr2 siRNA#2, forward 5’-aacucuucauacuucaccuucaggg-3’;  
hCdr2 siRNA#2, reverse 5’-cccugaaggugaaguaugaagaguu-3’;  
hCdr2 siRNA#3, forward 5’-auauuccuccuccauagucacccgc-3’;  
hCdr2 siRNA#3, reverse 5’-gcgggugacuauggaggaggaauau-3’;  
mCdr2 siRNA #1, forward 5’-agguggagcuucuacggcaaaugaa-3’;  
mCdr2 siRNA #2, reverse 5’-uucauuugccguagaagcuccaccu-3’;  
mCdr2 siRNA #2, forward 5’-ccacucaaacgaagcagcagugaga-3’;  
mCdr2 siRNA #2, reverse 5’-ucucacugcugcuucguuugagugg-3’;  
hPHD2 siRNA, forward 5’-ggacgaaagccaugguugcuuguua-3’;  
hPHD2 siRNA, reverse 5’-uaacaagcaaccauggcuuucgucc-3’;  
mPHD2 siRNA, forward 5’-uccgucacguugauaacccaaaugg-3’;  
mPHD2 siRNA, reverse 5’-ccauuuggguuaucaacgugacgga-3’.  
 
Tissue specimen and TMA construction. Two different TMAs were constructed as 
previously described (Kononen et al., 1998). A multitumor TMA containing 162 
malignant and benign specimens from the following tissues: testis (12), placenta (4), 
breast (16), liver (12), lung (8), pancreas (8), ovary (8), colon (8), GIST (2), skin (6), 
brain (6), thyroid (8), uterus (8), kidney (16), bladder (8), prostate (12), tonsil (6), lymph 
node (8) and spleen (2). Twelve distinct cell lines from embryonal kidney (HEK-293-T), 
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melanoma (HA98, HN2004, PF2000), mesothelioma (MET5A), colon cancer (SW480), 
renal carcinoma (786-O), lung carcinoma (H69), breast carcinoma (MCF7, SK BR7), 
cervix (HeLa) and prostate cancer (PC3) were also included. In addition, a TMA 
comprising 384 RCC and normal kidney specimens collected from the University 
Hospital of Zürich (Zürich, Switzerland). All samples were histologically reviewed and 
selected for the study on the basis of hematoxylin and eosin-stained tissue sections. 
This study was approved by the local commission of ethics (ref. number StV 38-2005). 
Clinical information for the renal TMA was obtained for 331 cases. Tumors were graded 
according to the Thoenes grading system and histologically classified according to the 
World Health Organization classification (Eble et al., 2004). 
 
Immunohistochemistry. TMA sections (2.5 m) were transferred to glass slides followed 
by immunohistochemical analysis according to the Ventana automat protocols. The 
same antibody used for Western blot analysis was applied for detection of Cdr2 (1:20). 
Analysis was performed with a Leitz Aristoplan microscope (Leitz). Pictures of RCC 
specimens were taken with a digital camera (JVC, KY-070). The intensity of the staining 
was classified as follows: absent, weak, moderate, and strong staining. 
 
Statistical analysis. Contingency table analysis, Chi-square tests, Kaplan-Meier curves, 
and log rank tests for evaluating correlations between Cdr2 and HIF-target genes as 
well as clinical parameters were calculated using StatView 5.0 (SAS, USA).  
 
Results 
Onconeural antigen Cdr2 interacts with PHD1 but is oxygen-independently regulated 
PHD1 was expressed as fusion protein with the Gal4 DNA-binding domain (G4-DBD) or 
LexA as bait in two independent yeast two-hybrid screenings of mouse and human 
testis cDNA libraries. Two mouse Cdr2 clones (accession number NM_007672) and a 
human Cdr2 cDNA clone (accession number NM_001802) were identified. No 
interaction was observed between Cdr2 and PHD2 or PHD3 in yeast (data not shown). 
The Cdr2:PHD1 interaction was confirmed in a mammalian system by transient 
transfection of HeLa cells with V5-tagged Cdr2 and myc-tagged PHD1 followed by co-
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immunoprecipitation (co-IP, Figure 1a). Additional co-IP experiments with Cdr2 deletion 
constructs demonstrated that PHD1 interacts with the N-terminal residues 1 to 208 of 
Cdr2 (data not shown).  
To investigate whether the Cdr2:PHD1 interaction is oxygen-dependent, we 
expressed PHD1 fused to the G4-DBD together with the VP16 activation domain (VP16-
AD) fused to Cdr2 in a mammalian two-hybrid system. As shown in Figure 1b, luciferase 
expression was significantly higher when the DBD-PHD1 and AD-Cdr2 fusion 
constructs were co-transfected than in transfections of either construct alone. In 
contrast to the significantly increased luciferase activity under hypoxic conditions 
following co-transfection of the positive control DBD-PHD1 with AD–HIF-1, luciferase 
expression remained unchanged after co-transfection of DBD-PHD1 with AD-Cdr2 
under hypoxic conditions compared to normoxia. Whereas all three PHD isoforms 
interacted with HIF-1, strong luciferase expression was only observed when Cdr2 was 
co-transfected with PHD1. Normoxic luciferase actitivities of the positive controls are 
low, because AD-HIF-1 is constantly degraded.  
PHD1 and Cdr2 were ubiquitously expressed in adult mouse tissues with most 
abundant mRNA levels in the testis (Supplementary Figure S1). To investigate whether 
Cdr2 gene expression is oxygen-dependently regulated by HIF-1, we analyzed Cdr2 
mRNA levels in mouse embryonic fibroblasts (MEFs), either wild-type (Hif1a+/+) or 
deficient (Hif1a-/-) for HIF-1 (Figure 1c). Cdr2 mRNA levels were not regulated in a 
HIF-1-dependent manner under hypoxic conditions, while transcription of the known 
HIF target gene N-myc downstream regulated gene 1 (NDRG1) was induced. These 
results suggest that the Cdr2 gene is neither a HIF target nor is Cdr2 transcription 
oxygen-dependently regulated in MEF cells. In addition, no oxygen-dependent 
transcriptional regulation of Cdr2 was observed in cervical HeLa, ovary SKOV3 and 
OVCAR3 adenocarcinoma cells, breast BT474 and colorectal HCT116 carcinoma tumor 
cells (data not shown).  
Even though Cdr2 mRNA is ubiquitously expressed, the only tissues reported to 
express Cdr2 protein are brain and testis as well as gynecological and breast tumors, 
indicating that Cdr2 is regulated at a post-transcriptional level (Corradi et al., 1997; 
Darnell et al., 2000). To investigate a possible Cdr2 protein regulation by PHD1, we 
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generated monoclonal antibodies against Cdr2 (Supplementary Figure S2). To this end, 
MBP-Cdr2 fusion protein was expressed in E. coli, affinity purified and used for the 
immunization of mice. Hybridoma supernatants were tested for the presence of anti-
Cdr2 antibodies and one clone (mAb33), recognizing MBP-Cdr2 fusion protein as well 
as transfected Cdr2 by immunoblotting, was obtained (Supplementary Figure S2a). 
Neither mouse Cdr2 nor human Cdr3 was recognized by mAb33 (Supplementary Figure 
S2b). Importantly, mAb33 recognized endogenous Cdr2 in ovary SKOV3 cells and the 
specificity of the Cdr2 signal was confirmed by RNAi-mediated downregulation of Cdr2 
gene expression (Supplementary Figure S2c). Anti-Cdr2 antibodies recognized two 
bands, running at ~62 and ~55 kDa, in cell lines as well as in in vitro transcription and 
translation experiments, suggesting that Cdr2 is post-translationally modified. 
Surprisingly, whereas the majority of ovary tumor tissues has been shown to react with 
PCD patient sera (Darnell et al., 2000), Cdr2 protein abundance in normoxic breast 
carcinoma cell lines MCF-7 and BT474 as well as in cervical HeLa, colorectal HCT116, 
hepatoma HepG2 and osteosarcoma U2-OS tumor cell lines was comparable to ovary 
adenocarcinoma SKOV3 and OVCAR3 cell lines (Supplementary Figure S2d).  
To investigate whether O2-dependent PHD activity is involved in the regulation of 
endogenous Cdr2 protein levels, we cultured ovary carcinoma SKOV3 cells under 
normoxic or hypoxic conditions, or in the presence of the PHD inhibitor 
dimethyloxalylglycine (DMOG). Although HIF-1 protein strongly accumulated in 
hypoxia and by PHD inhibition, endogenous Cdr2 protein abundance remained 
unaffected under these conditions (Figure 1d). We tested seven additional cell lines, 
(HeLa, OVCAR3, MCF-7, BT474, HCT116, HepG2 and U2-OS) as well as anoxia and 
anoxia/reoxygenation conditions, but found no evidence for PHD-dependent and/or O2-
dependent Cdr2 protein regulation (data not shown).  
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Fig.1. Cdr2 interacts with PHD1 but is not regulated by oxygen. (a) Total cell extracts from HeLa cells 
transiently transfected with V5-Cdr2 and myc-PHD1 were incubated with anti-myc (upper panel) or anti-
V5 (lower panel) antibodies or with isotype-matched control IgG, covalently bound to protein A agarose 
beads. Antibody-protein complexes were immunoprecipitated and analyzed by immunoblotting (IB) using 
anti-Cdr2 or anti-myc antibodies. IP, immunoprecipitate. (b) HeLa cells were transiently transfected with 
G4-DBD and VP16-AD fusion protein vectors and a Gal4-response element-driven firefly luciferase 
reporter, as well as a Renilla luciferase control vector. Following transfection, the cells were incubated 
under normoxic (20% O2) or hypoxic (0.2% O2) conditions, and luciferase reporter gene activities were 
determined 16 hours later. Mean values ± SEM of n=3 independent experiments are shown. Relative 
normoxic luciferase activities following transfection of G4-DBD-PHD1 were arbitrarily defined as 1. (c) 
Hif1a
+/+
 and Hif1a
-/-
 MEFs were cultured under normoxic (20% O2) or hypoxic (2% O2) conditions. Total 
RNA was extracted at indicated time points and mRNA levels of Cdr2, NDRG1 and ribosomal S12 were 
quantified by RT-qPCR. Transcript levels were normalized to S12 mRNA. (d) Ovary SKOV3 carcinoma 
cells were cultured under normoxic (20% O2) or hypoxic (0.2% O2) conditions, or in the presence of 1 
mM DMOG for 16 hours. Whole cell extracts were analyzed by immunoblotting using anti-Cdr2 
(mAb33), anti-HIF-1 and anti--actin antibodies. 
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Papillary renal cell carcinoma express high Cdr2 protein levels and show attenuated 
expression of HIF-target genes 
To analyze Cdr2 protein levels in human tumors, we performed immunohistochemistry 
analysis on 162 benign and malignant specimens of 20 different organs and 12 distinct 
cell lines using tissue microarray (TMA) technology (Kononen et al., 1998; Struckmann 
et al., 2008). As expected, Cdr2 staining was observed in brain as well as testis 
samples and somewhat weaker in breast and ovary tumors, but quite surprisingly the 
most intense Cdr2 protein signals were found in renal cell carcinoma (RCC) (data not 
shown). Subsequent analysis of a TMA containing 384 RCC and normal kidney 
samples revealed a significant difference (P < 0.001) in Cdr2 expression between 
histological RCC subtypes. Cdr2 protein expression was strongest in papillary RCC 
(pRCC) compared to clear cell (cc) and chromophobe RCC or benign oncocytoma 
(Table 1 and Figures 2a-c). No difference in Cdr2 protein levels was observed between 
papillary type 1 and type 2 RCC (data not shown). Due to the lack of high quality anti-
PHD1 antibodies, we were not successful in analysing PHD1 protein expression in 
these human tumor samples. RT-qPCR analysis of renal cancer samples from the TMA 
showed that Cdr2 transcript levels were slightly reduced in pRCC compared to normal 
kidney, despite the very strong Cdr2 protein staining in pRCC (Figure 2d). Cdr2 mRNA 
levels were even more decreased in ccRCC (Figure 2e). Whereas PHD1 and PHD2 
mRNA levels were slightly reduced in pRCC and ccRCC compared to normal kidney, 
induction of the HIF target genes PHD3, VEGF and CAIX by tumor hypoxia was 
strongly reduced in pRCC compared to ccRCC (Figures 2d and e). HIF-1and HIF-2 
mRNA levels were comparable in pRCC and ccRCC. However, in contrast to ccRCC 
where over 50% of the tumor samples showed positive HIF-1 protein staining as 
expected, all pRCC were HIF-1 negative and decreased vascularization in pRCC 
compared to clear cell and chromophobe RCC or oncocytoma was evident by reduced 
CD34 staining (data not shown). Regulation of Cdr2 protein expression was VHL-
independent (Supplementary Figure S3). In addition, normal kidney, pRCC and ccRCC 
tissues were analyzed for Cdr2 protein expression by immunoblotting (Figure 2f). 
Relative to normal kidney samples, Cdr2 protein levels were increased in pRCC and 
decreased in ccRCC, comparable to the TMA staining. Interestingly, additional faster 
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migrating bands were detected in pRCC samples and it remains to be investigated 
whether Cdr2 is alternatively spliced or proteolytically processed in pRCC. 
 
Table 1. Cdr2 immunostaining in chromophobe, clear cell and papillary RCC as well as oncocytoma. 
Absolute numbers of tumors are indicated in brackets.  
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Fig.2. Cdr2 protein levels are highly upregulated in pRCC. Examples from kidney TMA 
immunostaining for Cdr2; (a) normal renal tissue. (b) papillary RCC. (c) clear cell RCC. Total RNA was 
extracted from 5 different normal kidney, papillary RCC (d) as well as ccRCC (e) samples and transcript 
levels of Cdr2, PHD1, PHD2, PHD3, VEGF, CAIX, HIF-1 and HIF-2 were quantified by RT-qPCR 
and normalized to ribosomal L28 mRNA levels. Normal renal tissue mRNA levels were arbitrarily defined 
as 1 and data presented as mean ± SEM relative to normal kidney transcript levels. (f) Whole cell 
extracts of TMA tissue samples were analyzed for Cdr2 (mAb33) and -actin protein levels by 
immunoblotting.  
 
Cdr2 attenuates HIF-dependent transcriptional regulation 
Since neither Cdr2 gene expression nor protein abundance were regulated by HIF or 
PHD function, we next sought to investigate whether Cdr2 itself influences HIF-
dependent gene regulation in tumor cells. Therefore, HeLa cells were transiently co-
transfected with increasing amounts of Cdr2 or control lacZ expression vectors, together 
MANUSCRIPT II 
 
105 
 
with the HIF-dependent, HRE-driven reporter gene plasmid pH3SVL and a Renilla 
luciferase control plasmid. Notably, hypoxic luciferase activity was significantly reduced 
by Cdr2 overexpression compared to control transfections in a concentration-dependent 
manner (Figure 3a).  
To determine whether attenuation of HIF-dependent gene activity by Cdr2 
overexpression depends on the presence of functional HREs, we transiently co-
transfected Cdr2 and HIF-dependent reporter gene constructs harboring either wild-type 
or mutated HREs from the transferrin enhancer. PHD2 overexpression was used as 
control. As shown in Figure 3b, significant suppression of hypoxic reporter gene activity 
by Cdr2 overexpression was dependent on functional HREs. That attenuating effects of 
Cdr2 are specific to HIF function could be confirmed by measuring HIF-dependent 
reporter gene activity in MEFs either deficient for HIF-1 (Hif1a-/-) or transiently 
reconstituted with a HIF-1 expression plasmid (data not shown).  
To analyze the role of Cdr2 in the transcriptional regulation of HIF-dependent 
genes in a HIF-1 wild-type background, total RNA was isolated from cells transiently 
transfected with lacZ, PHD2 or Cdr2 and cultured under normoxic or hypoxic conditions. 
Analysis of transcript levels of CAIX, VEGF, GLUT1 and PHD3 showed that expression 
of these genes was induced by hypoxia as expected but attenuated by Cdr2 
overexpression (Figure 3c). These data suggest that exogenous Cdr2 overexpression 
leads to a suppressed hypoxic induction of HIF target genes. In contrast, transcript 
levels of GLUT1, CAIX, PHD2 and PHD3 were not regulated under hypoxic conditions 
or by overexpression of PHD2 or Cdr2 in Hif1a-/- MEFs (Supplementary Figure S4a). 
Notably, transient reconstitution of HIF-1 in these cells partially restored hypoxic 
induction of HIF-dependent reporter activity and the inhibitory effect mediated by Cdr2 
overexpression (Supplementary Figure S4b). Quantification of HIF-1, HIF-2 and 
ARNT mRNA levels revealed no regulation by Cdr2 overexpression, indicating that 
attenuation of HIF-dependent transcriptional regulation is not at the mRNA level 
(Supplementary Figure S4c).  
Furthermore, siRNA-mediated Cdr2 downregulation was used to evaluate whether 
modulation of endogenous Cdr2 gene expression affects HIF-dependent reporter gene 
activity. Compared to control siRNA transfection, HIF-dependent luciferase activity was 
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significantly increased by Cdr2 depletion (Figure 3d). PHD2 downregulation served as 
positive control and resulted in scarcely detectable normoxic HIF-1 protein levels. 
Immunoblot analysis was not sensitive enough to detect normoxic HIF-1 under Cdr2 
RNA interference conditions. Neither PHD2 nor Cdr2 downregulation increased HIF-
dependent luciferase activity under hypoxic conditions (data not shown).  
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Fig.3. Cdr2 attenuates HIF-dependent transcription. (a) HeLa cells were transiently co-transfected with 
indicated amounts of Cdr2 or control lacZ expression vectors and pH3SVL as well as pRL-SV40 Renilla 
luciferase reporter vectors and cultivated for 16 hours under hypoxic (0.2% O2) conditions before 
relative luciferase activities were determined. The results are mean values ± SEM of n=5 independent 
experiments performed in triplicates. (b) HeLa cells were co-transfected with Cdr2 or PHD2 expression 
vectors and wild-type or mutated HRE-driven luciferase reporter genes as well as pRL-SV40 and 
cultivated for 16 hours under hypoxic (0.2% O2) conditions. (c) HeLa cells were transiently transfected 
with the indicated expression vectors and cultured under normoxic (open bars) or hypoxic (closed bars) 
conditions for 16 hours. Total RNA was extracted and CAIX, VEGF, GLUT1 and PHD3 transcript levels 
were quantified by RT-qPCR and normalized to ribosomal L28 mRNA. Data are mean values ± SEM of 
n=3 independent experiments. (d) HeLa cells were transfected with pH3SVL as well as pRL-SV40 and in 
addition with PHD2, control or Cdr2 siRNA oligonucleotides. Data are mean values ± SEM of n=3 
independent experiments performed in triplicates. Endogenous Cdr2, PHD2, HIF-1 -actin protein 
levels were analyzed by immunoblotting. P values were obtained by unpaired t tests (**, P < 0.01). 
 
Cdr2 decreases hypoxic HIF-1accumulation and modulates PHD1 protein levels 
We analyzed whether Cdr2 overexpression influences hypoxically stabilized HIF-1 
protein levels. As shown in Figure 4a, overexpression of Cdr2 reduced hypoxic HIF-1 
protein accumulation in a dose-dependent manner. To explore the concomitant role of 
Cdr2 and PHD1 in the negative regulation of HIF-1 stability and/or transactivation 
activity, we co-transfected pH3SVL and control pRL-SV40 reporter vectors together with 
Cdr2 and/or PHD1 expression plasmids. Hypoxic induction of HIF-dependent reporter 
gene activity was reduced by exogenous Cdr2 or PHD1 expression and an even 
stronger attenuation was observed when Cdr2 and PHD1 were co-overexpressed 
(Figure 4b). Strikingly, increased PHD1 protein levels were observed when Cdr2 was 
concomitantly transfected and immunoblot analysis of hypoxic endogenous HIF-1 
protein accumulation under Cdr2 and PHD1 overexpression conditions showed that 
HIF-1protein abundance was more efficiently reduced compared to Cdr2 or PHD1 
expression alone (Figure 4b). Similarly to the human pRCC samples, endogenous 
PHD1 mRNA levels were not affected by Cdr2 overexpression suggesting that 
increased PHD1 protein levels result from a post-transcriptional mechanism (data not 
shown).  
 Next we investigated the effect of concomitant endogenous Cdr2 downregulation 
and myc-tagged PHD1 overexpression on HIF-dependent reporter gene activity (Figure. 
4c). HIF-dependent luciferase activity was significantly augmented by Cdr2 siRNA, 
whereas it was reduced by V5-Cdr2 overexpression, confirming the results in Figure 3d 
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and 3a, respectively. In addition, Cdr2 siRNA-mediated elevated luciferase activity was 
significantly reduced by overexpression of increasing amounts of myc-PHD1 under 
normoxic as well as hypoxic conditions and repression of HIF-dependent luciferase 
activity under hypoxic conditions by myc-PHD1 expression was even more pronounced 
when V5-Cdr2 was co-transfected. Consistent with increased myc-PHD1 protein levels 
under Cdr2 overexpression conditions (Figure 4b), downregulation of endogenous Cdr2 
prominently reduced myc-PHD1 protein abundance under normoxic and hypoxic 
conditions (compare lane 4 to 7 in Figure 4c), further suggesting a regulation of PHD1 
protein abundance by Cdr2.  
To investigate whether Cdr2-mediated suppression of hypoxic HIF activity is 
dependent on PHD1, we co-transfected pH3SVL reporter vector together with Cdr2 
and/or PHD1 expression plasmids in PHD1-deficient (Phd1-/-) MEFs. Indeed, whereas 
Cdr2 overexpression alone weakly increased HIF-dependent reporter gene activity, 
Cdr2 reduced relative luciferase activity when co-transfected together with PHD1, 
suggesting that the Cdr2-mediated effect was PHD1 dependent (Figure 4d). Vice versa, 
induction of HIF-dependent reporter gene activity by siRNA-mediated Cdr2 
downregulation is also dependent on PHD1 (Figure 4e).  
 
Fig.4. Cdr2 overexpression reduces hypoxic HIF-1 protein accumulation. (a) HeLa cells were 
transiently transfected with the indicated expression vectors and cultured under hypoxic conditions for 16 
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hours. HIF-1, V5-Cdr2 and -actin were detected by immunoblotting. A representative immunoblot is 
shown (top) and normalized hypoxic HIF-1 protein levels are presented as mean values ± SEM of n=3 
independent experiments (bottom). (b) HeLa cells were transiently co-transfected with pH3SVL, pRL-
SV40, lacZ, Cdr2 and/or PHD1 constructs and cultured under 20% O2 or 0.2% O2 conditions for 16 
hours. (c) HeLa cells were transfected with pH3SVL, pRL-SV40 and V5-Cdr2 or myc-PHD1 as well as 
with Cdr2 or control siRNA oligonucleotides. Data are mean values ± SEM. Myc-PHD1, V5-Cdr2, Cdr2 
and -actin protein levels were analyzed by immunoblotting. P values were obtained by unpaired t tests 
(*, P < 0.05). (d) Phd1
-/-
 MEF cells were transiently co-transfected with pH3SVL, lacZ, Cdr2 and/or 
PHD1 and cultured as in b. Luciferase activities were determined and normalized to total protein content 
in the lysates. Data are mean values ± SEM of n=3 independent experiments (*, P < 0.05). (e) Phd1
+/+
 
and Phd1
-/-
 MEF cells were first transfected with Cdr2, PHD2 or control siRNA oligonucleotides and 24 
hours later again with the same siRNA oligonucleotides together with pH3SVL and pRL-SV40. Data are 
mean values ± SEM of n=3 independent experiments performed in triplicates. Endogenous PHD2 and 
Cdr2 protein levels were analyzed by immunoblotting. P values were obtained by unpaired t tests (*, P < 
0.05). 
 
Cdr2 represses HIF-1 transactivation activity by interfering with p300 recruitment 
We next examined whether Cdr2 might also interfere with HIF-1 transactivation activity. 
HIF-1 contains two transactivation domains (TAD) involved in the recruitment of 
general transcriptional co-activators, namely an N-terminal TAD (N-TAD) that overlaps 
with the oxygen-dependent degradation domain (ODDD) and a C-terminal TAD (C-TAD) 
(Figure 5a) (Jiang et al., 1997; Pugh et al., 1997). Using G4-DBD fusions with HIF-1 
fragments containing either the N- or C-TAD in mammalian one-hybrid experiments, we 
observed that hypoxically induced C-TAD activity was significantly reduced by Cdr2 
overexpression, whereas N-TAD activity remained unaffected (Figure 5b). Furthermore, 
HIF-1 C-TAD activity was reduced by Cdr2 in a concentration-dependent manner 
(Figure 5c).  
To investigate whether recruitment of the general transcriptional co-activator p300 
to the HIF-1 C-TAD is modulated by Cdr2, we performed mammalian two-hybrid 
experiments. HeLa cells were transiently co-transfected with G4-DBD p300 CH1 
domain, VP16-AD HIF-1 CTAD and a Gal4-responsive luciferase reporter plasmid as 
well as Cdr2 or lacZ expression vectors. Incubation under hypoxic conditions resulted in 
a two-fold induction of luciferase activity which was significantly reduced by Cdr2 
overexpression (Figure 5d). Proteasomal inhibition by MG132 has been shown to 
stabilize CITED2, which reduces HIF-1 transactivation activity by interfering with the 
HIF-1:p300 interaction (Shin et al., 2008), and was used as positive control. Of note, 
we observed no significant interaction between Cdr2 and FIH under normoxic or 
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hypoxic conditions using mammalian two-hybrid analysis (data not shown). These 
results suggest that Cdr2 interferes with the recruitment of p300 by the HIF-1 C-TAD.  
 
Fig.5. Cdr2 reduces HIF-1 transactivation activity. (a) Schematic representation of the HIF-1 domain 
architecture and the G4-DBD and VP16-AD constructs used. (b) and (c), HeLa cells were transiently co-
transfected with pGH1530-778 or pGH1786-826 expression vectors (b) or pGH1786-826 alone (c), the Gal4-
response element driven firefly luciferase reporter pGRE5xE1b and a Renilla luciferase control vector, as 
well as with Cdr2 expression plasmids and lacZ control vectors (c). Twenty-four hours post-transfection, 
the cells were cultured under either normoxic or hypoxic conditions for an additional 16 hours, and 
firefly luciferase activities were determined and normalized to Renilla luciferase activity. Expression of 
the transfected Cdr2 was verified by immunoblotting against V5 and -actin served as loading control. 
(d) HeLa cells were transiently co-transfected with pG4CH1 (residues 300 to 523 of p300),  
pVP16H1723-826 and with Cdr2 expression plasmids as indicated. Twenty-four hours post-transfection, 
cells were cultured under normoxic or hypoxic conditions for 8 hours in the presence or absence of 5 M 
MG132. Luciferase activities were determined and normalized to total protein content in the lysates. 
Hypoxic HIF-1 accumulation and overexpression of the transfected Cdr2 was verified by 
immunoblotting against HIF- , V5 and -actin. Results are mean values of relative luciferase activities 
± SEM of at least n=3 independent experiments. P values were obtained by unpaired t tests (*, P < 0.05).  
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Discussion 
Cdr2 was identified in a search for novel PHD1 interacting proteins and comprehensive 
analysis of human tumor tissues revealed very strong Cdr2 protein expression in the 
papillary subtype of RCC. High Cdr2 protein levels correlated with strongly attenuated 
expression of HIF target genes in these solid tumors. Similarly, Cdr2 overexpression in 
different tumor cell lines reduced HIF-dependent transcriptional regulation, possibly due 
to both regulation of PHD1 protein expression and suppression of the transactivation 
activity of HIF-1.  
Paraneoplastic neurological degenerations (PNDs) are a diverse group of human 
neurodegenerative diseases associated with cancer and represent probably the most 
evident examples of tumor immunity in humans (Albert and Darnell, 2004; Darnell and 
Posner, 2003a). It has been suggested that paraneoplastic cerebellar degeneration 
(PCD) is initiated when the neuron-specific protein Cdr2 is aberrantly expressed in 
breast and ovarian tumors and thereby recognized as foreign tumor antigen (Darnell 
and Posner, 2003b). PCD patients typically lack neoplastic symptoms and the disease 
only becomes evident when Cdr2-specific immune cells, mainly CD8+ T cells, overcome 
immune tolerance in the brain and recognize neuronal Cdr2. Evidence for anti-tumor 
immune responses is supported by the fact that PCD patients show clinical and 
pathologic signs of suppression of tumor growth compared to other breast and ovarian 
cancer patients (Albert et al., 2000; Peterson et al., 1992). Furthermore, Santomasso et 
al. recently cloned the T cell receptor (TCR) genes from Cdr2-specific T lymphocytes. 
Subsequent expression in normal T cells transformed them into reactive cytotoxic T 
cells, able to lyse Cdr2-expressing human gynecologic tumor cells (Santomasso et al., 
2007). Cdr2 can be considered as an important tumor antigen, since Cdr2 protein was 
detected in 25% of breast and 60% of ovarian tumors from patients who did not develop 
neurological disorders (Darnell et al., 2000), suggesting that neoplastic Cdr2 protein 
expression and development of Cdr2-specific immune cells might be independent of 
autoimmune responses. Therefore, a functional monoclonal anti-Cdr2 antibody might be 
of diagnostic importance for the detection of Cdr2 in human breast and ovarian tumors, 
and might enable the development of an onconeural antigen-specific TCR-based 
therapy. 
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Our findings indicate that Cdr2 represents an important tumor antigen also for 
pRCC, as 54.2% of these tumors demonstrated strong Cdr2 protein staining compared 
to 7.8% of ccRCC and none of chromophobe RCC or oncocytoma (Table 1). With 10% 
of all renal cell carcinomas, pRCC represents the most frequent RCC subtype after 
ccRCC (80%) (Kovacs et al., 1997; Motzer et al., 1996). Whereas deletion on 
chromosome 3 with the VHL gene residing on 3p25 has been clearly linked to ccRCC, 
genetic heterogeneity in pRCC is diverse, often involving chromosomal 
trisomies/tetrasomies in chromosome 7 and 17 as well as losses of chromosome Y 
(reviewed by Moch and Mihatsch, 2002). Cdr2 is localized on 16p12.3 and genetically 
not linked to pRCC.  
Early signs of developing RCC are often absent and result in a high proportion of 
patients with metastases: 90-95% of these patients die within five years of diagnosis 
(Kosary and McLaughlin, 1993). Therefore, early detection of tumors is crucial and Cdr2 
might become of diagnostic importance as novel pRCC tumor marker. In this regard, it 
will be important to determine whether anti-Cdr2 antibodies and/or Cdr2 protein are 
present in the serum of these patients. Interestingly, cellular host immunity has been 
suggested to be important in regulating tumor growth, because of late relapses after 
nephrectomy, sustained stabilization without systemic treatment and rare spontaneous 
regressions (Oliver et al., 1989; Vogelzang et al., 1992).  
 Only 7.8% of ccRCC showed strong Cdr2 staining and there was no correlation 
to an attenuated HIF response in theses tumors (data not shown). This might be due to 
the fact that 71% ccRCC were characterized by loss of VHL and a constitutive active 
HIF response pathway, leading to a proangiogenic state. In contrast, a recent 
examination of 791 RCC patients by angiography showed that pRCC were the most 
frequent hypovascular or avascular renal tumors (Onishi et al., 2002). We found no 
evidence for a non-functional HIF signaling system in pRCC but hypothesize that strong 
Cdr2 protein expression in these tumors, resulting in increased PHD1, decreased HIF-
1 and hence suppressed activation of HIF target genes, might contribute to 
hypovascularization. Although pRCC is not a homogenous cancer, no difference in Cdr2 
protein levels was observed between papillary type 1 and type 2 RCC and the 
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pathophysiological significance of Cdr2 protein expression in relation to the different 
pRCC types remains to be determined.  
We showed that Cdr2 decreased HIF-dependent reporter as well as HIF target 
gene induction by suppressing both hypoxic HIF-1 protein accumulation and HIF 
transactivation activity. Vice versa, siRNA-mediated Cdr2 downregulation increased 
HIF-dependent reporter gene activity. Whereas PHD2 is generally considered to be 
mainly responsible for the normoxic turnover of HIF- protein (Berra et al., 2003; 
Takeda et al., 2006), Erez et al. recently showed that overexpression of PHD1 in colon 
carcinoma cells inhibits tumor growth in nude mice (Erez et al., 2003). Increased PHD1 
protein levels by Cdr2 overexpression might suggest that Cdr2 indirectly regulates HIF-
1 protein abundance by elevating PHD1 levels.  
 Overexpression of Cdr2 also suppressed the transactivation activity of G4HIF-
1786-826, possibly by interfering with p300 recruitment. Oxygen-dependent HIF-1 
asparaginyl residue 803 (N803) hydroxylation regulates HIF transcriptional activity by 
regulating p300/CBP recruitment. Cdr2 did not interact with FIH (data not shown) and it 
remains to be further investigated whether N803 is pivotal for HIF transactivation 
regulation by Cdr2. Interestingly, ectopic PHD2 expression in VHL-deficient cells has 
recently been shown to suppress HIF-1 transcriptional activity under hypoxic 
conditions without altering HIF-1 protein stability (To and Huang, 2005). Likewise, also 
the candidate tumor suppressor protein inhibitor of growth family member 4 (ING4) has 
recently been shown to associate with PHDs and affect HIF transactivation activity 
thereby regulating tumor growth and angiogenesis (Ozer et al., 2005). 
 Taken together, we show that strong Cdr2 protein expression is specific 
for the papillary RCC subtype, leads to attenuation of the hypoxic response pathway, 
probably by regulation of PHD1 protein abundance as well as HIF transactivation 
activity, and propose Cdr2 as novel cancer tumor antigen for pRCC.  
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Suppl. Fig.S1. Ubiquitous expression of Cdr2 and PHD1. Total RNA was extracted from indicated adult 
mouse tissues and transcript levels of PHD1 and Cdr2 were quantified by RT-qPCR and normalized to 
ribosomal S12 mRNA levels. Note the different scales for Cdr2 and PHD1.  
 
 
Suppl. Fig.S2. Generation of monoclonal anti-Cdr2 antibodies. MBP-hCdr2 was expressed in E.coli 
(TB1) and expression was induced with 0.2 mM isopropyl thiogalactoside (IPTG) for 4 hours at 37°C 
before cell harvest. MBP-hCdr2 was purified using affinity chromatography on amylose beads and used 
for immunization of mice. (a) Hybridoma cell lines were established and culture supernatant from clone 
#33 tested against the antigen or lysates from V5-hCdr2 transfected HeLa cells by immunoblotting. (b) 
Monoclonal antibody mAb33 reacted specifically with human Cdr2 but not with in vitro transcribed and 
translated (IVTT) mouse Cdr2 or closely related human Cdr3. As control, the membrane was incubated 
with anti-V5 tag antibodies. (c) SKOV3 cells were transiently transfected with a control and three 
different Cdr2 siRNA oligonucleotides. Total cell lysates were prepared 24 hours post-transfection and 
Cdr2 as well as -actin protein levels were determined by immunoblotting. (d) Indicated tumor cell lines 
were cultivated under normoxic conditions and total cell lysates analyzed by immunoblotting for Cdr2 as 
well as -actin.  
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Suppl. Fig.S3. Cdr2 protein levels are VHL-independently regulated. Ovary and breast carcinoma 
SKOV3 and BT474, embryonic kidney 293 as well as clear cell VHL-deficient as well as reconstituted 
RCC4, 786-0 and A498 cells were cultured under normoxic conditions and cellular extracts analyzed by 
immunoblotting for Cdr2 as well as -actin. 
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Suppl. Fig.S4. Cdr2-dependent attenuation of the HIF response pathway requires functional HIF- . 
(a) Indicated expression vectors were transiently transfected in Hif1a
-/-
 MEFs and cells were cultured 
under normoxic or hypoxic conditions for 16 hours, before total RNA was extracted. Transcript levels of 
GLUT1, PHD2, CAIX and PHD3 were quantified by RT-qPCR and normalized to ribosomal S12 mRNA. 
Data are mean values ± SEM of n=3 independent experiments. (b) MEFs deficient for Hif1a were 
transiently transfected with pH3SVL as well as pRL-SV40 and the indicated expression plasmids. Twenty-
four hours post-transfection, cells were cultivated under normoxic or hypoxic conditions for 16 hours 
before luciferase activity was measured. Results represent mean values ± SEM of n=3 independent 
experiments (*, P < 0.05). Expression of transfected Cdr2 was verified by immunoblotting against V5 and 
-actin. (c) HeLa cells were transiently transfected with lacZ, PHD2 or Cdr2 expression vectors and 
cultured under 20% O2 or 0.2% O2 conditions for 16 hours. Transcript levels of HIF- , HIF-  and 
ARNT were quantified by RT-qPCR and normalized to ribosomal L28 mRNA. Data are mean values ± 
SEM of n=3 independent experiments.  
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Abstract 
Neoplastic expression of the onconeuronal cerebellar degeneration-related antigen 
Cdr2 in ovary and breast tumors is associated with paraneoplastic cerebellar 
degeneration (PCD). Cdr2 protein expression is normally restricted to neurons, but 
tumoral Cdr2 expression triggers tumor immunity, thereby constraining tumor growth. 
So far, aberrant Cdr2 expression has mainly been described for breast and ovarian 
tumors. Previously, we found strong Cdr2 protein expression in the papillary subtype of 
renal cell carcinoma (pRCC) and showed that Cdr2 interacts with the hypoxia-inducible 
factor (HIF) prolyl-4-hydroxylase PHD1. Conversely, high Cdr2 protein levels correlated 
with decreased HIF-dependent gene expression in cells as well as in clinical pRCC 
samples, providing a possible explanation why pRCCs are the most hypovascular renal 
tumors. Here, we demonstrate that strong Cdr2 protein expression in clinical samples 
from pRCC patients correlates with elevated PHD1 protein levels, suggesting that high 
PHD1 levels attenuate HIF-dependent gene expression. Interestingly, survival analysis 
revealed a negative correlation between Cdr2 expression and patient survival in clear 
cell (cc) RCC patients. These findings provide evidence that Cdr2 might represent an 
important tumor antigen in kidney cancer and possibly in other cancer types as well. In 
contrast to ovary and breast tumor patients that developed PCD, no Cdr2 auto-
antibodies were detected in the serum of pRCC patients, which is in line with the fact 
that pRCC patients have not been reported to develop paraneoplastic 
neurodegenerative syndromes. This suggests that, despite a shared target antigen, 
tumor immunity and autoimmunity only partially overlap, and also highlights to which 
extent immuno-surveillance against cancer can be clinically silent. 
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Introduction 
Paraneoplastic cerebellar degeneration (PCD) is often associated with lung and 
gynecologic tumors and is thought to develop as a consequence of an autoimmune 
reaction directed against Purkinje cells (Darnell and Posner 2006). It has been 
suggested that the neuron-specific cerebellar degeneration-related protein Cdr2 is 
expressed by breast and ovarian cancers and thereby elicits an anti-tumor response 
mediated by Cdr2-specific antibodies and T lymphocytes resulting in neurological 
symptoms (Albert and Darnell 2004; Darnell and Posner 2003). Although Cdr2 is an 
ubiquitously expressed gene, post-transcriptional regulation has been suggested to 
restrict Cdr2 protein expression physiologically to immune-privileged organs, such as 
brain and testis, and pathologically to ovarian cancers (Corradi et al. 1997; Darnell et al. 
2000). However, Cdr2 protein levels were recently found to be comparably expressed in 
ovarian cancers and normal ovary tissue, as well as in tumors of other tissue origin. 
This suggests that Cdr2 antibody response in PCD might also be dependent on 
dysregulation of the immune system (Totland et al. 2011). 
The physiological function of Cdr2 is incompletely understood. Cdr2 was found to 
interact with c-Myc in yeast and in vitro (Okano et al. 1999). Immunohistochemical 
analysis of rat brain sections showed a significant co-localization of Cdr2 and c-Myc in 
the cytoplasm of Purkinje neurons and overexpression of Cdr2 was shown to lead to a 
redistribution of c-Myc into the cytoplasm, where it co-localized with Cdr2 (Okano et al. 
1999). More recently, Cdr2 was found to be regulated in a cell cycle dependent manner 
in cancer cells with highest protein levels during mitosis (O'Donovan et al. 2010). 
Regions of low oxygen partial pressures (hypoxia) are found in many tumor types and 
contribute to malignant progression, therapy resistance and poor patient’s prognosis 
(Brown and William 2004; Pouysségur et al. 2006). The master regulators of oxygen 
homeostasis are the heterodimeric hypoxia-inducible transcription factors (HIFs) and 
many of its target genes are involved in the adaptation of cancer cells to their hypoxic 
microenvironment (Wenger 2002; Wenger et al. 2005). Under normoxic conditions, a 
family of prolyl-4-hydroxylase domain (PHD) proteins hydroxylates the HIF subunits, 
targeting them for proteasomal degradation (Bruick and McKnight 2001; Maxwell et al. 
1999). In hypoxia, HIF is stabilized, translocates to the nucleus and forms a powerful 
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transcription factor together with its counterpart HIF-1/aryl hydrocarbon receptor 
nuclear translocator (ARNT) (Kaelin and Ratcliffe 2008; Schofield and Ratcliffe 2004). 
We previously identified Cdr2 as a novel PHD1 interacting protein and found increased 
PHD1 protein levels when Cdr2 was concomitantly overexpressed in cells 
(Balamurugan et al. 2009). However, endogenous PHD1 protein expression in RCC 
patients awaited further analysis due to the lack of specific anti-PHD1 antibodies. In this 
study, we found high PHD1 protein levels in pRCC and a strong correlation between 
PHD1 and Cdr2 expression in tumor tissue microarray analysis. Despite the high Cdr2 
levels, no Cdr2 auto-antibodies were detected in the sera of pRCC patients in contrast 
to patients diagnosed with PCD. This supports the notion that Cdr2 protein expression 
in cancer does not necessarily correlate with the development of paraneoplastic 
neurodegenerative disease and emphasizes the still poor mechanistic comprehension 
of these diseases.  
 
Materials and Methods 
Immunoblotting. Immunoblot analysis was performed as previously described 
(Balamurugan et al. 2009). Mouse anti-human Cdr2 was produced as described before 
(Balamurugan et al. 2009). Other antibodies used were rabbit anti-PHD1 (Novus 
Biologicals, Cambridge, United Kingdom, NBP1-40773) and mouse anti--actin (Sigma, 
Buchs, Switzerland). Secondary horseradish conjugated polyclonal goat anti-mouse and 
goat anti-rabbit antibodies were purchased from Pierce (Pierce, Lausanne, 
Switzerland). Chemiluminescence signals were detected using Supersignal West Dura 
substrate (Pierce) and signals were recorded with the LAS 4000 imaging system (Fuji, 
Bucher Biotec, Basel, Switzerland). 
 
ELISA. 96-well ELISA plates (CANDOR Biosciences, Wangen, Germany) were coated 
with 50 l recombinant Cdr2 capture antigen (200 ng/l) (Balamurugan et al. 2009) 
diluted in Tris-Cl (pH 9.4) overnight at 4°C. Wells were washed three times with 200 l 
PBS-0.05% Tween. 1% BSA in PBS was used to block the plate for 1.5 hours at room 
temperature. Horseraddish peroxidase conjugated goat anti human IgG F(ab)2-
fragment from Dianova diluted 1/100,000 in 1/3 LowCrossbuffer (Candor Bioscience) 
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was used as the secondary antibody. All sera were diluted 1/400 in 1/3 LowCrossbuffer 
in PBS and analyzed in duplicates. The PCD serum samples were obtained from J. 
Honnorat. Ethical approval for the serum samples of RCC patients was obtained from 
the local ethics committee and Swissmedic (EK-1017 and EK-1634). 
 
Immunohistochemistry. TMA sections (2.5 m) were transferred to glass slides followed 
by immunohistochemical analysis according to the Ventana automat protocols. The 
same antibodies that were used for immunoblot analysis were applied for detection of 
Cdr2 (1:20) and PHD1 (1:10). Analysis was performed with a Leitz Aristoplan 
microscope (Leica Microsystems, Heerbrugg, Switzerland). Pictures of RCC specimens 
were taken with a digital camera (JVC, Reinach, Switzerland, KY-070). Since there 
were no negative cases for Cdr2, the weak and moderate cases were classified as 1 
and the strong cases were classified as 2. Because general PHD1 staining was rather 
weak all positive cases were classified as 1 and the negative cases as 0. 
 
Kaplan-Meier survival analysis. The data were compiled with the software package 
SPSS, version 15.0 (SPSS Software, München, Germany). Spearman’s Rho was used 
to assess the statistical significance of the correlation between molecular and 
clinicopathological parameters. Univariate survival analysis was performed according to 
Kaplan-Meier (Kaplan and Meier 1958), and differences in survival curves were 
assessed with the log rank test. A p-value < 0.05 was considered statistically significant. 
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Results 
PHD1 expression strongly correlates with Cdr2 expression in pRCC 
To analyze PHD1 protein expression in clinical kidney samples that were previously 
probed for Cdr2 expression, immunohistochemical analysis (IHC) was performed on 
384 RCC and normal kidney samples using tissue microarray (TMA) technology 
(Kononen et al. 1998; Struckmann et al. 2008). PHD1 expression was strong in pRCC, 
weak in ccRCC (Fig. 1a) and absent in chromophobe RCC or benign oncocytoma (data 
not shown). Furthermore, 74% of pRCC samples with high PHD1 protein levels showed 
strong Cdr2 staining and 67% of PHD1 negative samples showed weak Cdr2 staining 
(*p = 0.006). In addition, normal kidney, pRCC and ccRCC tissues were analyzed for 
PHD1 protein expression by immunoblotting (Fig. 1b). Interestingly, the expression of 
the smaller PHD1 isoform (40 kDa) was increased in pRCC and decreased in ccRCC 
samples compared to normal kidney. Quantification of PHD1 p40 and PHD1 p43 
revealed that total PHD1 protein expression in pRCC was slightly higher compared to 
normal kidney and clearly higher compared to ccRCC (data not shown). As previously 
published Cdr2 protein expression was strongest in pRCC (Balamurugan et al. 2009). 
These findings suggest that Cdr2 might solely interact with the PHD1 p40 isoform.  
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Fig.1. PHD1 expression strongly correlates with Cdr2 expression in pRCC. a Examples from kidney 
tissue microarray (TMA) immunostaining for PHD1 and Cdr2. b Whole cell extracts of TMA tissue 
samples were analyzed for PHD1, Cdr2 and -actin protein levels by immunoblotting. 
 
Our findings indicate that Cdr2 represents an important tumor antigen not only for 
ovarian and breast cancer, but also for pRCC. To investigate whether high Cdr2 
expression in pRCC also elicits an autoimmune response and leads to the generation of 
Cdr2 antibodies, an enzyme-linked immunosorbent assay (ELISA) using recombinant 
Cdr2 purified from bacteria was established. Cdr2-coated 96-well plates were incubated 
with sera from 5 PCD, 12 pRCC, 6 ccRCC and 5 non-cancerous patients to detect Cdr2 
antibodies. No Cdr2 antibodies could be detected in any of the pRCC, ccRCC or control 
patients. In contrast, the sera of PCD patients showed high titers of Cdr2 antibodies and 
served as a positive control (Fig. 2a). These findings are in line with the fact that pRCC 
patients have not been described to develop symptoms of neurodegenerative disorders. 
Previously, Cdr2 has been reported to be increased in breast and ovarian cancer where 
it can cause an auto-immune response. Because we could demonstrate that Cdr2 is 
also strongly expressed in pRCC, we analyzed the correlation of Cdr2 expression with 
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patient survival (Fig. 2b). Cdr2 expression in RCC patients correlated with shorter 
patient survival times (p < 0.005).  
 
 
Fig.2. Serum of RCC patients does not contain Cdr2 auto-antibodies. a Serum samples from 5 PCD, 12 
pRCC, 6 ccRCC and 5 non-cancerous patients were analyzed for Cdr2-auto-antibody abundance by 
ELISA. b Kaplan-Meier survival analysis of the relationship between the expression of Cdr2 and the 
length of patient survival was conducted in 232 ccRCC patients. 
 
Discussion 
We previously reported that Cdr2 is not only highly expressed in breast and ovarian 
tumors, but also in pRCC as 54.2% of these tumors showed strong Cdr2 protein 
staining. In contrast, only 7.8% of ccRCC and none of the chromophobe RCC or 
oncocytoma were found to express high levels of the Cdr2 antigen (Balamurugan et al. 
2009). In addition, we found increased PHD1 protein levels when Cdr2 was 
overexpressed in HeLa cells, but were unable to analyze endogenous PHD1 levels in 
RCC samples because of the lack of specific anti-PHD1 antibodies (Balamurugan et al. 
2009). Using a newly available anti-PHD1 antibody, PHD1 protein expression was 
analyzed in a TMA containing 384 RCC and normal kidney samples, in which we 
previously found Cdr2 to be highly expressed in pRCC (Balamurugan et al. 2009). We 
found that endogenous PHD1 protein expression is high in pRCC and correlates with 
strong Cdr2 expression. This indicates that high neoplastic Cdr2 protein levels might 
stabilize PHD1 protein expression, which in turn attenuates HIF-dependent gene 
expression.  
Further analysis by immunoblotting revealed high expression levels of the PHD1 40 kDa 
isoform in pRCC compared to normal kidney. PHD1 has previously been shown to be 
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expressed as two different isoforms with molecular masses of 43 kDa and 40 kDa, 
respectively, due to the use of alternative translational initiation sites (Appelhoff et al. 
2004). A subsequent study surveying further cell lines to examine the occurrence of 
these isoforms revealed that the preference of the isoform was largely cell type specific 
(Tian et al. 2006). The protein stability of the two isoforms varied greatly, p43 being the 
more stable isoform. Our finding that PHD1p40 but not PHD1p43 is highly expressed in 
pRCC suggests that Cdr2 might specifically regulate the protein stability of the smaller 
isoform. Since previous studies were based on overexpressed or endogenous PHD1 in 
HeLa cell culture, which express only one PHD1 isoform, the isoform specific regulation 
of PHD1 could not be investigated (Tian et al. 2006). Further experiments using A549 
lung cancer, BT474 breast cancer or ND21 (a hybrid between mouse neuroblastoma 
and rat dorsal root ganglion neurons) cell lines could elucidate the Cdr2-specific 
regulation of the two PHD1 isoforms. 
High titers of anti-Cdr2 auto-antibodies and Cdr2-specific CD8+ T cells are often found 
in the blood and CSF of PCD patients and are likely to contribute to the pathogenesis of 
PCD by provoking apoptosis and necrosis of Purkinje cells (Darnell and Posner 2003; 
Storstein and Vedeler 2007). However, a Cdr2-specific immune response does not 
necessarily lead to PCD since such auto-antibodies have been described in cancer 
patients without symptoms of PCD (Darnell and Posner 2003; Monstad et al. 2009; 
Monstad et al. 2006). Moreover, high Cdr2 expression was not only detected in ovarian 
tumors but also in other cancer types and in normal ovary tissue (Totland et al. 2011). It 
is therefore unclear whether Cdr2 auto-antibodies are mechanistically involved in the 
pathogenic progression of PCD or if they rather represent a marker for an aggressive 
neurological disease (Greenlee 2006). Since we found that Cdr2 is also highly 
expressed in pRCC, the abundance of Cdr2 auto-antibodies in pRCC patients was 
analyzed by ELISA. While Cdr2 antibodies could readily be detected in the sera of PCD 
patients, none of the tested pRCC patient harbored Cdr2 antibodies in the serum. This 
supports the notion that neoplastic Cdr2 protein expression does not always correlate 
with the generation of Cdr2 auto-antibodies and the development of PCD (Peterson et 
al. 1992). The molecular mechanisms of Cdr2-mediated neurological degeneration are 
poorly understood. Comprehensive attempts to establish animal models to investigate 
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the pathological progression of PCD have hitherto failed (Tanaka et al. 1995; Tanaka et 
al. 1994; Tanaka et al. 1995). Such models are urgently needed to better understand 
the mechanisms of the PCD development and to finally develop successful treatment 
strategies. 
Hypoxia is a common feature of solid tumors (Endrich et al. 1979). It is strongly 
associated with malignant progression, metastatic outgrowth, resistance to therapy and 
overall poor prognosis in various tumor types (Brown 1998; Brown and William 2004; 
Pouysségur et al. 2006). Angiographic examination of 791 RCC patients revealed 
pRCCs to be the most frequent avascular or hypovascualar renal cancer subtype 
(Onishi et al. 2002). While there were not enough pRCC patients available to analyze 
survival rate, relatively high Cdr2 expression strongly correlated with decreased survival 
in ccRCC patients. This raises the possibility that a strong Cdr2 protein expression in 
tumors results in increased PHD1 expression and therefore decreased HIF-
1 -dependent gene expression that might 
contribute to hypovascularization and therefore to a worse outcome. In line with this 
hypothesis, survival of ccRCC patients with high Cdr2 expression levels was 
significantly decreased compared to patients with low Cdr2 levels.  
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4 Conclusion 
Early signs of RCC are often absent and result in a high proportion of patients with 
metastasis. Early detection of tumors is therefore essential and Cdr2 might become of 
diagnostic importance as a novel pRCC tumor marker. We therefore tried to establish 
an indirect ELISA for the detection of Cdr2 antigen in the serum of pRCC patients. Due 
to the lack of a good second Cdr2 antibody, this aim has not been achieved yet. 
Following tumor markers are routinely tested in case of suspicion of a specific cancer 
(modified list from American Cancer Society)r 
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Marker Cancer type 
Prostate-specific antigen (PSA) Prostate cancer 
Alpha feto-protein (AFP) Liver cancer, testicular cancer 
carcinoembryonic antigen (CEA) Prognosis of colorectal cancer, not for diagnosis 
CA125 Treatment and post-treatment of ovarian cancer, 
not for screening 
CA 72-4 Ovarian and pancreatic cancer and cancers 
starting in the digestive tract, especially stomach 
cancer 
Beta-2-microglobulin (B2M) Multiple myeloma, chronic lymphocytic leukemia 
(CLL) and some lymphomas, also elevated in 
kidney disease and hepatitis 
Bladder Tumor antigen (BTA) In the urine of patients with bladder cancer 
Chromogranin A Neuroendocrine tumors such as carcinoid 
tumors, neuroblastoma and small cell lung 
cancer 
Immunoglobulins Antibodies, IgA, IgG, IgD and IgM, in bone 
marrow cancers such as multiple myeloma 
Lactate dehydrogenase (LDH) Testicular cancer and other germ cell tumors, 
not useful for diagnosis but for monitoring 
Neuron-specific enolase (NSE) Neuroendocrine tumors such as small cell lung 
cancer, neuroblastoma and carcinoid tumors, 
not for screening but for follow ups 
S-100 Melanoma 
Thyroglobulin Common forms of thyroid cancer 
Table 1: Specific tumor markers suggested by the American Cancer Society  
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Licensing of Cdr2 antibody 
Our mouse monoclonal antibody #33 against human Cdr2 (Balamurugan et al. 2009) 
has been licensed to Novus and is out for sale (NBP2-10509). My contributions to the 
licensing procedure: 
 
- Testing and validating our hybridoma supernatant on different cell lines and by using 
different techniques (ELISA, IHC) 
- Mycoplasma cleaning of hybridoma cell line and retesting the supernatant 
- Retesting the nonfunctional antibody preparation of Novus by immunoblotting 
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Abstract 
The histone variant 2AX (H2AX) is phosphorylated at Ser139 by the PI3K-like kinase 
family members ATM, ATR and DNA-PK. Genotoxic stress is considered to be the main 
inducer of phosphorylated H2AX (H2AX) which forms distinct foci at sites of DNA 
damage where DNA repair factors accumulate. H2AX accumulation under severe 
hypoxic/anoxic (0.02% oxygen) conditions has recently been reported to follow 
replication fork stalling in the absence of detectable DNA damage. In this study, we 
found HIF dependent accumulation of H2AX in several cancer cell lines and mouse 
embryonic fibroblasts exposed to physiologically relevant chronic hypoxia (0.2% 
oxygen) which did not induce detectable levels of DNA strand breaks. The hypoxic 
accumulation of H2AX was delayed by RNAi mediated knockdown of HIF-1 or HIF-2 
and further decreased when both HIF-s were absent. Conversely, basal 
phosphorylation of H2AX was increased in cells with constitutively stabilized HIF-2. 
These results suggest that both HIF-1 and HIF-2 are involved in hypoxic H2AX 
accumulation which assumedly might increase the cell’s capacity to repair potential 
DNA damage caused by reoxygenation.  
 
Keywords: DNA damage response, oxygen sensing, tumor hypoxia 
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Introduction 
Tumor hypoxia and therapy resistance 
Hypoxia is a common feature of solid tumors and develops due to inadequate 
vascularization, tortuous blood vessels and high oxygen consumption. Transient 
blockage of red blood cell flux alternating with rapid alleviation leads to frequent 
periodical hypoxia followed by reoxygenation (Yasui et al., 2010). Reoxygenation, most 
likely mediated by the generation of reactive oxygen species (ROS), but not hypoxia 
can lead to detectable DNA damage (Hammond et al., 2003). Hypoxia is strongly 
associated with malignant progression, metastatic outgrowth, genetic instability, 
resistance to radio-and chemotherapy and overall poor patient prognosis in various 
tumor types. (Brown, 1998; Brown et al., 2004; Pouysségur et al., 2006). Therefore, a 
thorough understanding of the molecular pathways in the hypoxic tumor 
microenvironment is warranted in order to develop new strategies for efficient cancer 
therapy. 
 Central to the cellular response to hypoxia is the heterodimeric hypoxia-inducible 
transcription factor HIF, consisting of one of three oxygen-labile  subunits and a 
common constitutive  subunit (Wenger 2002; Schofield et al., 2004;). HIF activates a 
large number of oxygen regulated genes required for the adaptation of normal cells to 
hypoxia (Wenger et al., 2005). In tumors, HIF-1 is responsible for the generation of new 
blood vessels through transcriptional regulation of the vascular endothelial growth factor 
(VEGF), for pH regulation by increasing the expression of carbonic anhydrase (CA) IX, 
and for the aerobically increased glycolytic capacity of cancer cells, also known as 
Warburg effect (Seagroves et al., 2001; Minchenko et al., 2002; Svastova et al., 2004). 
Furthermore, hypoxic tumor cells are able to maintain metabolic functions without 
adequate oxygen supply via a switch to anaerobic fermentation (Pasteur effect) that is 
facilitated in a HIF-1 dependent manner (Schroeder et al., 2005). Therefore, high HIF-1 
levels in the hypoxic tumor microenvironment is a well established factor for aggressive 
tumor growth and a negative factor for cancer therapy (Ryan et al., 1998; Ryan et al., 
2000; Hopfl et al., 2002; Unruh et al., 2003; ). 
 Besides tumor hypoxia that leads to HIF-protein stabilization, the loss of tumor 
suppressor proteins such as pVHL, p53 or PTEN or oncogenes such as v-src can 
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contribute to high HIF- levels in cancer cells (Jiang et al., 1997; Krieg et al., 2000; Ravi 
et al., 2000; Zundel et al., 2000). Both HIF-1 and HIF-2 are widely overexpressed in 
many human cancers and are frequently associated with malignancy and poor 
prognosis (Birner et al., 2000; Aebersold et al., 2001). Furthermore, high HIF-1 protein 
levels have been shown to correlate with incomplete responses to chemotherapy and 
radiotherapy (Aebersold et al., 2001; Koukourakis et al., 2002; Bachtiary et al., 2003; 
Generali et al., 2006). Hypoxia per se affects radiation sensitivity since the radiation 
induced DNA damage is dependent on oxygen (Gray et al., 1953). In addition, 
decreased cell proliferation and lower drug concentrations in the hypoxic tumor areas 
contribute to the resistance to chemotherapy. However, the underlying molecular 
mechanisms causing therapy resistance of hypoxic tumor cells are incompletely 
understood, but it is likely that HIF downstream targets are directly involved in these 
processes. 
 
Targeting HIF to improve cancer therapy 
HIF-1 dependent hypoxic induction of the multidrug resistance MDR1 gene was one of 
the first described molecular mechanism explaining the involvement of HIF-1 in 
chemotherapy resistance in various tumor cells, including breast carcinoma, gastric 
cancer, colon cancer and glioma (Comerford et al., 2002; Wartenberg et al., 2003; Zhou 
et al., 2005; Nardinocchi et al., 2009). Hypoxically dysregulated apoptosis in response 
to chemotherapy might be another explanation (Erler et al., 2004; Sermeus et al., 2008). 
The role of HIF-1 in the regulation of apoptosis is very complex and context specific. 
The involvement of HIF-1 in apoptosis in certain cell types cannot be generalized since 
cells do not undergo apoptosis under degrees of hypoxia sufficient for HIF-1 induction 
(Wenger et al., 1998). In primary cells, hypoxia typically leads to cell cycle arrest and 
HIF-1 dependent apoptosis in case of more severe conditions (Greijer et al., 2004). 
However, HIF-1 functions as a robust suppressor of apoptosis in most transformed 
cells. We previously reported that transformed mouse embryonic fibroblasts (MEFs) 
were more sensitive to chemotherapy as well as to radiotherapy in the absence of HIF-
1 due to an impaired DNA double-strand break (DSB) repair capacity (Wirthner et al., 
2008). The underlying molecular mechanism involve markedly reduced expression of 
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DNA-PKcs, Ku80 and Ku70, three members of the DNA-dependent protein kinases 
(DNA-PK), in HIF-1 deficient MEFs. Our data were supported by a large number of 
studies that demonstrate reversal of radio- and chemoresistance by targeting HIF-1in 
various tumor types (Zhang et al., 2004; Moeller et al., 2005; Williams et al., 2005; 
Brown et al., 2006; Li et al., 2006; Li et al., 2006; Song et al., 2006; Sasabe et al., 
2007). For example, Li et al. showed that knockdown of HIF-1 in breast carcinoma 
cells repressed G0/G1 phase accumulation and relieved S phase block, thereby 
increasing sensitivity to chemotherapy and attenuating tumor growth (Li et al., 2006). 
Functional interference with HIF-1 in various tumor cells has been shown to result in 
enhanced cell death upon treatment with chemotherapeutic agents (Ricker et al., 2004; 
Peng et al., 2006; Hao et al., 2008; Sermeus et al., 2008; Flamant et al., 2010). On the 
other hand, experimentally increasing HIF-1 enhanced therapy resistance (Ji et al., 
2006; Martinive et al., 2006). Of note, HIF-1 in germ cells of Ceanorhabditis elegans has 
recently been reported to antagonize p53-mediated apoptosis upon to DNA damage 
(Sendoel et al., 2010).  
 The induction of DNA damage by cytotoxic agents has proved to be an effective 
strategy for cancer therapy (Einhorn, 2002; Agarwal et al., 2003; Pires et al., 2012). 
Mutations in DNA damage response (DDR) genes can lead to increased frequency and 
incorrect DNA damage repair, thereby contributing to genomic instability characteristic 
for cancer cells (Bolderson et al., 2009). Because HIF-1 mediated therapy resistance 
was only observed when DSB but not single-strand break (SSB) inducing agents were 
applied, we suspected that HIF-1 might be involved specifically in DNA-DSB repair 
(Unruh et al., 2003).  
 
The DNA-damage response in hypoxia 
Upon DNA damage, histone H2AX is rapidly phosphorylated at Serine 139 by ataxia 
teleangiectasia mutated (ATM) kinase, ATM- and Rad3-related (ATR) kinase and DNA-
PK (Fernandez-Capetillo et al., 2004; Zhang et al., 2006; Hurley et al., 2007). Previous 
studies suggested that severe hypoxia can elicit a DNA damage-like response, implying 
the activation of the ATR and ATM pathways and subsequent phosphorylation of H2AX 
(Hammond et al., 2003; Bencokova et al., 2009). More recently, Economopoulou et al. 
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identified a novel role for histone H2AX in hypoxia triggered angiogenesis 
(Economopoulou et al., 2009). Replication specific H2AX was found to be induced in 
an ATR dependent manner in endothelial cells exposed to milder hypoxia (1% O2). 
Whether HIF is involved in the hypoxic induction of H2AX has not been analyzed so 
far. Therefore, we investigated a potential role for HIF-1 and HIF-2 in the 
phosphorylation of H2AX under chronically hypoxic (0.2% O2) conditions. Hypoxic 
H2AX induction was observed in a range of cancer cell lines, was delayed in HIF-1 
deficient MEFs and after HIF-1 and HIF-2 knockdown in Hek293 cells, and was 
further decreased when both HIFs were downregulated. Vice versa, in 786-0 cells, 
devoid of pVHL and constitutively expressing HIF-2, H2AX phosphorylation was 
increased, and could be reversed by pVHL reconstitution. These results suggest that 
HIF plays a crucial role in the DNA damage response under hypoxia. 
 
Materials and methods 
Cell culture and lentiviral transductio.n All cell lines were cultured in high glucose 
Dulbecco's modified Eagle's medium (DMEM; Sigma, Buchs, Switzerland) as described 
previously (Stiehl et al. 2006). For chronic hypoxic exposure, cells were grown in a gas-
controlled glove box to handle the cells under constant oxygen (InvivO2 400, Ruskinn 
Technologies, Leeds, UK). Before medium change, all reagents were pre-equilibrated to 
the 0.2% oxygen containing gas mixture in the glove box. Cell number, size and viability 
were determined by trypan blue exclusion using an automatic cell analyzer (Vi-Cell, 
Beckman-Coulter, Nyon, Switzerland). Stable knockdown of HIF-1 and HIF-2 in 
HEK293 cells by RNA interference was achieved by lentiviral transduction of short 
hairpin (shRNA) constructs. Viral particles were produced in HEK293T human 
enbryonic kidney cells using the ViraPower lentiviral expression system according to the 
manufacturer's protocol (Invitrogen, Basel, Switzerland) as described previously (Stiehl 
et al. 2012). 
 
Immunoblot analysis. Histone immunoblotting was performed as described previously 
(Wirthner et al. 2008). Primary antibodies used were: H2AX (Millipore, Zug, 
Switzerland); total H2AX (Millipore), -actin (Sigma, Buchs, Switzerland). Horseraddish 
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peroxidase coupled secondary anti-mouse and anti-rabbit antibodies were purchased 
from Pierce (Lausanne, Switzerland). Chemiluminescence detection was performed 
using Supersignal West Dura (Pierce) and signals were recorded and quantified using a 
charge-coupled device camera (Lightimager LAS-4000mini, Fujufilm, Dielsdorf, 
Switzerland). Extracted histones were stained with Ponceau S (Sigma). 
 
Flow cytometry. Single cell suspensions were incubated with an antibody against 
H2AX and propidium iodide (PI) according to manufacturer's instructions. Stained cells 
were analyzed with a FACSCanto II utilizing FACSDiva software (BD Biosiences, 
Allschwil, Switzerland). 
 
Single cell electrophoresis (comet assays). Alkaline single cell electrophoresis was 
performed as described before (Wirthner et al. 2008). Briefly, MEFs were mixed with 
0.5% low melting-point agarose (Sigma), solidified on microscopy slides, and lysed with 
1% Triton-X100, 2.5 M NaCl, 100 mM EDTA, 10 mM Tris-HCl (pH 10.0) for 1 hour at 
4°C in the dark. Horizontal electrophoresis (~0.74 V/cm; 300 mA) was performed in 300 
mM NaOH, 1 mM EDTA for 30 minutes. Following SYBR green (Invitrogen) staining, 
DNA migration was visualized by fluorescence microscopy and the tail moment (% DNA 
in tail multiplied by tail length) was calculated from >150 cells per condition using the 
CometScore software package (TriTek, Sumerduck, VA, USA). Quantification of the 
median tail moments is shown as mean values ± standard error of the mean (SEM). 
Statistical analysis was performed applying two-tailed Student's t-test using GraphPad 
Prism version 4.0 (GraphPad Software, Ja Jolla, California, USA).  
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Results 
H2AX accumulation in chronic hypoxia 
Hammond et al. previously reported that severe hypoxia/anoxia (0.02% O2) leads to 
ATR dependent H2AX accumulation which was attributed to S-phase arrest (Hammond 
et al., 2002; Hammond et al., 2003). Because an atmospheric oxygen concentration of 
0.02% O2 results in a tissue partial pressure of oxygen which is most likely below the 
threshold for mitochondrial respiration, we investigated H2AX induction under 
physiologically relevant hypoxic conditions. To ensure unimpaired mitochondrial 
respiration, an atmospheric oxygen concentration of 0.2% O2 was chosen, 
corresponding to an oxygen partial pressure of approx. 1.5 mmHg. Reoxygenation 
induced ROS formation and DNA damage was prevented by replacing the cell culture 
medium every 24 hours with pre-equilibrated medium and by harvesting the cells inside 
of a hypoxic workstation. Several cancer cell lines were exposed to 0.2% O2 for 3 to 72 
hours, followed by analysis of H2AX Ser139 phosphorylation by immunoblotting. As 
shown in Figure 1A, H2AX accumulated time-dependently in all six cell lines and 
reached maximal induction after 24 - 48 hours of hypoxic exposure, depending on the 
cell line. Hypoxic H2AX induction in wild-type HEK293 cells with normal p53 was 
similar to SV40 large T antigen immortalized HEK293T cells, suggesting that p53 is not 
involved in hypoxic H2AX phosphorylation. Only wild-type HEK293 cells were used for 
subsequent experiments.  
 We next compared H2AX accumulation in hypoxia with the effects of the 
topoisomerase II inhibitor and DSB inducing agent etoposide (Burden et al., 1998). 
H2AX slowly accumulated in hypoxia with a maximum after 48 - 72 hours and declined 
after 96 hours (Figure 1B). One hour of etoposide treatment with concentrations from 
0.25 - 8 M resulted in a similar, dose-dependent increase in H2AX levels. Total H2AX 
levels remained unaffected after both hypoxic exposure and etoposide treatment 
(Figure 1B). 
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Fig.1. Phosphorylation of H2AX in chronic hypoxia. (A) The indicated cancer cell lines were cultured 
in 20% or 0.2% O2 for up to 72 hours and H2AX protein levels were analyzed by immunblotting.-actin 
served as a control for equal loading and blotting. (B) HEK293 cells were exposed to 20% or 0.2% O2 
for up to 96 hours or to various etoposide concentrations up to 8 M for one hour in normoxia. 
Phosphorylated and total H2AX were analyzed by immunoblotting.  
 
Hypoxic H2AX accumulation is HIF dependent 
The involvement of HIFin hypoxic H2AX phosphorylation was investigated by shRNA 
mediated stable knockdown of HIF-1 and/or HIF-2 in HEK293 cells. Hypoxic H2AX 
accumulation was delayed after shRNA mediated knockdown of either HIF-1 or HIF-
2with maximal levels only after 72 hours compared to 24 - 48 hours in the parental 
control (Figure 2A). Total H2AX remained unaffected (Figure 2A). Concomitant HIF-1 
and HIF-2 
H2AX at all time points (Figure 2B). 
 To corroborate these findings, two different MEF cell lines derived from two 
different HIF-1 knockout mouse strains were analyzed. These cell lines were either 
only immortalized by SV40 large T (MEF-Hif1a-/-T) or immortalized and transformed by 
H-ras (MEF-Hif1a-/-rT), respectively (Feldser et al., 1999; Ryan et al., 2000). Importantly, 
these MEF cell lines were shown to lack functional HIF-2 protein (Park et al., 2003). 
Confirming the results obtained with HEK293 cells, H2AX levels in wt MEFs 
accumulated after 24 hours exposure to 0.2% O2, but were strongly impaired in MEFs 
devoid of HIF-1. Total histone levels remained unaffected as shown by Ponceau S 
staining of the extracted histone fraction (Figure 2C). We previously reported increased 
susceptibility to DNA damage with enhanced phosphorylation of H2AX in MEF-Hif1a-/-rT 
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upon low dose (0.5 - 4 M) etoposide treatment (Wirthner et al., 2008). However, the 
HIF dependent difference of H2AX levels decreased with higher doses of etoposide 
and was invisible upon treatment with 8 M (Wirthner et al., 2008). In line with these 
findings, no HIF-1 dependent changes in H2AX induction could be observed after 
high dose (8 M) etoposide treatment which resulted in H2AX levels that were only 
slightly higher than the H2AX levels in HIF-1 positive MEFs after 24 hours of hypoxia 
(Figure 2C).  
 To further confirm the role of HIF in hypoxic H2AX accumulation, parental and 
HIF-1/HIF-2 double knockdown HEK293 cells were grown under 20% or 0.2% O2 
conditions for up to 72 hours before H2AX levels were quantified by FACS analysis. 
While 88% of parental cells were strongly H2AX positive after 48 and 72 hours of 
hypoxia, only 20 - 24% of the HIF-1/HIF-2 double knockdown HEKs showed similarly 
elevated H2AX staining (Figure 2D). 
 Finally, VHL-deficient 786-0 cells, containing constitutively stabilized HIF-2 
(Maxwell et al., 1999), and reconstituted 786-0-pVHL cells were cultured under 20% or 
0.2% O2 conditions for 4 - 72 hours and analyzed by immunoblotting. In line with our 
findings above, both basal and hypoxic levels of H2AX were substantially higher in 
786-0 cells compared to 786-0-pVHL cells (Figure 2E). 
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Fig.2. HIFs are required for hypoxic H2AX accumulation. (A, B) Parental, shRNA-mediated HIF-1 
or HIF-2 knockdown (shHIF1A or shHIF2A, respectively) or HIF-1/HIF-2 double knockdown 
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(shH1A/H2A) HEK293 cells were grown under 20% or 0.2% O2 conditions for the indicated time points. 
Phosphorylated and total -actin served as a control for equal 
loading and blotting. (C) MEF-Hif1a
+/+
rT, MEF-Hif1a
-/-
rT, MEF-Hif1a
+/+
T, MEF-Hif1a
-/-
T were grown 
under 20% or 0.2% O2 conditions for 4 or 24 hours or treated with 8 M etoposide for 1 hour. Ponceau S 
staining was used as a control for equal extraction and loading of histones. (D) Parental and HIF-
1/HIF-2 double knockdown (shH1A/H2A) HEK293 cells were grown under 20% or 0.2% O2 
conditions for the time points indicated before H2AX levels were analyzed by FACS. H2AX positive 
cells were gated as indicated by the rectangles and quantified relative to the total cell number. (E) 768-0 
and 786-0-pVHL cells were grown under 20% or 0.2 % O2 conditions for 24 to 72 hours and H2AX and 
-actin protein levels were analyzed by immunoblotting. 
 
Hypoxic H2AX accumulation is independent of DNA-DSB formation 
Hypoxia has previously been suggested to induce genetic instability, associated with 
increased HIF-1 levels (Bristow et al., 2008). However, the previously published lack of 
detectable DNA damage at 0.02% O2 suggests that hypoxic H2AX accumulation might 
be partially or fully independent of DNA-DSB formation (Hammond et al., 2003). To 
directly assess DNA-SSB and DNA-DSB formation under 0.2% O2 conditions, we 
performed alkaline single-cell electrophoresis (comet assays) in wild-type and HIF-1 
deficient MEFs and concomitantly determined H2AX protein levels by immunoblotting. 
As shown in Figure 3A, emergence of DNA-DSB induced by 1 M etoposide could be 
visualized reliably by "comet halo" formation. Quantification of the median of the tail 
moment demonstrated a significant (p < 0.0001) 4-fold increase following treatment with 
1 M etoposide for 1 hour but not after up to 24 hours of 0.2% O2 (Figure 3B, upper 
panel). In contrast, H2AX levels in HIF-1 wild-type MEFs were even higher after 12 
and 24 hours of hypoxia than following treatment with 1 M etoposide (Figure 3B, lower 
panel). Taken together, these data suggest that DNA-DSB is not a major determinant of 
hypoxic H2AX induction. 
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Fig.3. Hypoxia does not induce detectable DNA strand breaks. (A) Representative example of a comet 
assay. DNA fragmentation in wildtype MEFs was induced by exposure to 1 M etoposide for 1 hour. 
DNA was stained with SYBR green and all images were acquired with fixed exposure times. (B) DNA 
fragmentation was quantified by determining the median tail moment of at least 150 comets per condition 
using CometScore software. Data are shown was mean values ± SEM.  
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Discussion 
Hypoxic regions in solid tumors result from an imbalance between cellular oxygen 
consumption and oxygen delivery as a consequence of inefficient tumor vasculature 
and limited oxygen diffusion (Chitneni et al., 2011). Rapid and frequent variations in red 
blood cell flux cause temporal and spatial variations in the degree of hypoxia within the 
same tumor. We found that chronic hypoxia triggers the phosphorylation of the histone 
variant 2AX in a HIF dependent manner. In line with a previous report (Hammond et al., 
2003), we showed that H2AX levels after chronic hypoxia were comparable with 
etoposide treatment. Hypoxia (0.2% O2) did not lead to detectable DNA damage when 
analyzed by alkaline single cell electrophoresis. Furthermore, proliferation and cell 
viability were not altered, even after long term (3 days) hypoxic exposure (data not 
shown). However, conditions close to anoxia have been reported to have direct 
cytotoxic effects and elicit apoptosis (Papandreou et al., 2005). In line with our previous 
findings (Wirthner et al., 2008), 53BP1 dose-dependently accumulated in distinct 
nuclear foci upon treatment with etoposide and partially overlapped with H2AX staining 
(data not shown). These foci are most likely sites of DNA-DSBs. In contrast, in chronic 
hypoxia H2AX did not accumulate in nuclear foci but showed a more diffuse pattern 
throughout the nucleus (data not shown). A similar granular H2AX and ATM phospho-
S1981 staining has been reported previously to occur in response to severe hypoxia 
(0.02% O2) (Hammond et al., 2003; Bencokova et al., 2009). Hammond et al. found that 
severe hypoxia leads to replication fork stalling and ATR dependent H2AX 
accumulation during S-phase (Hammond et al., 2002; Hammond et al., 2003). 
Moreover, diffuse and pan-nuclear H2AX staining has been found to occur upon non-
ionizing UV-C irradiation, independent of DNA-DSBs (Marti et al., 2006). Infection with 
inactivated adeno-associated virus has been shown to lead to replication fork stalling 
and a diffuse H2AX nuclear staining which was essential for subsequent cell cycle 
arrest in the absence of DNA damage (Fragkos et al., 2009). However, the mechanism 
behind this diffuse H2AX distribution pattern as well as its functional relevance are 
currently unknown. 
 DNA-DSBs are serious lesions that can lead to genomic instability if improperly 
repaired, or ultimately to cell death if the repair machinery is saturated. It is essential 
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that the cell closely monitors such stress conditions and initiates signals for an adequate 
response. Phosphorylation of H2AX on serine 139 is established as a sensitive marker 
for DNA-DSBs (Bonner et al., 2008). H2AX is regarded as a key component for DNA 
repair, even though it seems dispensable for the initial recognition of DNA-DSBs and 
H2AX-deficient mice are viable (Celeste et al., 2002; Celeste et al., 2003).  
 The physiologic relevance of hypoxia induced H2AX is poorly understood. A 
recent report showed that hypoxia triggered neovascularization required endothelial 
H2AX and H2AX was induced in an ATR dependent manner in moderate hypoxia due 
to replicative stress (Economopoulou et al., 2009). Genetic inactivation of H2AX was 
sufficient to suppress tumor angiogenesis and growth in xenograft models. However, 
this study did not address the question whether HIFs are involved in this effect. In the 
present work, we were able to show that HIF is an integral factor required for efficient 
phosphorylation of H2AX under physiologically hypoxic conditions. Hypoxic H2AX 
induction was delayed in the absence of HIF- We previously reported that DNA-PK 
expression was reduced in MEF-Hif1a-/-rT cells (Wirthner et al., 2008), raising the 
possibility that DNA-PK might be the responsible kinase for H2AX phosporylation in 
chronic hypoxia. DNA-PK has been shown to phosphorylate H2AX in different cell lines 
and in vivo in response to DNA damage (Stiff et al., 2004; Koike et al., 2008; An et al., 
2010), under hypertonic conditions (Reitsema et al., 2005) and during apoptotic DNA 
fragmentation (Mukherjee et al., 2006). Of note, a recent report showed DNA-PK 
activation in hypoxia, resulting in increased HIF dependent gene expression (Bouquet et 
al., 2011). These data suggest that DNA-PK might be both upstream and downstream 
of HIF.  
 In summary, our data indicate a novel DNA-DSB independent and currently 
unknown mechanism by which HIF downstream effectors are involved in histone H2AX 
phosphorylation during hypoxia. Whether increased H2AX is preparing the cell for a 
DNA endangering ROS surge following reoxygenation, or whether there is a yet to be 
discovered novel function of H2AX independent of DNA-DSB repair, remains to be 
investigated. 
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2 Abbreviations 
A Amyloid beta 
ADAM  disintegrin and and metalloprotease domain 
AICD Amyloid precursor protein intracellular domain 
APH-1 Anterior pharynx-defective 1 
APLP Amyloid precursor protein like protein 
APP Amyloid precursor protein 
ARNT Aryl hydrocarbon receptor nuclear translocator 
BACE -site APP cleaving enzyme 1 
bHLH Basic helix-loop-helix 
CAIX Carbonic anhydrase 9 
CaM Calmodulin 
CBP CREB-binding protein 
ccRCC Clear cell renal cell carcinoma 
Cdr2 Cerebellar degeneration-related protein 2 
COX-2 Cyclooxygenase 2 
CTAD C-terminal transactivation domain 
cyps Cyclophilins 
DFX Desferroxamine 
DMOG Dimethyloxalylglycine 
EGL-9 Egg-laying abnormal-9 
EPAS-1 Endothelial PAS protein 1 
EPO Erythropoietin 
FAD Familial Alzheimer disease 
FH Fumarate hydratase 
FIH Factor inhibiting HIF 
FKBP FK506 binding protein 
HLF HIF-1 like factor 
GLUT1 Glucose transporter 1 
GOE Great oxygenation event 
GSAP -secretase acivating protein 
HIF Hypoxia-inducible factor 
HRE Hypoxia-response element 
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IPAS Inhibitory PAS protein 
MAPK Mitogen-activated protein kinase 
MEF Mouse embryonic fibroblast 
MMP9 Matrix metalloproteinase 9 
mTOR Mammalian target of rapamycin 
NCT Nicastrin 
NDRG1 N-myc downstream-regulated gene 1 
NFB Nuclear factor-kappa B 
NICD Notch intracellular domain 
NO Nitric oxide 
NOS Nitric oxide synthase 
NTAD N-terminal transactivation domain 
ODDD Oxygen-dependent degradation domain 
PAS PER-ARNT-SIM 
PCD Paraneoplastic cerebellar degeneration 
Pen-2 Presenilin enhancer 2 
PION Pigeon homolog (drosophila) 
PI3K Phosphatidyl inositol-3 kinase 
PKA Protein kinase A 
pO2 Oxygen partial pressure 
PPIase Peptidyl prolyl cis/trans isomerase 
pRCC Papillary renal cell carcinoma 
RNAi RNA interference 
SNP Single nucleotide polymorphism 
ROS Reactive oxygen species 
SHH Sonic hedgehog protein 
TAD Transactivation domain 
UTR Untranslated region 
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